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1 Introduction
Cancer is the third leading cause of death worldwide. Of the estimated 60
million deaths that occurred worldwide in 2004, 13% have been attributed
to cancer, following cardiovascular diseases (29%) and infectious or para-
sitic diseases (16%). Moreover, the number of deaths caused by cancer is
expected to nearly double by 2030 (World Health Organization, 2008). Can-
cer is a genetic disease thought to develop by clonal selection after a series
of mutation events. Thus, tumour specimens derived from the same tis-
sue show considerable heterogeneity of mutated genes, and each tumour
is unique and responds differently to therapy (Sjöblom et al., 2006). In the
process of clonal selection, malignant cells often loose regulation of cell
growth, become resistant to apoptosis, down-regulate molecules that al-
low detection of aberrant cells by the immune system or start to secrete
soluble factors such as cytokines. In advanced stages of cancer, malignant
cells can also migrate to other tissues and grow metastases.
Resection, radiation and chemotherapeutic agents are still the treatment
of choice for malignant diseases. However, such therapy is not specific for
malignant cells, and systemic application is accompanied by high toxici-
ties. During the last decade, a number of therapeutic agents that specifi-
cally target tumour cells, such as monoclonal antibodies and tyrosine ki-
nase inhibitors, have become available and revolutionised cancer therapy
(Gerber, 2008; Voltz and Gronemeyer, 2008).
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1.1 Classical Hodgkin’s lymphoma
Classical Hodgkin’s lymphoma is a cancer of the immune system that com-
prises approximately 0.5% of newly diagnosed cancers. It has a bimodal
age-incidence curve with a peak at 15 to 34 years and a second peak at
60 years and above. The neoplastic cells represent the Hodgkin-Reed-
Sternberg cells and are of B cell origin. Interestingly, malignant cells com-
prise only a small fraction of the tumour mass and are surrounded by an
inflammatory infiltrate of healthy lymphocytes, eosinophils, fibroblasts,
macrophages and plasma cells (Young and Iland, 2007).
While classical Hodgkin’s lymphoma is one of the most curable cancers in
adults, non-responders, tumour relapses and long-term toxicities of the
treatment make it necessary to look for alternative drugs (Fuchs et al.,
2006). Current therapeutic schemes for classical Hodgkin’s lymphoma
do not specifically target the malignant cells, therefore therapies would
benefit from drugs that effect a specific anti-tumour response (table 1.1).
The surface molecule CD30, a 120kDa glycoprotein belonging to the tu-
mour necrosis factor receptor superfamily, presents a good target for im-
munotherapy, as it is expressed almost exclusively on the cell surface of
activated lymphocytes and malignant lymphoid cells such as the Hodgkin-
Reed-Sternberg cells of Hodgkin’s lymphoma (Chiarle et al., 1999). CD30 is
shed from Hodgkin-Reed-Sternberg cells in large quantities which poses a
major problem for targeted immunotherapy. However, shedding can effec-
tively be inhibited by hydroxamate inhibitors of metalloproteases (Matthey
et al., 2004).
An overproduction of TH2 cytokines in the tumour lesion is attributed to
suppress an adequate immune response against the malignant Hodgkin-
Reed-Sternberg cells (Skinnider and Mak, 2002). The balance between TH1
and TH2 cytokines determines which immune response results from infec-
tion with a pathogen: TH1 cells help in eliminating intracellular pathogens,
whereas TH2 cells target extracellular pathogens. Hence, the defective im-
mune response in classical Hodgkin’s lymphoma might be turned into an
efficient anti-tumour response by administration of TH1 cytokines, thus
tipping the balance in favour of a TH1 reaction. However, clinically effec-
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Table 1.1: Drugs used in the ABVD and BEACOPP protocols for the therapy of
classical Hodgkin’s lymphoma (Young and Iland, 2007).
Drug Class ABVD BEACOPP
Bleomycin anthracycline x x
Cyclophosphamide alkylating agent x
Dacarbazine alkylating agent x
Doxorubicin anthracycline x x
Etoposide topoisomerase inhibitor x
Prednisone glucocorticoid x
Procarbazine alkylating agent x
Vinblastine mitotic inhibitor x
Vincristine mitotic inhibitor x
tive doses of recombinant cytokines often lead to severe side effects, thus a
means of targeting cytokines to the tumour site needs to be explored.
1.2 Cytokines
Cytokines are low-molecular-weight proteins secreted by cells that, after
binding to their receptors, regulate cellular functions in a paracrine or au-
tocrine fashion. Among other functions, cytokines play a significant role
in regulating immune responses. Cytokines secreted by T cells are usually
termed interleukins (IL), while cytokines induced in response to viral infec-
tions are called interferons (IFN) (Murphy et al., 2008; Skinnider and Mak,
2002).
Interleukin-2
Human interleukin-2 (IL-2) is a 15.5kDa glycoprotein which is mainly pro-
duced by activated CD4+ lymphocytes of the TH1 phenotype. IL-2 delivers
3
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potent proliferation signals to T cells, B cells and natural killer (NK) cells in
vitro. Moreover, IL-2 augments the in vitro cytolytic activity of NK cells and
monocytes. In vivo, IL-2 mainly supports the differentiation of regulatory T
cells, thus preventing immune reactions from overshooting. The cytokine
may also regulate the in vivo expansion of recently activated T cells.
IL-2 receptors are mainly expressed by cells of the immune system and
composed from three subunits. The IL-2Rα chain (CD25) does not seem
to be involved in intramolecular signalling, whereas the IL-2Rβ chain
(CD122), that is shared with the IL-15 receptor, signals via Jak3-, STAT5-
and AKT-dependent pathways. The common cytokine receptor γc chain
(CD132) is shared by a number of cytokine receptors and signals via MAP
kinase and PI3 kinase pathways. The IL-2Rβ and γc chains form an
intermediate-affinity receptor complex, while all three receptor subunits
assemble to a high-affinity receptor (Ma et al., 2006; Thèze, 1999).
Recombinant IL-2 has been approved by the United States Food and Drug
Administration for use in adults with metastatic melanoma and metastatic
renal cell carcinoma. High-dose IL-2 therapy has shown complete and
durable responses in approximately 10% of treatment-naïve patients with
advanced renal cell carcinoma. However, systemic administration of IL-2
elicits life-threatening side effects. Grade 3 to 4 toxicities include hy-
potension, capillary leak syndrome, arrhythmia and neurotoxicity. As of
2001, the incidence of treatment-related mortality has been as high as 1%
(Atkins, 2009; Dutcher et al., 2001).
Interleukin-12
Human interleukin-12 (IL-12) is a 70kDa heterodimeric glycoprotein (p70)
composed of two disulfide-linked subunits with molecular weights of
35kDa (p35) and 40kDa (p40). The p35 chain shows limited homology
with other single-chain cytokines, whereas p40 is homologous to the ex-
tracellular domain of the hematopoietic receptor family. Both subunits are
required for biologically active IL-12. The expression of p40 determines
a cell’s ability to secret IL-12, while p35 controls the absolute amount of
4
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IL-12 produced. IL-12 is mainly produced by phagocytic cells, acts as a
pro-inflammatory cytokine, favours the differentiation of TH1 cells and in-
hibits the differentiation of TH2 cells. The cytokine induces proliferation
in activated T and NK cells, enhances the cytotoxic activity of NK cells and
favours the generation of cytotoxic CD8+ cells. Moreover, IL-12 induces ac-
tivated T and NK cells to secrete the TH1 cytokine IFN-γ, which in turn en-
hances production of IL-12 in granulocytes, thus forming a positive feed-
back loop. In contrast, the TH2 cytokines TGF-β and IL-10 are potent in-
hibitors of IL-12 production.
IL-12 receptors are mainly expressed on activated T and NK cells. The
IL-12Rβ1 chain (CD212) is shared with the IL-23 receptor, binds to p40
and does not seem to be involved in intramolecular signalling, while the
IL-12Rβ2 chain interacts with p35 and signals through phosphorylation of
Jak2, Tyk2 and the transcription factors STAT1, STAT3, STAT4 and STAT5.
The cellular functions of IL-12 are mainly mediated by phosphorylation of
STAT4 (Hölscher, 2004; Thèze, 1999; Thomson and Lotze, 2003).
In vivo, IL-12 mediates efficient anti-tumour responses by triggering both
innate and adaptive immune responses against tumour cells, and by in-
hibiting angiogenesis. The anti-tumour effects of IL-12 are mostly medi-
ated by indirect mechanisms, particularly by enhancing the endogenous
production of IFN-γ. However, long-term IL-12 monotherapy inhibits
IFN-γ production and induces immunosuppression in humans. More-
over, systemic administration of IL-12 elicits severe toxicities. Grade 3 to 4
toxicities include dyspnea, stomatitis, transaminitis and leukopenia. Two
treatment-related deaths have been reported (Weiss et al., 2007; Wigginton
and Wiltrout, 2002).
1.3 Immunocytokines
One of the major problems of current cancer therapy is that most drugs nei-
ther specifically target malignant cells, nor accumulate at the tumour le-
sion. Unless primary tumour and metastases are directly accessible, drugs
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have to be administered systemically and patients generally suffer from
side effects, while toxicities lead to the use of suboptimal doses. Cytokines
exhibit particularly severe toxicities when administered systemically, as
they are highly effective in nanomolar to picomolar concentrations. More-
over, side effects of cytokine administration may be amplified by the in-
duction of cytokine secretion and positive feedback loops.
With the advance of monoclonal antibodies and hybridoma technology
(Köhler and Milstein, 1975), a plethora of antibodies have been raised
against tumour-associated antigens. Subsequently, such diverse agents
as radioactive substances, chemotherapeutic agents, toxins, enzymes and
prodrugs have been targeted to malignant cells by conjugation to mon-
oclonal antibodies or single-chain fragment variants (scFv) derived from
these antibodies (Schrama et al., 2006). To decrease the severe side ef-
fects of systemically administered cytokines, antibodies and single-chain
fragment variants have also been conjugated to cytokines. The resulting
fusion proteins, termed immunocytokines, accumulate at tumour lesions
and display anti-tumour activity in vivo. Moreover, immunocytokines that
include the Fc domain of an antibody enhance the anti-tumour activity of
a cytokine by inducing antibody-dependent cellular cytotoxicity (ADCC)
(Davis and Gillies, 2003).
For the therapy of classical Hodgkin’s lymphoma, our group has generated
an scFv that retains the idiotypic profile of the anti-CD30 monoclonal an-
tibody HRS3 (Hombach et al., 1998). Anti-CD30 immunocytokines have
been generated by fusing the HRS3 scFv to human IL-2 or murine single-
chain IL-12 using the hinge or Fc regions of human IgG1 as linkers (Heuser
et al., 2003, 2004). Murine IL-12 has been chosen instead of its human
counterpart because we want to assess immunocytokine activity on both
human lymphocytes and in mouse models. Human IL-12 does not stim-
ulate murine lymphocytes, whereas murine IL-12 is active on human and
murine lymphocytes (Schoenhaut et al., 1992). In contrast, human IL-2
stimulates human and murine T cells with similar efficacies (Mosmann
et al., 1987).
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1.4 Objectives of this study
Researchers have proposed to treat cancer with a combination of IL-2
and IL-12, as these cytokines activate separate pathways, reciprocally up-
regulate each other’s receptors and induce complimentary biological ef-
fects (Wigginton and Wiltrout, 2002). In vivo, IL-2 and IL-12 show a strong
synergistic effect that is mostly attributed to enhanced activation of cy-
totoxic T and NK cells. Moreover, immunosuppression and inhibition of
IFN-γ production during monotherapy with IL-12 can be overcome by
concurrent administration of low-dose IL-2 . Finally, effective cytokine
doses of combination therapy with IL-2 and IL-12 seem to be lower and
side effects much reduced compared to therapy with a single cytokine
(Weiss et al., 2007).
Accordingly, our group has found that the combination of an immunocy-
tokine with IL-2 domain and an immunocytokine with IL-12 domain en-
hances activation of resting NK cells and tumour cell lysis in vitro, com-
pared to either immunocytokine alone (Hombach et al., 2005). As the si-
multaneous administration of two immunocytokines may induce prob-
lems such as competition on binding to CD30, we have generated the novel
anti-CD30 immunocytokine HRS3scFv-hi-IL12-Fc-IL2. This immunocyto-
kine has been designed for the therapy of classical Hodgkin’s lymphoma
and combines human IL-2 and single-chain murine IL-12 in one molecule.
Figure 1.1 gives an overview on the anti-CD30 immunocytokines used in
this study.
The objective of this study is to assess whether an immunocytokine with
combined IL-2 and IL-12 domains is more suited for the immunotherapy
of classical Hodgkin’s lymphoma in terms of lymphocyte activation and tu-
mour cell lysis than immunocytokines with each cytokine domain. We aim
to explore whether the novel immunocytokine HRS3scFv-hi-IL12-Fc-IL2
augments secretion of the TH1 cytokine IFN-γ, which may be important
for overcoming the misguided TH2 immune reaction in classical Hodgkin’s
lymphoma. We will reveal that the insertion of an additional cytokine do-
main into immunocytokines does not alter avidity and specificity of bind-
ing. As the influence of dimerisation mediated by the Fc domain of an an-
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Figure 1.1: Expression cassettes of the anti-CD30 immunocytokines used in this
study. Immunocytokines and the fusion protein HRS3scFv-Fc were generated by
fusing DNA coding for the anti-CD30 scFv HRS3 to DNA coding for the Fc region of
human IgG1, the hinge region of human IgG1, human IL-2 or murine single-chain
IL-12. Linker: (GlySer4)3 linker. Hinge: hinge region of human IgG1. LKappa and
BiP signal: leader sequences needed for protein secretion. Black triangles: signal
cleavage sites.
tibody on the biodistribution of immunocytokines is not clear, we further
want to compare the biodistribution of two anti-CD30 immunocytokines
that are identical except for lacking or containing an Fc domain. At the
same time, we want to ascertain that anti-CD30 immunocytokines accu-
mulate at the tumour. Finally, we intend to estimate suitability of the im-
munocytokine HRS3scFv-hi-IL12-Fc-IL2 for use in cancer patients by in-
vestigating whether immunocompetent mice tolerate systemic adminis-
tration of this immunocytokine, and whether tumour growth is inhibited
in this setting.
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2.1 Chemicals
Chemicals were obtained from Fluka (Neu-Ulm, Germany), Merck (Darm-
stadt, Germany), Roth (Karlsruhe, Germany) and Sigma-Aldrich (Stein-
heim, Germany). Na131I was obtained from Polatom (Otwock-S´wierk,
Poland).
2.2 Solutions, media and buffers
Solutions and media were prepared according to Ausubel (2005) and Coli-
gan (2005) unless mentioned otherwise. All solutions were prepared from
double distilled water (ddH2O). If needed, pH was corrected by addition of
1 M or 5 M solutions of HCl, HOAc or NaOH prior to sterilisation. Thermally
unstable ingredients such as antibiotics were added when sterilised solu-
tions had cooled down to 50°C or below.
2.3 Sterilisation procedures
Pipette tips and thermally stable solutions were autoclaved (121°C,
2×105 Pa). Thermally unstable solutions were sterilised by filtration
through 200nm Sterifix™ filters (B. Braun, Melsungen, Germany). Glass-
ware was heat-sterilised (180°C, ≥4h). Performance of heat-sterilisation
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procedures was controlled with heat indicators for every item. Ster-
ilisation efficiency was also tested at regular intervals with spores of
Geobacillus stearothermophilus (autoclaving) or Bacillus atrophaeus (heat-
sterilisation).
2.4 DNA plasmids
Table 2.1: List of DNA plasmids used in this study.
ID Plasmid Characteristics (Reference)
#435 pBullet-Lk CC49-
scFv-Fc-CD3ζ
contains the mammalian expression
cassette of the TAG-72-specific immu-
noreceptor CC49scFv-Fc-CD3ζ (Hom-
bach et al., 1998)
#440 pRSV-Lk HRS3scFv-
Fc
contains the mammalian expression
cassette of the anti-CD30 immunocyto-
kine HRS3scFv-Fc (Heuser et al., 2004)
#508 pRSV-Lk HRS3scFv-
Fc-IL2
contains the mammalian expression
cassette of the anti-CD30 immunocy-
tokine HRS3scFv-Fc-IL2 (Heuser et al.,
2004)
#603 pRSV-Lk HRS3scFv-
hi-IL12
contains the mammalian expression
cassette of the anti-CD30 immunocy-
tokine HRS3scFv-hi-IL12 (Heuser et al.,
2003)
#619 pRSV-Lk HRS3scFv-
Fc-hi-IL12
contains the mammalian expression
cassette of the anti-CD30 immunocyto-
kine HRS3scFv-Fc-hi-IL12 (Hombach
et al., 2005)
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Table 2.1: List of DNA plasmids used in this study (continued).
ID Plasmid Characteristics (Reference)
#653 pGT60 hB7.2 contains the mammalian expression
cassettes encoding for the hygromycin
resistance gene, the Herpes simplex
thymidine kinase and human B7.2 (In-
vivoGen, Toulouse, France)
#715 pRSV-Lk HRS3scFv-
hi-IL12-Fc-IL2
contains the mammalian expression
cassette of the anti-CD30 immunocyto-
kine HRS3scFv-hi-IL12-Fc-IL2 (unpub-
lished)
#841 pcDNA3.1 CD30 contains the mammalian expression
cassette coding for the surface marker
CD30 (unpublished)
#844 pORF IL15 contains DNA coding for human IL-15
(InvivoGen)
#944 pRSV-Lk 763.74-
scFv-Fc
contains the mammalian expression
cassette of the anti-melanoma im-
munocytokine 763.74scFv-Fc (unpub-
lished)
#977 pBullet-Lk SCA431-
scFv-Fc-CD4tm-
CD3ζ
contains the mammalian expression
cassette of the CEA-specific immuno-
receptor SCA431scFv-Fc-CD4tm-CD3ζ
(Chmielewski, 2007)
#1024 pJR IL7 contains DNA coding for murine IL-7;
kindly provided by Prof. Dr. Thomas
Blankenstein, Max-Delbrück-Centrum
für Molekulare Medizin, Berlin-Buch,
Germany (pBA IL7 in Hock et al., 1991)
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Table 2.1: List of DNA plasmids used in this study (continued).
ID Plasmid Characteristics (Reference)
#1041 pcDNA3.1 IL21 contains DNA coding for murine IL-21;
kindly provided by Prof. Dr. Naomi Tay-
lor, Institut de Génétique Moléculaire
de Montpellier, Montpellier, France
#1070 pMT/BiP V5-His A Drosophila Expression System™ (Invit-
rogen, Karlsruhe, Germany); inducible
expression of secreted proteins in cells
of Drosophila melanogaster
#1078 pBullet HRS3scFv-
CD3ζ
contains DNA coding for anti-CD30-
scFv HRS3
#1080 pCoHygro expression in Drosophila cells; con-
tains expression cassette encoding for
the hygromycin resistance gene (Invit-
rogen)
#1082 pMT/BiP HRS3-
scFv-Fc
expression in Drosophila cells; contains
expression cassette of the anti-CD30
immunocytokine HRS3scFv-Fc
#1083 pMT/BiP HRS3-
scFv-Fc-hi-IL12
expression in Drosophila cells; contains
expression cassette of the anti-CD30
immunocytokine HRS3scFv-Fc-hi-IL12
#1086 pMT/BiP HRS3-
scFv-Fc-IL2
expression in Drosophila cells; contains
expression cassette of the anti-CD30
immunocytokine HRS3scFv-Fc-IL2
#1100 pMT/BiP HRS3-
scFv-hi-IL12-Fc-IL2
expression in Drosophila cells; con-
tains expression cassette of the anti-
CD30 immunocytokine HRS3scFv-hi-
IL12-Fc-IL2
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Table 2.1: List of DNA plasmids used in this study (continued).
ID Plasmid Characteristics (Reference)
#1103 pMT/BiP SCA431-
scFv-Fc
expression in Drosophila cells; contains
expression cassette of the anti-CEA im-
munocytokine SCA431scFv-Fc
#1117 pMT/BiP SCA431-
scFv-Fc-IL7
expression in Drosophila cells; contains
expression cassette of the anti-CEA im-
munocytokine SCA431scFv-Fc-IL7
#1118 pMT/BiP SCA431-
scFv-Fc-IL15
expression in Drosophila cells; contains
expression cassette of the anti-CEA im-
munocytokine SCA431scFv-Fc-IL15
2.5 Synthetic oligonucleotides
Oligonucleotides were synthesised by Eurogentec (Cologne, Germany), In-
vitrogen (Karlsruhe, Germany) and MWG-Biotech (Munich, Germany).
Table 2.2: List of synthetic oligonucleotides used in this study. Restriction sites
(sites) in sequences are indicated by lines. C: The oligonucleotide has been used
for cloning procedures. S: The oligonucleotide has been used for sequencing.
ID Name Sites Sequence (5’ to 3’) Usage
#38 HRS3-VL-
BamHI-3’
BamHI ACC TGG ATC CGC CCG
TTT GAT TTC
S
#55 IL-2SX XhoI TCA ACT CGA GTC GAC
TCA AGT CAG TGT TGA
GAT GAT
C
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Table 2.2: List of synthetic oligonucleotides used in this study (continued).
ID Name Sites Sequence (5’ to 3’) Usage
#75 SeqRSV-S TTG GTG TGC ACC TCC
AAG CTC CTC
S
#76 SeqFc-AS CGG TCC CCC CAG GAG
TTC AGG TGC
S
#95 IL12-hi-S BamHI TG AAG GAT CCC GCC
GAG CCC AAA TCT CCT
GAC AAA ACT CAT ACA
TGC CCA CCA ATG TGG
GAG CTG GAG AAA GAC
GTT
S
#111 IL12-Li-AS-1 AGA TCC GCC GCC ACC
CGA CCC
S
#113 IL12-Li-AS-2 CTT GAT GTT GAA CTT
CAA GTC CAT GTT TC
S
#127 hIgG-Seq-S C AAC TGG TAC GTG
GAC GGC G
S
#128 hIgG-Seq-AS C ATT GCT CTC CCA
CTC CAC GG
S
#135 pBullet-5’-
Seq neu
GG ACC TTA CAC AGT
CCT GCT GAC CA
S
#136 pBullet-3’-
Seq neu
C GTA CTA TAG GCT
TCA GCT GGT GAT ATT
G
S
#195 5’-Seq-Fc-End A TGC TCC GTG ATG
CAT GAG GCT CT
S
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Table 2.2: List of synthetic oligonucleotides used in this study (continued).
ID Name Sites Sequence (5’ to 3’) Usage
#238 S-HRS3-hi-
Bam
BamHI GGC ACC AAG CTG GAA
ATC AAA CGG GCG GAT
CCC GCC
C
#251 mIgG1-S AAC TGG GAG GCA GGA
AAT ACT TTC ACC
S
#253 Seq-p40-S2 ACT CCC CAT TCC TAC
TTC TCC CTC
S
#317 Seq-VH#680 TGA GGA GAC GGT GAC
CGT GGT
S
#324 SCA431-Vk-
Gly-Linker S
TCG GGC GGT GGC GGG
TCG GGT GGC GGC GGA
TCT GAC ATC CAG CTG
ACC CAG TCT CCA GCA
ATC A
S
#363 AS-mIgG AT GGT GAG CAC ATC
CTT GGG C
S
#433 HRS3-pMT-S NcoI C GAA CCA TGG GTG
GCC CAG GTG CAA CTG
CAG
C
#469 pMT-BiP Seq-
S
C ATC TCA GTG CAA
CTA AA
S
#470 pMT-BiP Seq-
AS
TAG AAG GCA CAG TCG
AGG
S
#471 pMT-SCA431-
S
NcoI G GGG CCA TGG AGA
GGT GTC CAC TCC CAG
C
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Table 2.2: List of synthetic oligonucleotides used in this study (continued).
ID Name Sites Sequence (5’ to 3’) Usage
#472 pMT-SCA431-
AS
BstXI,
NotI
TTT TGC GGC CGC TCA
CTT ACC AGG AGA GTG
GGA
C
#490 pMT-mIL7-
BstX-S
BstXI CTC TCC CAC TCT CCT
GGT AAG GAG TGC CAC
ATT AAA GAC
C, S
#491 pMT-mIL7-
Not-AS
NotI,
XhoI
AC TCG AGC GGC CGC
TCA TAT ACT GCC CTT
CAA AAT
C
#492 pMT-hIL15-
BstX-S
BstXI CTC TCC CAC TCT CCT
GGT AAG AAC TGG GTG
AAT GTA ATA
C, S
#493 pMT-hIL15-
Not-AS
NotI,
XhoI
AC TCG AGC GGC CGC
TCA AGA AGT GTT GAT
GAA CAT
C
#495 pMT-mIL21-
Not-AS
NotI,
XhoI
AC TCG AGC GGC CGC
TCA GGA GAG ATG CTG
ATG AAT
C
#496 mIgG1-S2 GTG CCC AGG GAT TGT
GGT TGT
S
#512 pMT-mIL21-
shortSP-BstX-
S
BstXI CTC TCC CAC TCT CCT
GGT AAG CCA GAT CGC
CTC CTG ATT
C
#513 pRSV-Seq-AS TCA CAA ATT TCA CAA S
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2.6 Bacterial strains
The following bacterial strains were used for cloning, transformation and
the amplification of plasmids:
• Escherichia coli DH5α (Hanahan, 1985)
Genotype: F – endA hsdR17 supE44 thi-1 recA1 gyrA relA1 ∆(lacZYA-
argF)Φ 80d lacZ∆M15
• Escherichia coli One Shot™ INV110 (Invitrogen)
Genotype: F’ {tra∆36 proAB lacIq lacZ∆M15} rpsL (StrR) thr leu endA
thi-1 lacY galK galT ara tonA tsx dam dcm supE44 ∆(lac-proAB)
∆(mcrC-mrr)102::Tn10 (TetR)
2.7 Primary cells
Human peripheral blood mononuclear cells
Human peripheral blood mononuclear cells (PBMC) were isolated from
fresh blood or buffy coats (platelet and leukocyte fraction from blood do-
nations) of healthy donors. Buffy coats were obtained from Transfusions-
medizin der Uniklinik Köln.
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2.8 Cell lines
Table 2.3: List of cell lines used in this study.
Cell line Species Characteristics (Reference)
293T human embryonic kidney 293 cell line (ATCC CRL-
1573™) stably expressing the SV40 large T anti-
gen; neomycin resistant (DuBridge et al., 1987)
L540 human CD30+ cell line derived from Hodgkin’s lym-
phoma (Diehl et al., 1982); kindly provided
by PD Dr. Hinrich Hansen, Uniklinik Köln,
Cologne, Germany
L540Cy human CD30+ mutant subline of L540, recultured from
a tumour developing in a cyclophosphamide-
treated nude mouse (von Kalle et al., 1992);
kindly provided by PD Dr. Hinrich Hansen
MeWo human cell line derived from a metastasis of melanoma
(Bean et al., 1975; ATCC HTB-65™)
C15A3 mouse MC38 cell line stably expressing CEA; neomycin
resistant (Hoffmann et al., 2001)
MC38 mouse methylcholanthrene-induced colon carcinoma
cell line (Corbett et al., 1975)
SL2 insect cell line derived from late embryonic stages
of Drosophila melanogaster (Schneider, 1972;
ATCC CRL-1963™); kindly provided by Dr.
Ralph Willemsen, Erasmus MC, Rotterdam, The
Netherlands
1116-NS-
19-9
mouse hybridoma, secretes antibody directed against
CA-19-9 (Koprowski et al., 1979; ATCC HB-
8059™)
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Table 2.3: List of cell lines used in this study (continued).
Cell line Species Characteristics (Reference)
9G10 mouse hybridoma, secretes anti-idiotypic antibody
bearing the internal image of the HRS3-binding
epitope (Pohl et al., 1992)
HRS3 mouse hybridoma, secretes monoclonal antibody di-
rected against CD30 (Pfreundschuh, 1989)
OKT3 mouse hybridoma, secretes monoclonal antibody di-
rected against CD3 (Kung et al., 1979; ATCC
CRL-8001™)
T84.66A3.
1A.1F2
mouse hybridoma, secretes antibody directed against
CEA (Wagener et al., 1983; ATCC HB-8747™)
2.9 Antibodies
Table 2.4: List of antibodies used in this study.
Antibody Species,
Isotype
Con-
jugate
Clone Source
anti-human
IgG
goat – poly-
clonal
Southern Biotech
(Birmingham,
AL, USA)
anti-human
IgG
goat biotin poly-
clonal
Southern Biotech
anti-human
IgG, F(ab’)2
goat PE poly-
clonal
Southern Biotech
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Table 2.4: List of antibodies used in this study (continued).
Antibody Species,
Isotype
Con-
jugate
Clone Source
anti-mouse IgG goat – poly-
clonal
Southern Biotech
anti-mouse IgG goat biotin poly-
clonal
Southern Biotech
anti-mouse
IgG1
goat PE poly-
clonal
Southern Biotech
anti-human
IL-2
mouse
IgG1κ
– 5344.111 BD Pharmingen
(Heidelberg,
Germany)
anti-human
IL-2
mouse
IgG1κ
biotin B33-2 BD Pharmingen
anti-mouse
IL-12 (p40/p70)
rat
IgG1
– C15.6 BD Pharmingen
anti-mouse
IL-12 (p40/p70)
rat
IgG2a
biotin C17.8 BD Pharmingen
anti-human
IFN-γ
mouse
IgG1κ
– NIB42 BD Pharmingen
anti-human
IFN-γ
mouse
IgG1κ
biotin B133.5 Pierce Endogen
(Rockford, IL,
USA)
anti-human
CD3
mouse
mIgG2a
– OKT3 purified from
hybridoma
supernatants
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Table 2.4: List of antibodies used in this study (continued).
Antibody Species,
Isotype
Con-
jugate
Clone Source
anti-human
CD3
mouse
IgG1κ
FITC UCHT1 Dako (Hamburg,
Germany)
anti-human
CD30
mouse
IgG1
– HRS3 purified from
hybridoma
supernatants
anti-human
CD30
mouse
IgG1
PE HRS4 Immunotech
(Praha, Czech
Republic)
anti-human
CD56
mouse
IgG1κ
PE MY31 BD Pharmingen
anti-763.74 mouse
IgG1
– MK2-72.
8854
kindly provided
by Soldano
Ferrone,
University of
Pittsburgh
Cancer Institute,
Pittsburgh, PA,
USA
anti-human
CEA
mouse
IgG1κ
– T84.66A3.
1A.1F2
purified from
hybridoma
supernatants
anti-HRS3 mouse
IgG1
– 9G10 purified from
hybridoma
supernatants
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Table 2.4: List of antibodies used in this study (continued).
Antibody Species,
Isotype
Con-
jugate
Clone Source
anti-HMW-
MAA
mouse
IgG1
PE EP-1 Miltenyi Biotech
(Bergisch-
Gladbach,
Germany)
anti-human
pSTAT4
(pY693)
mouse
IgG2bκ
PE 38/p-
STAT4
BD Pharmingen
anti-BrdU, Fab mouse perox-
idase
BMG 6H8 Roche
Diagnostics,
Penzberg,
Germany
human IgG human
IgG
– poly-
clonal
Southern Biotech
murine IgG1 mouse
IgG1
– 1116-NS-
19-9
purified from
hybridoma
supernatants
murine IgG1 mouse
IgG1κ
FITC DAK-G01 Dako
murine IgG1 mouse
IgG1κ
PE 679.1
Mc7
Immunotech
murine IgG2b mouse
IgG2bκ
PE 27-35 BD Pharmingen
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2.10 Sera
Foetal calf serum (FCS) was obtained from Biochrom (Berlin, Germany).
Normal mouse serum was obtained from Dako.
2.11 Recombinant proteins
Table 2.5: List of recombinant proteins used in this study. According to the man-
ufacturer, 1.8×107 IU Proleukin™ S correspond to 1.1mg human IL-2.
Protein Produced in MW Source
human Fc 293T 50kDa
(SDS-PAGE)
kindly provided by PD
Dr. Hinrich Hansen
des-alanyl-1,
serine-125
human IL-2
Escherichia
coli
15.6kDa Proleukin™ S (Novartis
Pharma, Nürnberg,
Germany)
murine IL-12 Spodoptera
frugiperda
54kDa EMD Chemicals
(Darmstadt, Germany)
human IFN-γ1b Escherichia
coli
38kDa Imukin™ (Boehringer
Ingelheim Pharma,
Ingelheim am Rhein,
Germany)
human CD30-Fc 293T 200kDa
(SDS-PAGE)
kindly provided by PD
Dr. Hinrich Hansen
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2.12 Software
Ubuntu™ Linux (Canonical, Douglas, Isle of Man, UK)
The statistical language R 2.9 (R Development Core Team, 2009) was used
to plot graphs and calculate statistics. Absorption curves from ELISA exper-
iments were fitted to three-parameter logistic models using the R add-on
package drc 1.7 (Ritz and Streibig, 2005). Data from flow cytometry experi-
ments were analysed using flowViz from the R add-on package Bioconduc-
tor 2.4 (Gentleman et al., 2004). Input files for use in R were exported from
spreadsheets generated in OpenOffice.org 2.x and 3.0 (Sun Microsystems,
Santa Clara, CA, USA). Figures were drawn in Inkscape 0.46. Source files
were edited using GNU Emacs 22.x (Free Software Foundation, Boston,
MA, USA). This document was typeset using pdfTeX 1.4 and KOMA-Script
3.0 . References were managed in JabRef 2.4.
Windows™ (Microsoft Corporation, Redmond, WA, USA)
DNA sequences were analysed in Vector NTI Advance 10.3 (Invitrogen). Pa-
rameters of the äktaPrime™ chromatograph were monitored in real-time
using the application UNICORN 4.0 (Amersham Biosciences, Freiburg,
Germany). Absorption data of microtitre plates were read using SoftMax
Pro 1.2 (Molecular Devices, Sunnyvale, CA, USA). Flow cytometer data
were read using FACSdiva 5.0 (BD Biosciences, Heidelberg, Germany).
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Methods were performed or adapted according to Ausubel (2005) and Col-
igan (2005). The fusion proteins HRS3scFv-Fc and SCA431scFv-Fc lack a
cytokine domain and therefore do not match the term “immunocytokine”.
In order to simplify the description of methods, use of the term “immu-
nocytokine” in this chapter is extended to include these fusion proteins.
Amounts of substance and related units were always calculated for the
non-dimerised state of immunocytokines in order to make calculations
and figures less confusing. If handled differently, 10pmol of dimerised im-
munocytokine would require 20pmol cytokine standard for equivalence.
3.1 Bacteria
Bacteria cells were handled in gene technology labs of security level S1.
3.1.1 Bacteria culture
Bacteria cells were cultured overnight at 37°C, either in liquid LB medium
(rotated at 200 rpm) or on LB plates. Genetically modified bacteria were
selected by adding 200µg/ml ampicillin or 50µg/ml kanamycin to media.
LB plates were stored at 4°C for up to two weeks. For long-term storage,
700µl bacteria cultures were mixed with 300µl of 87% (v/v) glycerol and
stored at −80°C.
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3.1.2 Generation of chemically competent bacteria (Hanahan,
1983)
Bacteria colonies were inoculated in 500ml of LB medium and cultured
(37°C, 200 rpm) until the suspension reached an OD600nm of 0.5. The sus-
pension was chilled on ice for 15min and cells were centrifuged for 15min
(3000×g, 4°C). The pellet was immediately suspended in 60ml of ice-cold
TfB I buffer. The suspension was incubated on ice for 10min and cen-
trifuged again for 15min (3000×g, 4°C). The pellet was suspended in 4ml
of ice-cold TfB II buffer and stored at −80°C in 100µl aliquots. Transfor-
mation of 1ng plasmid DNA resulted in approximately 1×103 bacterial
colonies.
TfB I buffer
100mM RbCl, 50mM MnCl2, 30mM KOAc, 10mM CaCl2 and 15% (v/v)
glycerol were dissolved in ddH2O, adjusted to pH 5.8 and filter-
sterilised (prepared fresh)
TfB II buffer
10mM RbCl, 10mM MOPS, 75mM CaCl2 and 15% (v/v) glycerol were
dissolved in ddH2O, adjusted to pH 6.8 and filter-sterilised (prepared
fresh)
3.1.3 Transformation by heat-pulse (Hanahan, 1983)
Competent bacteria were thawed on ice and 10ng to 100ng plasmid DNA
were added. The suspension was mixed and incubated on ice for 20min.
Bacteria were heat-pulsed for 90s (42°C), chilled for 60s, diluted in 500µl
LB medium and incubated for 60min (37°C, 200 rpm) to express antibi-
otic resistance. Finally, bacteria were cultured overnight on LB plates with
antibiotics.
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3.2 Plasmid DNA
3.2.1 Preparation of plasmid DNA
Plasmid DNA was prepared from fresh bacteria cultures by anion-exchange
chromatography following alkaline lysis. DNA was eluted with sterile
10mM TRIS buffer and stored at −20°C. The following reaction kits were
used according to the manufacturer’s recommendations:
• peqGOLD™ Plasmid Miniprep Kit I (Peqlab, Erlangen, Germany)
• QIAGEN™ Plasmid Midi Kit (Qiagen, Hilden, Germany)
• QIAGEN™ Plasmid Maxi Kit (Qiagen)
10mM TRIS buffer
10mM TRIS were dissolved in ddH2O, adjusted to pH 8.4, autoclaved
and stored at room temperature
3.2.2 Quantification of DNA
DNA concentrations were quantified by means of a spectrophotometer.
DNA diluted in 10mM TRIS buffer was placed in quartz cuvettes and ab-
sorbance at the wavelengths 230nm, 260nm, 280nm and 320nm was
determined. 10mM TRIS buffer was used as blank. Double-stranded
DNA in 10mM TRIS buffer has a specific absorption coefficient A260nm of
0.020ml/(µgcm). Purity was estimated by the ratio between absorbance at
260nm and 280nm. Ratios ranging from 1.8 to 1.9 indicated highly purified
DNA preparations.
3.2.3 Ethanol precipitation of DNA
For precipitations or buffer exchange, DNA solutions were mixed with
0.1volumes of 3 M NaOAc (pH 5.2) and 2.5 volumes of ice-cold 96% (v/v)
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ethanol. DNA was precipitated at −80°C for 15min and centrifuged for
5min (25000×g, 4°C). The supernatant was removed, the pellet was
washed with 1ml of 70% (v/v) ethanol and centrifuged again for 5min
(25000×g, 4°C). The supernatant was removed and the pellet was vacuum
dried in a Concentrator 5301 (Eppendorf, Hamburg, Germany). Finally, the
DNA was dissolved in 10mM TRIS buffer or ddH2O.
3.2.4 Agarose gel electrophoresis
DNA fragments were separated by electrophoresis in 1% (w/v) agarose
gels. Gels were run at 10V/cm in TAE buffer with 100ng/ml ethidium bro-
mide. Before electrophoresis, 6× DNA Loading Dye (Fermentas, St. Leon-
Rot, Germany) was added to DNA samples. GeneRuler™ 1kb DNA ladder
(Fermentas) was used as size standard. DNA was visualised in a UV trans-
illuminator (254nm) and photographed.
3.2.5 Isolation of DNA from agarose gels
DNA fragments were separated by agarose gel electrophoresis in presence
of ethidium bromide. The DNA bands of interest were then excised with a
scalpel under UV light (312nm). Finally, DNA fragments were isolated from
the agarose gel using the QIAquick™ Gel Extraction Kit (Qiagen) according
to the manufacturer’s recommendations.
3.2.6 Digestion of DNA
DNA was digested using restriction endonucleases (Roche Diagnostics) in
the appropriate SuRE/Cut™ buffers (Roche Diagnostics) according to the
manufacturer’s recommendations. Digestions with two different restric-
tion endonucleases were performed in one step if buffers and reaction con-
ditions were compatible.
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3.2.7 Ligation of DNA
DNA fragments were ligated using T4 DNA ligase (1U; Roche Diagnos-
tics) according to the manufacturer’s recommendations. Plasmid and in-
sert DNA were added in a molar ratio of 1 : 3 to yield 100ng plasmid DNA.
The ligation mixture was incubated overnight at 14°C and transformed into
bacteria.
3.2.8 Polymerase chain reaction
PCR reactions were carried out in 500-µl reaction tubes using thermal cy-
clers by Biometra (Göttingen, Germany) and Eppendorf. The following re-
action mix was used:
Template DNA: 1ng to 100ng
Upstream primer oligonucleotide: 200nM
Downstream primer oligonucleotide: 200nM
PCR Nucleotide Mix 1: 200µM of
each dNTP
10× Polymerase buffer 1 2: 5µl
Pwo DNA polymerase 1: 2.5U
ddH2O: ad 50µl
1 Roche Diagnostics
2 100mM TRIS-HCl, 20mM MgSO4, 50mM (NH4)2SO4, 250mM KCl, pH 8.85
To minimise condensation or evaporation of samples, the thermal cycler’s
lid was heated to 104°C during PCR. The following thermal cycler program
was routinely used:
Initialisation: 96°C 240s
Denaturation: 96°C 60s
Annealing: 55°C 60s 30 cycles
Elongation: 72°C 60s
Final elongation: 72°C 240s
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Elongation time was adjusted to the length of the amplified fragment (Pwo
polymerase: ≈ 1000bp/min, Taq polymerase: ≈ 2000bp/min). In case a re-
action did not yield amplified DNA, annealing temperature was optimised
by means of a gradient thermal cycler.
3.2.9 Colony PCR
Colony PCR allows to screen for recombinant plasmid DNA in bacterial
clones. Individual clones were picked and cultured overnight on LB plates
with antibiotics. Bacteria of each clone were picked with a pipette tip and
dipped for 2min into 500-µl reaction tubes filled with the following reac-
tion mix:
Upstream primer oligonucleotide: 200nM
Downstream primer oligonucleotide: 200nM
PCR Nucleotide Mix 1: 200µM of
each dNTP
10× Polymerase buffer 1 2: 1µl
Taq DNA polymerase 1: 0.25U
ddH2O: ad 10µl
1 Roche Diagnostics
2 100mM TRIS-HCl, 15mM MgCl2, 500mM KCl, pH 8.3
The pipette tips were removed and a standard PCR was carried out using
the same oligonucleotides and thermal cycler program as during cloning.
During the initialisation step (96°C, 240s), DNA is both released from the
bacteria cells and denatured. Finally, PCR products were separated by
agarose gel electrophoresis and visualised in a UV transilluminator.
3.2.10 Dideoxy DNA sequencing
DNA was sequenced by the dideoxy chain termination method using the
“BigDye™ Terminator v3.1 Cycle Sequencing Kit” (Applied Biosystems,
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Warrington, UK) and a thermal cycler (Eppendorf). The following reaction
mix was used:
Template DNA: 150ng
Sequencing primer oligonucleotide: 2µM
5× BigDye Sequencing Buffer 1: 2µl
2.5× Ready Reaction Premix 1: 4µl
ddH2O: ad 10µl
1 Applied Biosystems
The PCR was performed using the following thermal cycler program:
Initialisation: 96°C 60s
Denaturation: 96°C 30s
Annealing: 50°C 15s 90 cycles
Elongation: 60°C 240s
After PCR, 10µl ddH2O were added to each sample. Finally, samples were
analysed at the Cologne Centre for Genomics (University of Cologne) using
a 3730 DNA Analyser (Applied Biosystems).
3.3 Tissue culture
Tissue culture was carried out in gene technology labs of security level S1
using laminar flow cabinets of Sicherheitsklasse II (Heraeus, Hanau, Ger-
many).
3.3.1 Mammalian tissue culture
Mammalian cells were cultured in a humidified atmosphere with 5% (v/v)
CO2 at 37°C. The culture medium “RPMI 1640 with GlutaMAX I™” (Gibco,
Karlsruhe, Germany) was supplemented with 10% (v/v) FCS, 25IU/ml
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penicillin G and 25µg/ml streptomycin (Gibco). Media were stored at
4°C.
3.3.2 Insect tissue culture
Insect cells were cultured either in a humidified atmosphere at 28°C
or in a FibraStage™ bioreactor (New Brunswick Scientific, Nürtingen,
Germany) at room temperature. The culture medium “Schneider’s In-
sect Medium (Revised)” (Gibco) was supplemented with 10% (v/v) heat-
inactivated FCS, 25IU/ml penicillin G and 25µg/ml streptomycin (Gibco).
Protein production in cells transfected with Drosophila Expression Sys-
tem™ plasmids (Invitrogen) was induced by addition of CuSO4 in a final
concentration of 500µM. Media were stored at 4°C.
Heat inactivation of serum
Serum was heated for 30min in a water bath (56°C) and stored at 4°C.
3.3.3 Passage of adherent cells
To passage adherent cells, culture supernatants were removed and cells
were washed once with 10ml PBS. Cells were detached by adding 500µg/ml
trypsin and 200µg/ml EDTA in a volume sufficient to cover the entire tissue
culture surface. After 2 to 5min, trypsin was blocked by resuspending the
detached cells in 10ml fresh growth medium. A small volume of condi-
tioned medium was added and the cell suspension was diluted with fresh
medium in a ratio of 1 : 2 to 1 : 10, depending on the cell line.
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3.3.4 Passage of cells growing in suspension
To passage cells growing in suspension, cells were centrifuged for 5min
(300×g). Supernatants were removed while retaining a small volume of
conditioned growth medium. The cell suspension was then diluted with
fresh medium in a ratio of 1 : 2 to 1 : 10, depending on the cell line.
3.3.5 Subcloning
Cells were passaged, plated in microtitre plates (5 cells/ml to 500 cells/ml,
200µl/well) and cultured for a few weeks until clones appeared. Super-
natants from each well were screened by ELISA for secreted protein. Clones
producing high amounts of protein were expanded and cryoconserved.
3.3.6 Cryoconservation
For long-time storage of cell lines, 5×106 to 1×107 cells were centrifuged
for 5min (300×g) and resuspended in a mixture of 450µl conditioned
growth medium and 450µl fresh growth medium. The cell suspension was
placed in a cryovial and 100µl of the cryoprotectant DMSO were slowly
run down the vial’s wall. The cryovial was placed in a “Cryo 1°C Freezing
Container”™” (Nalgene, Roskilde, Denmark) that had been pre-chilled to
−20°C, and the freezing container was transferred to a −80°C freezer. On
the following day, the cryovial was transferred to and stored in liquid nitro-
gen.
3.3.7 Calcium phosphate co-precipitation of DNA
(A) SL2 cells were seeded in six-well-plates (3×106 cells, 3ml medium)
and incubated overnight. In a reaction tube, 19µg plasmid DNA
coding for an immunocytokine and 1µg DNA of the hygromycin
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B resistance plasmid pCoHygro (#1080) were mixed and ethanol-
precipitated. Precipitated DNA was dissolved in 270µl ddH2O and 30µl
of a 2.5 M CaCl2 solution were added.
(B) 293T cells were seeded in six-well-plates (2×106 cells, 3ml medium)
and incubated overnight. In a reaction tube, 19µg plasmid DNA
coding for the protein of interest and 1µg DNA of the hygromycin
B resistance plasmid pGT60 hB7.2 (#653) were mixed and ethanol-
precipitated. Precipitated DNA was dissolved in 270µl ddH2O and 30µl
of a 2.5 M CaCl2 solution were added.
A 15-ml tube was set up with 300µl 2× HeBS buffer. While bubbling the
2× HeBS buffer with a 1-ml pipette attached to a mechanical pipettor, the
DNA solution from A or B was added dropwise. The tube was immediately
vortexed for 5s and incubated for 20min at room temperature to allow pre-
cipitate formation. Cells were washed twice with PBS, resuspended in 3ml
medium and the calcium phosphate co-precipitate was added. Cells were
incubated for 8 hours and washed twice with medium.
2.5 M CaCl2
2.5 M tissue-culture grade CaCl2 (Sigma-Aldrich) were dissolved in
ddH2O, filter-sterilised and stored at −20°C
2× HeBS buffer
280mM NaCl, 50mM HEPES and 1.5mM Na2HPO4 were dissolved in
ddH2O, adjusted to pH 7.05, filter-sterilised and stored at 4°C for up
to one month
3.3.8 Lipofection
The negatively charged plasmid DNA forms complexes with cationic lipids.
Such complexes are then able to cross the membranes of cells and cell nu-
clei (Felgner et al., 1987).
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FectoFly™ II (Polyplus, Illkirch, France)
SL2 cells were seeded in six-well-plates (2×106 cells, 1.6ml medium) and
incubated for 3 hours. In a reaction tube, 9µg plasmid DNA coding for an
immunocytokine were mixed with 0.45µg DNA of the hygromycin B resis-
tance plasmid pCoHygro (#1080) and 100µl of a 150mM NaCl solution. In
a second tube, 9µl FectoFly™ II were mixed with 100µl of a 150mM NaCl
solution. The contents of the second tube were added to the first tube,
vortexed for 10s and incubated for 30min at room temperature to allow
complex formation. Finally, cells were transfected by adding the DNA com-
plexes and incubated overnight.
Fugene™ HD (Roche Diagnostics)
SL2 cells were seeded in six-well-plates (2×106 cells, 1.6ml medium) and
incubated for 3 hours. In a reaction tube, 2µg plasmid DNA coding for an
immunocytokine were mixed with 0.1µg DNA of the hygromycin B resis-
tance plasmid pCoHygro (#1080). Sterile ddH2O was added to a final vol-
ume of 100µl. To allow complex formation, 5µl Fugene™ HD were added,
thoroughly mixed for 2s and incubated for 15min at room temperature. Fi-
nally, cells were transfected by adding the DNA complexes and incubated
overnight.
Insectogene™ (Biontex, Planegg, Germany)
SL2 cells were seeded in six-well-plates (2×106 cells, 1.6ml medium) and
incubated for 3 hours. In a reaction tube, 5µg plasmid DNA coding for an
immunocytokine were mixed with 0.25µg DNA of the hygromycin B resis-
tance plasmid pCoHygro (#1080). Serum-free medium was added to a final
volume of 100µl. In a second tube, 32µl Insectogene™ were mixed with
68µl serum-free medium. The contents of the first tube were added to the
second tube, mixed and incubated for 15min at room temperature to al-
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low complex formation. Cells were washed with medium, transfected by
adding the DNA complexes and incubated overnight.
3.3.9 Selection of stably transfected cells
Stably transfected clones were selected by adding hygromycin B
(300µg/ml; InvivoGen) to the medium 24 hours after transfection. Cells
were cultured until colonies appeared and subcloned.
3.3.10 FibraStage™ bioreactor
The FibraStage™ system (New Brunswick Scientific) is a bioreactor for
up to four FibraStage™ bottles. Each bottle is a closed system that can
be filled with 500ml medium and contains 10g of FibraCel™ disks with
a total surface area of 12000cm2 for cell adhesion. Bottles are locked in
a holder and medium is pumped through the FibraCel™ disk layer by
the programmable vertical motion of a platform. SL2 cells stably trans-
fected with plasmid DNA coding for an immunocytokine were cultured
in the FibraStage™ system at room temperature with the programs given
in table 3.1. Medium was replaced by 450ml fresh medium three times a
week.
A FibraStage™ bottle was inoculated with 2×108 SL2 cells suspended in
30ml conditioned medium, and 470ml fresh medium were added. The
FibraStage™ system was programmed for “inoculation” and started im-
mediately. After 4 hours, the FibraStage™ system was switched to the
“growth” program. Protein production was induced after 6 days by addi-
tion of CuSO4 in a final concentration of 500µM, and the FibraStage™ sys-
tem was switched to the “production” program. Three to five weeks later,
FibraStage™ bottle and cells were discarded. Culture parameters for an
initial run of the FibraStage™ bioreactor are given in figure 3.1. In con-
trast to the information given in the manufacturer’s protocol, cell growth
in FibraStage™ bottles couldn’t be monitored.
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Figure 3.1: FibraStage™ culture parameters. A FibraStage™ bottle was inocu-
lated with SL2 cells (2×108 cells, 30ml growth medium). Fresh growth medium
(470ml) was added immediately and the FibraStage™ system was run with the
“growth” program. After 8 days, the system was switched to the “production” pro-
gram. Medium was replaced every few days by 450ml fresh growth medium and
pH of culture supernatants was determined. Protein production was induced after
3 days by adding CuSO4 (final concentration: 500µM). In growth phase and from
days 15 to 27, culture medium was supplemented with 10% (v/v) heat-inactivated
FCS. Lower figure: graphical representation of supplements that were added to the
culture medium.
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Table 3.1: FibraStage™ programs for the cultivation of SL2 cells. The programs
given in this table control the vertical movement of a platform pumping medium
through FibraStage™ bottles. The speed parameters control mixing of the medium,
whereas the delay parameters influence gas and nutrient exchange.
Program Duration Up Speed Top Delay
Down Speed Bottom Delay
Inoculation 4h 2.0mm/s 20s
2.0mm/s 0s
Growth 6d 1.0mm/s 10s
1.0mm/s 180s
Production ad libitum 1.0mm/s 10s
1.0mm/s 1800s
3.3.11 Isolation of peripheral blood mononuclear cells
Human peripheral blood mononuclear cells (PBMC) were isolated from
fresh blood or buffy coats of healthy donors by density gradient centrifuga-
tion on an isosmotic polysaccharide solution with a density of 1.077g/ml.
Erythrocytes and polymorphonuclear leukocytes migrate through the gra-
dient and serum remains above the gradient, while monocytes, lympho-
cytes and platelets accumulate at the boundary between blood sample and
gradient.
Buffy coats were diluted 1 : 2 with PBS, whereas fresh blood was used undi-
luted. In a 50-ml tube, 25ml blood were layered over 15ml Lympho-
prep™ (Axis-Shield, Oslo, Norway). The centrifuge’s brake was turned
off and the tube was centrifuged for 30min (700×g, 20°C). PBMCs were
collected, washed three times with PBS and either magnetically sepa-
rated or incubated in RPMI 1640 medium supplemented with 10% (v/v)
FCS, 1000IU/ml human IL-2 and 100ng/ml of the anti-CD3 antibody
OKT3. After 48 hours, PBMCs were cultured in medium supplemented with
10% (v/v) FCS and 400IU/ml human IL-2.
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3.3.12 Magnetic cell separation (MACS™)
T cells or natural killer cells were isolated from PBMCs using “MACS™ Iso-
lation Kits” (Miltenyi Biotech). Erythrocytes and all non-matching lym-
phocyte subsets were labelled with a cocktail of biotinylated antibodies
and bound to magnetic “Anti-Biotin MicroBeads”. Bound cells were then
depleted (negative selection) on columns set-up in a strong magnetic field,
thus yielding highly purified and unlabelled lymphocyte subsets.
MACS™ buffer
0.5% (w/v) BSA were dissolved in “autoMACS™ Rinsing Solution”
(2mM EDTA in PBS, pH 7.2; Miltenyi Biotech), filter-sterilised and
chilled to 4°C (prepared fresh)
Isolation of T cells (MACS™ Pan T Cell Isolation Kit II)
To isolate human T cells, 2×108 freshly isolated human PBMCs were cen-
trifuged for 10min (300×g) and resuspended in 800µl MACS™ buffer. B
cells, NK cells, dendritic cells, monocytes, granulocytes and erythroid cells
were labelled with 200µl “Pan T Cell Biotin-Antibody Cocktail” for 10min
(4°C) and 600µl MACS™ buffer were added. Labelled cells were bound to
400µl “Anti-Biotin MicroBeads” for 15min (4°C). The cells were washed
with MACS™ buffer and resuspended in 1ml MACS™ buffer. An LS Col-
umn™ (Miltenyi Biotech) pre-rinsed with 3ml MACS™ buffer was placed
in a strong magnetic field on top of a sterile 15-ml tube. The cell suspension
was applied and the column was washed three times with 3ml MACS™
buffer. Complete effluent was collected and contained approximately
1×108 T cells (figure 3.2). Isolated T cells were washed three times with
PBS and incubated in RPMI 1640 medium supplemented with 400IU/ml
human IL-2 and 5µg/ml leucoagglutinin (PHA-L). After 48 hours, cells were
washed twice with medium, transferred to a new flask and incubated in
medium supplemented with 1000IU/ml human IL-2.
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Figure 3.2: Purity of isolated lymphocyte subsets. T cells were isolated from hu-
man peripheral blood using the “MACS™ Pan T Cell Isolation Kit II”. Isolated T
cells (2×105 cells; black line) and peripheral blood mononuclear cells as con-
trol (2×105 cells; grey line) were stained with the anti-CD3-FITC antibody or an
isotype-matched FITC-conjugated antibody (dotted line) as control (A). NK cells
were isolated from human peripheral blood using the “MACS™ NK Cell Isola-
tion Kit, human”. Isolated NK cells (2×105 cells; black line) and peripheral blood
mononuclear cells as control (2×105 cells; grey line) were stained with the anti-
CD56-PE antibody or an isotype-matched PE-conjugated antibody (dotted line) as
control (B). Finally, cells were analysed by flow-cytometry. Insets: scatter plots of
the isolated lymphocyte subsets.
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Isolation of natural killer cells (MACS NK Cell Isolation Kit, human)
To isolate human NK cells, 1×108 freshly isolated human PBMCs were cen-
trifuged for 10min (300×g) and resuspended in 400µl MACS™ buffer. T
cells, B cells, stem cells, dendritic cells, monocytes, granulocytes and ery-
throid cells were labelled with 100µl “NK Cell Biotin-Antibody Cocktail, hu-
man” for 10min (4°C) and 300µl MACS™ buffer were added. Labelled cells
were bound to 200µl “NK Cell Anti-Biotin MicroBead Cocktail, human” for
15min (4°C). The cells were washed with MACS™ buffer and resuspended
in 500µl MACS™ buffer. An LS Column™ (Miltenyi Biotech) pre-rinsed
with 3ml MACS™ buffer was placed in a strong magnetic field on top of
a sterile 15-ml tube. The cell suspension was applied and the column was
washed three times with 3ml MACS™ buffer. Complete effluent was col-
lected and contained approximately 8×106 NK cells (figure 3.2). Isolated
NK cells were washed three times with PBS, resuspended in RPMI 1640
medium and used directly.
3.4 Proteins
3.4.1 Preparation of affinity chromatography media
Antibodies and immunocytokines were affinity-purified using either agar-
ose or Sepharose™ coupled to antibodies. Anti-m-IgG agarose was ob-
tained from Sigma-Aldrich and packed into C10/10™ columns (Amer-
sham Biosciences). Polyclonal anti-h-IgG antibodies or the anti-HRS3 anti-
idiotypic antibody 9G10 were coupled to NHS-activated Sepharose™ (GE
Healthcare, Freiburg, Germany) as described below. Coupled media and
packed columns were stored at 4°C and used for up to 25 purifications.
Blocking buffer A
500mM 2-aminoethanol and 500mM NaCl were dissolved in ddH2O,
adjusted to pH 8.3 and degassed (prepared fresh)
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Blocking buffer B
100mM NaOAc and 500mM NaCl were dissolved in ddH2O, adjusted
to pH 4.0 and degassed (prepared fresh)
Coupling of antibodies to HiTrap™ HP columns
A “HiTrap™ NHS-activated HP column” (1ml or 5ml column volume; GE
Healthcare) was prepared for coupling by washing with six column vol-
umes of ice-cold 1mM HCl. One column volume of PBS containing 1mg/ml
antibody was injected and incubated for 60min at room temperature.
Uncoupled NHS-groups were blocked by washing with six column volumes
blocking buffer A, six column volumes blocking buffer B and six column
volumes blocking buffer A. After incubation for 30min at room tempera-
ture, the column was washed with six column volumes blocking buffer B,
six column volumes blocking buffer A and six column volumes blocking
buffer B. Finally, the column was washed with two column volumes PBS
containing 0.1% (w/v) sodium azide and stored at 4°C.
Coupling of antibodies to Sepharose™ beads
Sepharose™ beads were sedimented by centrifugation at 6000×g for
10min.
For coupling, 10ml “NHS-activated Sepharose™ 4 FastFlow” (GE Health-
care) were washed with 150ml of ice-cold 1mM HCl. After washing with
50ml of ice-cold PBS, the beads were resuspended in 20ml PBS contain-
ing 5mg antibody and incubated overnight at 4°C in a moving roller bottle.
Uncoupled NHS-groups were blocked by incubation with 30ml blocking
buffer A for 4 hours at room temperature. The beads were then washed six
times, alternately with 30ml blocking buffer B and 30ml blocking buffer A.
Finally, coupled beads were washed with 30ml PBS, resuspended in 20ml
PBS containing 0.1% (w/v) sodium azide and stored at 4°C.
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3.4.2 Affinity chromatography
Tissue culture supernatants containing antibodies or immunocytokines
were centrifuged for 5min (1000×g) and stored at −20°C until use.
Frozen supernatants (1.5l) containing either antibodies or immunocy-
tokines were thawed in a water bath of 37°C and centrifuged for 10min
(6000×g, 4°C) to clear from cellular debris. Supernatants were transferred
to clean tubes, centrifuged again for 60min (6000×g, 4°C) and vacuum-
filtered through Durapore™ membranes (450nm, 4µg/cm2 protein bind-
ing; Millipore, Schwalbach, Germany).
(A) Supernatants were pumped through a column packed with antibody-
coupled medium (1ml/min, 4°C).
(B) Supernatants were incubated with antibody-coupled Sepharose™
beads in a moving roller bottle for 4 hours (4°C). Beads were col-
lected three times by centrifugation (6000×g, 10min) and packed into
a C10/10™ column (Amersham Biosciences).
The column from A or B was connected to an äktaPrime™ chromatograph
(ambient temperature: 10°C; Amersham Biosciences). After washing with
PBS, protein bound to the column was eluted with 100mM glycine buffer
(pH 3.0) and collected in 1.5-ml tubes pre-loaded with 100µl of 10× PBS.
Finally, the column was washed with PBS containing 0.1% (w/v) sodium
azide. The process was completely automated to ensure consistent pu-
rification results (appendix C). Absorbance at 280nm and conductivity of
effluent were monitored in real-time. Fractions containing protein were
determined from absorbance measurements, pooled in Visking™ dialysis
membranes (size 2; MWCO: 12kDa to 14kDa; Medicell International, Lon-
don, UK) and dialysed overnight against PBS at 4°C.
The dialysed protein solution was concentrated to approximately 1ml
using Vivaspin™ 15 concentrators (4°C; MWCO: 30kDa; Sartorius, Göt-
tingen, Germany). Finally, the protein solution was supplemented with
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3% (v/v) of either heat-inactivated FCS or heat-inactivated normal mouse
serum and stored at −80°C in aliquots of 50µl.
100mM glycine buffer
100mM glycine were dissolved in ddH2O, adjusted to pH 3.0, filter-
sterilised and stored at 4°C for up to one month
3.4.3 Quantification of proteins (Pace et al., 1995)
The molar absorption coefficient of a protein depends on the content of
tryptophan, tyrosine and cystine (disulfide bonds). ² 280nm can be pre-
dicted reliably for proteins containing tryptophan residues:
² 280nm = 5500∗
∑
Trp+1490∗∑Tyr+125∗∑cystine
Concentrations of protein solutions were determined by blanking a spec-
trophotometer with the solvent and measuring absorbance at 330nm and
280nm. Absorbance values were corrected for light scattering and protein
concentrations were calculated using the Beer-Lambert law:
A corr =A 280nm−1.929∗A 330nm
c= A corr
² 280nm∗d
3.4.4 Radiolabelling of immunocytokines
Experiments involving work with radionuclides were supervised by PD Dr.
Stefan Guhlke and carried out at the Klinik und Poliklinik für Nuklearmedi-
zin in Bonn. Jan-Philipp Hering assisted in biodistributions experiments.
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Radiolabelling buffer
0.2 M NaOAc was dissolved in ddH2O, adjusted to pH 5.0 and stored at
room temperature
1 M NaHCO3 buffer
1 M NaHCO3 was dissolved in ddH2O and stored at room temperature
Rudinger reagent solution
380µM (2,5-dioxopyrrolidin-1-yl) 3-(4-hydroxyphenyl) propanoate
(Rudinger reagent; Pierce Endogen) was dissolved in DMSO (pre-
pared fresh)
Chloramine-T solution A
180µM chloramine-T was dissolved in ddH2O (prepared fresh)
Chloramine-T solution B
1.05mM chloramine-T was dissolved in radiolabelling buffer (pre-
pared fresh)
Radiolabelling in presence of chloramine-T (Greenwood et al., 1963)
Immunocytokines were radiolabelled by dissolving approximately 20MBq
Na131I in 10µl PBS and adding 1.7nmol immunocytokine (10mM in PBS)
and 15µl chloramine-T solution A. After incubation for 90s at room tem-
perature, a sample was taken to determine labelling efficiency by thin layer
chromatography (section 3.4.5) and the labelled immunocytokine was im-
mediately desalted (section 3.4.6) and affinity-purified (section 3.4.7).
Coupling to Bolton-Hunter reagent (Bolton and Hunter, 1973)
Bolton-Hunter reagent was freshly prepared by dissolving approximately
50MBq Na131I in 100µl radiolabelling buffer and adding 10µl Rudinger
reagent solution and 10µl chloramine-T solution B. After incubation for
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120s at room temperature, 300µl ddH2O were added and Bolton-Hunter
reagent was extracted with 600µl benzene. Bolton-Hunter reagent was
then condensed to a plastic reaction tube by evaporating 100µl benzene
extract in an air stream. Coupling was started by adding 1.2nmol immuno-
cytokine (8mM in PBS) and 30µl of 1 M NaHCO3 buffer. After incubation for
60min at room temperature, labelling efficiency was determined by thin
layer chromatography (section 3.4.5) and the radiolabelled immunocyto-
kine was desalted (section 3.4.6).
3.4.5 Thin layer chromatography of radiolabelled
immunocytokines
Efficiency of radiolabelling was determined by thin layer chromatogra-
phy. A few microlitres of radiolabelled immunocytokine were spotted on
an ITLC-SG™ strip (Pall, Dreieich, Germany), the strip was placed in an
elution chamber and chromatographed using normal saline (B. Braun) as
mobile phase. When the solvent front had reached the end of the strip,
the ITLC-SG™ strip was removed from the chamber, cut at an RF of 0.5
and radioactivity of both halves was counted by means of a Curiemeter.
Bound radionuclide elutes at an RF below 0.5, whereas unbound radionu-
clide elutes at an RF above 0.5. Labelling efficiency was calculated as fol-
lows:
Labelling efficiency= cpm (RF < 0.5)
cpm total
3.4.6 Desalting of radiolabelled immunocytokines
Radiolabelled protein was desalted to remove chemical reagents and un-
bound radioactivity. The protein solution was diluted in PBS to a final vol-
ume of 500µl and applied to a PD-10™ column (Amersham Biosciences).
The tube used for labelling was washed with 500µl PBS, which was also ap-
plied to the column, and the column was eluted with 9ml PBS. Effluent was
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collected in 1ml-fractions and radioactivity of each fraction was counted
by means of a Curiemeter. Fraction #4 contained the main amount of radi-
olabelled protein and was used for biodistribution experiments. Elution of
unbound radioactivity started at fraction #8.
3.4.7 Affinity chromatography of radiolabelled
immunocytokines
Radiolabelled immunocytokine was affinity-purified using the anti-
idiotypic antibody 9G10 coupled to a HiTrap™ HP column (column vol-
ume: 1ml). Desalted immunocytokine was applied to the column and the
tube that had contained the immunocytokine was washed with 1ml PBS,
which was also applied to the column. Effluent was twice re-applied to
the column to ensure quantitative binding of the immunocytokine. The
column was then washed with PBS until radioactivity of 1ml effluent was
below 0.001MBq (Curiemeter). Bound immunocytokine was eluted with
100mM glycine buffer (pH 3.0) in steps of 250µl (first 5ml) or 1ml and
radioactivity of each fraction was counted by means of a γ-counter. To
raise pH to 7.2, 12.5µl of 1 M NaHCO3 buffer were added to the first twenty
fractions. Fractions #7 and #8 were pooled and used for biodistribution
experiments. Finally, the column was washed with 25ml PBS containing
0.1% (w/v) sodium azide and stored at 4°C.
3.5 Assays
3.5.1 Enzyme-linked immunosorbent assay (ELISA; Engvall
and Perlmann, 1971)
Unless mentioned otherwise, incubations were carried out at room tem-
perature on a shaker.
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MaxiSorp™ microtitre plates (Nunc, Langenselbold, Germany) were
coated with capture antibody for 120min (1µg/ml in PBS, 50µl/well). To
block unspecific binding, plates were incubated overnight with 3% (w/v)
BSA dissolved in PBS (200µl/well, 4°C, not shaken) and washed five times
with PBS-T (200µl/well). Plates were incubated with supernatants or serial
dilutions of samples for 60min (50µl/well) and washed five times with
PBS-T (200µl/well). Wells were then incubated with biotinylated detection
antibody for 60min (200ng/ml to 500ng/ml in PBS, 50µl/well) and plates
were washed five times with PBS-T (200µl/well). Bound detection antibod-
ies were conjugated to streptavidin-β-peroxidase for 30min (50mU/ml in
PBS, 50µl/well; Roche Diagnostics) and plates were washed five times with
PBS-T (200µl/well). Finally, conjugated antibodies were visualised by incu-
bation with the substrate ABTS (1mg/ml in ABTS Buffer, 50µl/well; Roche
Diagnostics) and detected by means of a microtitre plate reader (405nm
with 490nm as reference). Concentrations of samples were calculated by
one of the following methods:
(A) The absorption curve of a standard with known concentration was fit-
ted to a three-parameter logistic model. Sample concentrations were
then calculated by comparing the absorption of a sample with the fit-
ted standard curve.
(B) Absorption curves of each sample were fitted to a three-parameter lo-
gistic model. ED50 values were calculated from fitted curves and com-
pared with the ED50 value of a standard with known concentration.
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The following ELISA tests were carried out:
Antigen Capture
antibody 1
Detection
antibody 2
Detection limit
human IgG /
human Fcγ1
anti-human
IgG 3
anti-human IgG
(biotin) 3 4
1ng/ml
murine IgG /
murine Fcγ1
anti-mouse
IgG 3
anti-mouse IgG
(biotin) 3
500pg/ml
human IL-2 anti-human
IL-2
anti-human IL-2
(biotin)
10IU/ml
murine IL-12 anti-mouse
IL-12
anti-mouse IL-12
(biotin)
500pg/ml
human IFN-γ anti-human
IFN-γ
anti-human
IFN-γ (biotin)
20pg/ml
immunocyto-
kine
9G10 (anti-
idiotype)
anti-human IgG
(biotin) 3
30pM
immunocyto-
kine
9G10 (anti-
idiotype)
anti-human IL-2
(biotin)
60pM
immunocyto-
kine
9G10 (anti-
idiotype)
anti-mouse IL-12
(biotin)
30pM
murine IgG
(in sera)
HRS3scFv-Fc anti-mouse IgG
(biotin) 3 4
15ng/ml
1 1µg/ml in PBS
2 500ng/ml in PBS
3 polyclonal antibody
4 200ng/ml in PBS
PBS-T
0.1% (v/v) polysorbate 20 (Tween™ 20; Merck) was dissolved in PBS
and stored at room temperature
49
Methods
3.5.2 Binding inhibition
Binding inhibition was determined by means of ELISA. MaxiSorp™ mi-
crotitre plates (Nunc) were coated with capture antibody and unspecific
binding was blocked as described in section 3.5.1. Serial dilutions of
a competitor or PBS as control (50µl/well) were mixed with a constant
amount of immunocytokine (50µl/well). Plates were incubated for 60min
on a shaker (50µl/well, room temperature) and washed five times with
PBS-T (200µl/well). Plates were then incubated with detection antibody,
streptavidin-β-peroxidase and ABTS as described in section 3.5.1. Absorp-
tion of each well was detected by means of a microtitre plate reader (405nm
with 490nm as reference). Binding inhibition was calculated as follows:
Inhibition= 1 − A immunocytokine with competitor
A immunocytokine without competitor
3.5.3 Radioimmunoassay (RIA; Yalow and Berson, 1960)
Unless mentioned otherwise, incubations were carried out at room tem-
perature on a shaker.
PolySorp™ tubes (Nunc) were coated with capture antibody for 120min
(2µg/ml in PBS, 400µl/tube). To block unspecific binding, tubes were in-
cubated overnight with 3% (w/v) BSA dissolved in PBS (3ml/tube, 4°C, not
shaken) and washed five times with PBS (3ml/tube). Tubes were then in-
cubated with serial dilutions of radiolabelled immunocytokine for 60min
(400µl/tube). After washing five times with PBS (3ml/tube), radioactivity
in each tube was counted by means of a γ-counter.
Alternatively, PolySorp™ LockWell™ strips (Nunc) were coated with cap-
ture antibody for 120min (1µg/ml in PBS, 50µl/well). To block unspe-
cific binding, strips were incubated overnight with 3% (w/v) BSA dissolved
in PBS (200µl/well, 4°C, not shaken) and washed five times with PBS-T
(200µl/well). Strips were then incubated with serial dilutions of radiola-
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belled immunocytokine for 60min (50µl/well). After washing five times
with PBS-T (200µl/well), strips were broken apart and radioactivity in each
well was counted by means of a γ-counter.
3.5.4 Immunofluorescence
Unless mentioned otherwise, incubations were carried out at 4°C in the
dark. PBS for washing was pre-chilled to 4°C. Antibodies were diluted ac-
cording to the manufacturer’s instructions.
(A) For immunofluorescence, 2×105 cells were washed with PBS, stained
with a fluorochrome-conjugated antibody for 30min and washed
three times with PBS.
(B) For indirect immunofluorescence, 2×105 cells were washed with PBS,
stained with an antibody for 30min and washed three times with PBS.
Bound antibody was detected by incubation with a fluorochrome-
conjugated antibody for 30min. Finally, cells were washed three times
with PBS.
(C) To determine binding of immunocytokines to cells, 2×105 cells were
washed with PBS, incubated with 4pmol immunocytokine for 30min
on ice and washed three times with PBS. Bound immunocytokine was
detected by incubation with the anti-h-IgG1-PE antibody for 30min.
Finally, cells were washed three times with PBS.
Stained cells from A, B or C were analysed by means of a FACSCanto™ flow
cytometer (BD Biosciences). Immunofluorescence data were analysed by
plotting two-dimensional scatter plots and gating the relevant cell subsets.
Density curves with a fixed area of 1 were then calculated from the detected
fluorescence of gated cells. The smoothing bandwidth of density curves
was adapted to each experiment. Data were transformed using the asinh10
transformation (figure 3.3).
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Figure 3.3: The asinh10 transformation. In flow-cytometry analysis, an asi nh
transformation was used instead of logarithmic transformations to avoid prob-
lems for values x ≤ 0. The transformation asi nh(x)/ln(10)− log10(2) was termed
asi nh10 to indicate that values are close to l og10(x) for x > 1 and identical for
x > 1000.
3.5.5 Proliferation of peripheral blood mononuclear cells
Proliferation of activated peripheral blood mononuclear cells (PBMC)
was determined by incorporation of the thymidine analogue 5-bromo-2’-
deoxyuridine (BrdU) and subsequent detection by ELISA. MaxiSorp™ mi-
crotitre plates that were used to culture PBMCs were handled aseptically.
Pre-activated PBMCs were washed three times with growth medium, trans-
ferred to a new flask and cultured in fresh medium without added IL-2.
After 24 hours, PBMCs were washed three times with medium and used.
MaxiSorp™ microtitre plates (Nunc) were coated with capture antibody
for 120min on a shaker (5µg/ml in PBS, 50µl/well, room temperature). To
block unspecific binding, plates were incubated overnight with 10% (v/v)
FCS in RPMI 1640 medium (200µl/well, 4°C) and washed three times with
PBS (200µl/well). One plate was incubated with 4pmol filter-sterilised
immunocytokine dissolved in growth medium for 60min on a shaker
(100µl/well, room temperature) and washed three times with PBS. Each
well was then filled with 100µl medium. A second plate was incubated with
4pmol filter-sterilised immunocytokine dissolved in medium for 60min
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on a shaker (100µl/well, room temperature). PBMCs were added to both
plates (2.5×104 cells/well, 100µl/well) and cultured for up to 96 hours. As
blank, one well of each plate was incubated with 200µl medium alone.
BrdU (Roche Diagnostics) dissolved in PBS was added to the plates in a
final concentration of 10nM and PBMCs were cultured for an additional 8
to 12 hours. Plates were centrifuged for 10min (300×g) and supernatants
were removed by suction. The empty plates were dried for 15min using a
hair-dryer and stored at 4°C for up to 7 days.
The following incubations were carried out at room temperature on a
shaker. PBMCs were fixed by incubation with FixDenat™ for 30min
(100µl/well; Roche Diagnostics) and plates were emptied by flicking.
Incorporated BrdU was detected by incubation with the peroxidase-
conjugated anti-BrdU antibody for 90min (50µl/well) and plates were
washed three times with PBS. Bound conjugated antibody was visualised
by incubation with the substrate ABTS (1mg/ml in ABTS Buffer, 50µl/well;
Roche Diagnostics) and detected by means of a microtitre plate reader
(405nm with 490nm as reference).
3.5.6 Cytolysis of tumour cells (Jost et al., 1992)
To determine cytolysis of tumour cells mediated by immunocytokines,
5×104 tumour cells were suspended in 100µl filter-sterilised RPMI 1640
medium containing 5ng immunocytokine. After incubation for 60min on
ice, cells were washed three times with medium and resuspended in 100µl
medium. Tumour cells were plated in one well of a round-bottom mi-
crotitre plate and 100µl RPMI 1640 medium containing either 4×104 hu-
man NK cells or no cells were added. Plates were cultured for 24 hours and
100µl supernatant were removed from each well. Viability of NK cells and
tumour cells was visualised by adding 50µl medium, 50µl XTT reagent so-
lution and 1µl electron coupling reagent solution to each well. Plates were
incubated at 37°C and absorption was detected after 30min, 60min and
90min by means of a microtitre plate reader (450nm with 650nm as refer-
ence).
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Cytolysis was calculated as follows:
Cytolysis= 1 − A tumour cells with NK cells−A NK cells
A tumour cells−A medium
Electron coupling reagent solution
1.25mM phenazine methylsulfate was dissolved in PBS, filter-
sterilised and stored at −20°C
XTT reagent solution
1mg/ml XTT sodium salt (Biomol, Hamburg, Germany) was dis-
solved in RPMI 1640 medium containing 10% (v/v) FCS, filter-
sterilised and stored at −20°C
3.5.7 Phosphorylation of STAT4 (Uzel et al., 2001)
Pre-activated human T cells were washed twice with serum-free medium,
transferred to a new flask and cultured in serum-free medium. After
24 hours, T cells were washed with medium, 2×105 T cells were resus-
pended in 100µl PBS containing 2% (v/v) FCS and 10µl of 20nM immuno-
cytokine or murine IL-12 were added. Reaction tubes were incubated for
30min in a water bath of 37°C, 110µl pre-warmed “BD Cytofix Buffer” (BD
Pharmingen) were added and the reaction tubes were returned to the wa-
ter bath for 10min. Cells were washed with ice-cold PBS, suspended in 1ml
ice-cold “Phosflow™ Perm Buffer III” (BD Pharmingen) and permeabilised
for 30min on ice. Cells were washed twice with ice-cold “Stain Buffer FBS”
(BD Pharmingen) and stained with 20µl of the anti-pSTAT4-PE antibody
for 30min (room temperature, in the dark). Cells were washed with ice-
cold “Stain Buffer FBS” and fluorescence was determined by means of a
FACSCanto™ flow cytometer (BD Biosciences).
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3.6 Experiments on mice
Experiments on mice were approved by Bezirksregierung Köln. Mice were
obtained from Charles River Laboratories (Sulzfeld, Germany) and 8 to 12
weeks old. The animals were maintained at 20°C under SPF conditions.
Injections were carried out by Samir-Ghali Tawadros. For calculations, we
assumed that the blood volume of an average mouse (20g) amounted to
1.5ml.
3.6.1 Biodistribution
Female SCID mice received s.c. injections of 3×107 L540Cy cells in one
flank. When the animals had developed tumours after three to five weeks,
immunocytokine was radiolabelled (section 3.4.4). Mice received injec-
tions of radiolabelled immunocytokine into the tail vein and were sacri-
ficed after 12, 24, 48 or 72 hours. Organs were recovered, weighed and ra-
dioactivity was counted by means of a γ-counter. Detected counts were
compensated for radioactive decay. For every organ and point in time, the
injected dose per gram of tissue (% ID/g) was calculated:
%ID/g= A organ
A injected∗m organ
∗100 %
Tissue retention was calculated as % ID/g (72h) divided by % ID/g (24h).
3.6.2 Tumour growth in mice
Tumour cells were suspended in 200µl of sterile PBS and s.c. injected. To
show that cells were viable and free of contaminations, tumour cells re-
maining from injections were re-cultured for a week. Tumour size was
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measured three to seven times a week by means of a calliper and calcu-
lated as follows:
V tumour = height∗width∗depth
2
After mice had been sacrificed, tumour tissue was recovered, embedded in
“Tissue-Tek™ O.C.T Compound” (Sakura Finetek, Staufen, Germany) and
frozen at −80°C.
3.6.3 Serum samples
Blood samples from mice were taken after warming the tail under infrared
light. The tail was disinfected with 70% (v/v) ethanol and the dilated tail
vein was cut with a sterile scalpel. Blood drops were caught in a reaction
tube and bleeding was stopped by applying gentle pressure with a gauze
pad. The tube was transferred to a refrigerator and blood was allowed to
clot overnight at 4°C. After centrifugation for 15min (600×g, room temper-
ature), serum was transferred to a new reaction tube and stored at−80°C.
3.7 Statistics
The statistical language R 2.9 (R Development Core Team, 2009) was used
to plot graphs and calculate statistics. Absorption curves from ELISA ex-
periments were fitted to three-parameter logistic models using the R add-
on package drc 1.7 (Ritz and Streibig, 2005) and fitting was visually con-
trolled.
Normal distribution of samples was assumed. To determine significance of
a difference between two groups, samples were tested by an unpaired two-
sided Welch-corrected t-test. The null hypothesis that there was no differ-
ence between groups was rejected for p-values of 0.05 and below. Binding
56
Statistics
inhibition (section 3.5.2) and cytolysis of tumour cells (section 3.5.6) were
calculated prior to statistical analysis. Control values marked with an as-
terisk were averaged before use:
Cytolysis= 1 − A tumour cells with NK cells−A
∗
NK cells
A∗tumour cells−A∗medium
Inhibition= 1 − A immunocytokine with competitor
A immunocytokine without competitor
All experiments were repeated at least once with similar results, except for
the cytolysis of tumour cells and experiments on mice.
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4 Results
4.1 Immunocytokines are expressed in insect cells
The objective of this study was to compare the novel anti-CD30 immu-
nocytokine HRS3scFv-hi-IL12-Fc-IL2 (combined IL-2 and IL-12 domains)
with the immunocytokines HRS3scFv-Fc-hi-IL12 (IL-12 domain), HRS3-
scFv-Fc-IL2 (IL-2 domain) and the fusion protein HRS3scFv-Fc (without
cytokine domains). An experimental prerequisite was the production of
large amounts of purified protein within a reasonable time frame. Tra-
ditional cell culture methods were laborious and unlikely to yield the re-
quired protein concentrations. We used the FibraStage™ bioreactor for
bulk protein production, as it allowed cell culture in high densities and si-
multaneous expression of up to four different recombinant proteins, while
still being easy to handle.
We expressed immunocytokines in Schneider’s Drosophila line 2 (SL2)
cells. Therefore, expression cassettes coding for immunocytokines were in-
serted into the Drosophila Expression System™ DNA vector pMT/BiP V5-
His A (#1070). Finally, a transfection method for stable expression in SL2
cells was established.
The DNA plasmids pMT/BiP SCA431scFv-Fc (#1103), pMT/BiP SCA431-
scFv-Fc-IL7 (#1117) and pMT/BiP SCA431scFv-Fc-IL15 (#1118) were solely
generated for the “Adoptive engineered T cell targeting to activate cancer
killing” (ATTACK) project of the European Union. As these plasmids have
been used to determine a suitable transfection method for insect cells,
however, their generation is described in sections 4.1.6 to 4.1.8.
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4.1.1 Generation of the plasmid pBullet HRS3scFv-CD3ζ
(#1078)
To ease insertion of existing expression cassettes into the Drosophila Ex-
pression System™ DNA vector, DNA coding for the anti-CD30 scFv HRS3
was flanked by restriction sites needed for subsequent cloning procedures
and inserted into the DNA vector pBullet.
DNA coding for the anti-CD30 scFv HRS3 was amplified from the plasmid
pRSV-Lk HRS3scFv-Fc (#440) by PCR using the oligonucleotides HRS3-
pMT-S and S-HRS3-hi-Bam. The amplified DNA was thereby flanked with
the restriction sites NcoI at the 5’ end and BamHI at the 3’ end. The 0.75kb
DNA fragment was purified and digested by the restriction enzymes NcoI
and BamHI. The plasmid DNA pBullet-Lk CC49scFv-Fc-CD3ζ (#435) was
also digested by the restriction enzymes NcoI and BamHI, thereby deleting
the Lk CC49-Fc DNA. The two DNA fragments were purified and ligated to
generate the new plasmid pBullet HRS3scFv-CD3ζ (#1078; figure 4.1). The
newly generated plasmid was transformed into Escherichia coli for ampli-
fication and the recombined expression cassette was verified by DNA se-
quencing (appendix B.1).
4.1.2 Generation of the plasmid pMT/BiP HRS3scFv-Fc (#1082)
To allow expression of the anti-CD30 fusion protein HRS3scFv-Fc in insect
cells, an expression cassette coding for the fusion protein was inserted into
the DNA vector pMT/BiP V5-His A (#1070).
DNA coding for the scFv HRS3 was isolated from the plasmid pBul-
let HRS3scFv-CD3ζ (#1078) by digestion with NcoI and BamHI. DNA cod-
ing for the Fc region of human IgG1 was isolated by digesting the plas-
mid pRSV-Lk HRS3scFv-Fc (#440) with BamHI and XhoI. The vector DNA
pMT/BiP V5-His A (#1070) was digested by the restriction enzymes NcoI
and XhoI to allow insertion of the expression cassette into the MCS.
The three DNA fragments were purified and ligated to generate the new
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Figure 4.1: Generation of the plasmid pBullet HRS3scFv-CD3ζ (#1078). DNA
coding for the anti-CD30 scFv HRS3 was amplified from the plasmid pRSV-
Lk HRS3scFv-Fc (#440) by PCR using the oligonucleotides HRS3-pMT-S and S-
HRS3-hi-Bam. The 0.75kb DNA fragment was purified and digested by NcoI and
BamHI. The plasmid DNA pBullet-Lk CC49scFv-Fc-CD3ζ (#435) was also digested
by NcoI and BamHI. The two DNA fragments were purified and ligated to generate
the new plasmid pBullet HRS3scFv-CD3ζ (#1078).
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plasmid pMT/BiP HRS3scFv-Fc (#1082; figure 4.2). The newly generated
plasmid was transformed into Escherichia coli for amplification and the
recombined expression cassette was verified by DNA sequencing (ap-
pendix B.2).
4.1.3 Generation of the plasmid pMT/BiP HRS3scFv-Fc-hi-IL12
(#1083)
To allow expression of the anti-CD30 immunocytokine HRS3scFv-Fc-hi-
IL12 in insect cells, an expression cassette coding for the immunocytokine
was inserted into the DNA vector pMT/BiP V5-His A (#1070).
DNA coding for the scFv HRS3 was isolated from the plasmid pBul-
let HRS3scFv-CD3ζ (#1078) by digestion with NcoI and BamHI. DNA cod-
ing for the Fc region of human IgG1, the hinge region of human IgG1 and
murine single-chain IL-12 (p40-p35) was isolated by digesting the plasmid
pRSV-Lk HRS3scFv-Fc-hi-IL12 (#619) with BamHI and XhoI. The vector
DNA pMT/BiP V5-His A (#1070) was digested by the restriction enzymes
NcoI and XhoI to allow insertion of the expression cassette into the MCS.
The three DNA fragments were purified and ligated to generate the new
plasmid pMT/BiP HRS3scFv-Fc-hi-IL12 (#1083; figure 4.3). The newly gen-
erated plasmid was transformed into Escherichia coli for amplification and
the recombined expression cassette was verified by DNA sequencing (ap-
pendix B.3).
4.1.4 Generation of the plasmid pMT/BiP HRS3scFv-Fc-IL2
(#1086)
To allow expression of the anti-CD30 immunocytokine HRS3scFv-Fc-IL2
in insect cells, an expression cassette coding for the immunocytokine was
inserted into the DNA vector pMT/BiP V5-His A (#1070).
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Figure 4.2: Generation of the plasmid pMT/BiP HRS3scFv-Fc (#1082). DNA cod-
ing for the scFv HRS3 was isolated from the plasmid pBullet HRS3scFv-CD3ζ
(#1078) by digestion with NcoI and BamHI. DNA coding for the Fc region of hu-
man IgG1 was isolated by digesting the plasmid pRSV-Lk HRS3scFv-Fc (#440) with
BamHI and XhoI. The vector DNA pMT/BiP V5-His A (#1070) was digested by NcoI
and XhoI. The three DNA fragments were purified and ligated to generate the new
plasmid pMT/BiP HRS3scFv-Fc (#1082).
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Figure 4.3: Generation of the plasmid pMT/BiP HRS3scFv-Fc-hi-IL12 (#1083).
DNA coding for the scFv HRS3 was isolated from the plasmid pBullet HRS3scFv-
CD3ζ (#1078) by digestion with NcoI and BamHI. DNA coding for the Fc region
of human IgG1, the hinge region of human IgG1 and murine single-chain IL-12
(p40-p35) was isolated by digesting the plasmid pRSV-Lk HRS3scFv-Fc-hi-IL12
(#619) with BamHI and XhoI. The vector DNA pMT/BiP V5-His A (#1070) was di-
gested by NcoI and XhoI. The three DNA fragments were purified and ligated to
generate the new plasmid pMT/BiP HRS3scFv-Fc-hi-IL12 (#1083).
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DNA coding for the scFv HRS3, the Fc region of human IgG1 and human
IL-2 was amplified from the plasmid pRSV-Lk HRS3scFv-Fc-IL2 (#508) by
PCR using the oligonucleotides HRS3-pMT-S and IL-2SX. The amplified
DNA was thereby flanked with the restriction sites NcoI at the 5’ end and
XhoI at the 3’ end. The 1.9kb DNA fragment was purified and digested by
the restriction enzymes NcoI and XhoI. The vector DNA pMT/BiP V5-His A
(#1070) was also digested by the restriction enzymes NcoI and XhoI to allow
insertion of the expression cassette into the MCS. The two DNA fragments
were purified and ligated to generate the new plasmid pMT/BiP HRS3scFv-
Fc-IL2 (#1086; figure 4.4). The newly generated plasmid was transformed
into Escherichia coli for amplification and the recombined expression cas-
sette was verified by DNA sequencing (appendix B.4).
4.1.5 Generation of the plasmid
pMT/BiP HRS3scFv-hi-IL12-Fc-IL2 (#1100)
To allow expression of the anti-CD30 immunocytokine HRS3scFv-hi-IL12-
Fc-IL2 in insect cells, an expression cassette coding for the immunocyto-
kine was inserted into the DNA vector pMT/BiP V5-His A (#1070).
DNA coding for the scFv HRS3, the hinge region of human IgG1, murine
single-chain IL-12 (p40-p35), the Fc region of human IgG1 and human IL-2
was amplified from the plasmid pRSV-Lk HRS3scFv-hi-IL12-Fc-IL2 (#715)
by PCR using the oligonucleotides HRS3-pMT-S and IL-2SX. The amplified
DNA was thereby flanked with the restriction sites NcoI at the 5’ end and
XhoI at the 3’ end. The 3.5kb DNA fragment was purified and digested by
the restriction enzymes NcoI and XhoI. The vector DNA pMT/BiP V5-His A
(#1070) was also digested by the restriction enzymes NcoI and XhoI to allow
insertion of the expression cassette into the MCS. The two DNA fragments
were purified and ligated to generate the new plasmid pMT/BiP HRS3scFv-
hi-IL12-Fc-IL2 (#1100; figure 4.5). The newly generated plasmid was trans-
formed into Escherichia coli for amplification and the recombined expres-
sion cassette was verified by DNA sequencing (appendix B.5).
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Figure 4.4: Generation of the plasmid pMT/BiP HRS3scFv-Fc-IL2 (#1086). DNA
coding for the scFv HRS3, the Fc region of human IgG1 and human IL-2 was ampli-
fied from the plasmid pRSV-Lk HRS3scFv-Fc-IL2 (#508) by PCR using the oligonu-
cleotides HRS3-pMT-S and IL-2SX. The 1.9kb DNA fragment was purified and di-
gested by NcoI and XhoI. The vector DNA pMT/BiP V5-His A (#1070) was also di-
gested by NcoI and XhoI. The two DNA fragments were purified and ligated to gen-
erate the new plasmid pMT/BiP HRS3scFv-Fc-IL2 (#1086).
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Figure 4.5: Generation of the plasmid pMT/BiP HRS3scFv-hi-IL12-Fc-IL2
(#1100). DNA coding for the the scFv HRS3, the hinge region of human IgG1,
murine single-chain IL-12 (p40-p35), the Fc region of human IgG1 and human IL-2
was amplified from the plasmid pRSV-Lk HRS3scFv-hi-IL12-Fc-IL2 (#715) by PCR
using the oligonucleotides HRS3-pMT-S and IL-2SX. The 3.5kb DNA fragment was
purified and digested by NcoI and XhoI. The vector DNA pMT/BiP V5-His A (#1070)
was also digested by NcoI and XhoI. The two DNA fragments were purified and
ligated to generate the new plasmid pMT/BiP HRS3scFv-hi-IL12-Fc-IL2 (#1100).
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4.1.6 Generation of the plasmid pMT/BiP SCA431scFv-Fc
(#1103)
The expression cassette coding for the anti-CEA fusion protein SCA431-
scFv-Fc was generated and inserted into the Drosophila Expression Sys-
tem™ DNA vector pMT/BiP V5-His A (#1070).
DNA coding for the scFv SCA431 and the Fc region of murine IgG1 was am-
plified from the plasmid pBullet-Lk SCA431scFv-Fc-CD4tm-CD3ζ (#977)
by PCR using the oligonucleotides pMT-SCA431-S and pMT-SCA431-AS.
The amplified DNA was thereby flanked with the restriction sites NcoI at
the 5’ end and NotI at the 3’ end. In addition, the C-terminal lysine of
the murine Fc region – that had been changed to isoleucine by previous
cloning procedures – was restored. The 1.4kb DNA fragment was puri-
fied and digested by the restriction enzymes NcoI and NotI. The vector
DNA pMT/BiP V5-His A (#1070) was also digested by the restriction en-
zymes NcoI and NotI to allow insertion of the expression cassette into the
MCS. The two DNA fragments were purified and ligated to generate the
new plasmid pMT/BiP SCA431scFv-Fc (#1103; figure 4.6). The newly gen-
erated plasmid was transformed into Escherichia coli for amplification and
the recombined expression cassette was verified by DNA sequencing (ap-
pendix B.6).
4.1.7 Generation of the plasmid pMT/BiP SCA431scFv-Fc-IL7
(#1117)
The expression cassette coding for the anti-CEA immunocytokine SCA431-
scFv-Fc-IL7 was generated and inserted into the Drosophila Expression
System™ DNA vector pMT/BiP V5-His A (#1070).
DNA coding for murine IL-7 was amplified from the plasmid pJR IL7
(#1024) by PCR using the oligonucleotides pMT-mIL7-BstX-S and pMT-
mIL7-Not-AS. The amplified DNA was thereby flanked with the restriction
sites BstXI at the 5’ end and NotI at the 3’ end. The 0.4kb DNA fragment
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Figure 4.6: Generation of the plasmid pMT/BiP SCA431scFv-Fc (#1103). DNA
coding for the scFv SCA431 and the Fc region of murine IgG1 was amplified
from the plasmid pBullet-Lk SCA431scFv-Fc-CD4tm-CD3ζ (#977) by PCR using the
oligonucleotides pMT-SCA431-S and pMT-SCA431-AS. The 1.4kb DNA fragment
was purified and digested by NcoI and NotI. The vector DNA pMT/BiP V5-His A
(#1070) was also digested by NcoI and NotI. The two DNA fragments were purified
and ligated to generate the new plasmid pMT/BiP SCA431scFv-Fc (#1103).
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was purified and digested by the restriction enzymes BstXI and NotI. The
plasmid DNA pMT/BiP SCA431scFv-Fc (#1103) was also digested by the re-
striction enzymes BstXI and NotI to allow insertion of the amplified DNA.
The two DNA fragments were purified and ligated to generate the new
plasmid pMT/BiP SCA431scFv-Fc-IL7 (#1117; figure 4.7). The newly gen-
erated plasmid was transformed into Escherichia coli for amplification and
the recombined expression cassette was verified by DNA sequencing (ap-
pendix B.7).
4.1.8 Generation of the plasmid pMT/BiP SCA431scFv-Fc-IL15
(#1118)
The expression cassette coding for the anti-CEA immunocytokine SCA431-
scFv-Fc-IL15 was generated and inserted into the Drosophila Expression
System™ DNA vector pMT/BiP V5-His A (#1070).
DNA coding for human IL-15 was amplified from the plasmid pORF IL15
(#844) by PCR using the oligonucleotides pMT-hIL15-BstX-S and pMT-
hIL15-Not-AS. The amplified DNA was thereby flanked with the restriction
sites BstXI at the 5’ end and NotI at the 3’ end. The 0.35kb DNA fragment
was purified and digested by the restriction enzymes BstXI and NotI. The
plasmid DNA pMT/BiP SCA431scFv-Fc (#1103) was also digested by the re-
striction enzymes BstXI and NotI to allow insertion of the amplified DNA.
The two DNA fragments were purified and ligated to generate the new plas-
mid pMT/BiP SCA431scFv-Fc-IL15 (#1118; figure 4.8). The newly gener-
ated plasmid was transformed into Escherichia coli for amplification and
the recombined expression cassette was verified by DNA sequencing (ap-
pendix B.8).
4.1.9 Evaluation of transfection efficiency in insect cells
High transfection efficiencies of expression plasmids in insect cells were
needed to increase the probability to generate high-producer cell clones.
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Figure 4.7: Generation of the plasmid pMT/BiP SCA431scFv-Fc-IL7 (#1117). DNA
coding for murine IL-7 was amplified from the plasmid pJR IL7 (#1024) by PCR
using the oligonucleotides pMT-mIL7-BstX-S and pMT-mIL7-Not-AS. The 0.4kb
DNA fragment was purified and digested by BstXI and NotI. The plasmid DNA
pMT/BiP SCA431scFv-Fc (#1103) was also digested by BstXI and NotI. The two DNA
fragments were purified and ligated to generate the new plasmid pMT/BiP SCA431-
scFv-Fc-IL7 (#1117).
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Figure 4.8: Generation of the plasmid pMT/BiP SCA431scFv-Fc-IL15 (#1118).
DNA coding for human IL-15 was amplified from the plasmid pORF IL15 (#844)
by PCR using the oligonucleotides pMT-hIL15-BstX-S and pMT-hIL15-Not-AS. The
0.35kb DNA fragment was purified and digested by BstXI and NotI. The plas-
mid DNA pMT/BiP SCA431scFv-Fc (#1103) was also digested by BstXI and NotI.
The two DNA fragments were purified and ligated to generate the new plasmid
pMT/BiP SCA431scFv-Fc-IL15 (#1118).
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Figure 4.9: Comparison of transfection procedures for insect cells. SL2 cells were
co-transfected with plasmid DNA coding for the anti-CEA fusion proteins SCA431-
scFv-Fc, SCA431scFv-Fc-IL7 or SCA431scFv-Fc-IL15 by calcium phosphate co-
precipitation of DNA or lipofection with the transfection reagents Fugene™ HD,
Insectogene™ or FectoFly™ II. Protein production was induced after 24 hours by
adding CuSO4 (final concentration: 500µM). Two days later, protein concentra-
tions were detected from culture supernatants by ELISA using antibodies directed
against the murine IgG domain (n.d.: not detected). Each bar corresponds to one
sample.
Therefore, we determined the transfection efficiencies of calcium phos-
phate co-precipitation of DNA or lipofection with the transfection reagents
FectoFly™ II, Fugene™ HD or Insectogene™.
SL2 cells were seeded in six-well-plates and transfected with plasmid DNA
coding for the anti-CEA fusion proteins SCA431scFv-Fc, SCA431scFv-Fc-
IL7 or SCA431scFv-Fc-IL15. Protein production was induced after 24 hours
by addition of CuSO4. Two days later, concentrations of the respective
proteins were determined from supernatants by ELISA of the Fc domain
of IgG1 (Fcγ1) that is present in all of the generated fusion proteins (fig-
ure 4.9).
Transfection efficiencies of each transfection reagent were very similar for
three different plasmids. Transfection of SL2 cells by Fugene™ HD re-
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Figure 4.10: Transfected insect cells secrete immunocytokines. SL2 cells were co-
transfected with plasmid DNA coding for one of the generated anti-CD30 or anti-
CEA fusion proteins and the hygromycin B resistance plasmid pCoHygro (#1080)
using Fugene™ HD. After 24 hours, transfected cells were selected by addition
of hygromycin B (final concentration: 300µg/ml) and protein production was in-
duced by adding CuSO4 (final concentration: 500µM). After 7 days, protein con-
centrations were detected from culture supernatants by ELISA using antibodies di-
rected against the human IgG domain (black bars) or the murine IgG domain (grey
bars). Each bar corresponds to one sample.
sulted in a mean protein concentration of 1.6µg/ml, whereas protein con-
centrations of cells transfected by FectoFly™ II or Insectogene™ were 10-
to 20-fold lower. No protein was detected in SL2 cells transfected by cal-
cium phosphate co-precipitation or mock-transfected cells.
Fugene™ HD was chosen as transfection reagent in further experiments
due to its superior transfection efficiency. In addition, the morphology of
SL2 cells transfected with Fugene™ HD remained unchanged in contrast
to the other transfection reagents.
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4.1.10 Insect cells are stably transfected to express
immunocytokines
We established high-producer cell clones of insect cells that stably ex-
pressed recombinant protein by co-transfection of SL2 cells with the hy-
gromycin B resistance plasmid pCoHygro (#1080) and plasmid DNA coding
for one of the anti-CD30 or anti-CEA fusion proteins. After 24 hours, trans-
fected cells were selected by addition of hygromycin B. Resistant clones
appeared after four weeks and were subcloned (figure 4.10). Protein pro-
duction was induced by adding CuSO4. After 24 hours, supernatants were
screened for expressed protein by ELISA of the Fcγ1 domain that is present
in all of the generated fusion proteins. High-producer cell clones were
raised and stored in liquid nitrogen.
Concentrations of anti-CD30 fusion protein in culture supernatants were
recorded by ELISA using the anti-idiotypic antibody 9G10 and the biotiny-
lated anti-h-IgG antibody which detects the human Fcγ1 domain that is
present in all anti-CD30 fusion proteins. Stably transfected SL2 clones
that were grown in the FibraStage™ bioreactor at an estimated density
of 5×106 cells/ml produced 2mg/l to 8mg/l recombinant fusion protein
within three days. Protein expression was constant over the observation
time of four to five weeks.
4.2 Purified immunocytokines specifically bind to
CD30
In this study, immunocytokines and fusion proteins that contain the Fc
domain of IgG1 (Fcγ1) were affinity-purified and detected using polyclonal
anti-IgG antibodies, whereas the immunocytokine HRS3scFv-hi-IL12
which lacks an Fcγ1 domain was affinity-purified using the monoclonal
anti-idiotypic antibody 9G10. We routinely obtained 0.5mg to 2.0mg pu-
rified protein from 1.5l of cell culture supernatant. Purified proteins were
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stored at −80°C in PBS containing 3% (v/v) of either FCS (in vitro studies)
or normal mouse serum (studies in mice).
Purified immunocytokines and fusion proteins were analysed for integrity
of the protein by binding to the anti-idiotypic antibody 9G10 and detect-
ing the respective Fcγ1 and cytokine domains. Specificity of binding of
the anti-CD30 fusion proteins was determined from binding to the anti-
idiotypic antibody 9G10 or a control antibody with irrelevant specificity,
and by analysing the binding inhibition mediated by CD30. In addition,
we assessed binding of the CD30 fusion proteins to CD30+ and CD30– tu-
mour cells.
In this study, the anti-idiotypic antibody 9G10 that bears the internal im-
age of the HRS3-binding epitope (Pohl et al., 1992) served as a substitute
for immobilised CD30. Validity of this substitute was determined from the
binding inhibition experiment.
The experiments described in this and the next section yielded the same re-
sults for anti-CD30 fusion proteins that had been expressed in either mam-
malian 293T cells or SL2 insect cells. Therefore, the study will not distin-
guish between proteins expressed in either cells.
4.2.1 Detection of the individual domains of purified
immunocytokines
To determine whether immunocytokines were intact after purification and
storage, the HRS3 scFv of anti-CD30 immunocytokines was captured using
the anti-idiotypic antibody 9G10. The human Fcγ1 domain, the human
IL-2 domain and the murine IL-12 domain were detected by ELISA using
antibodies specific to the respective domain (figure 4.11).
Anti-CD30 fusion proteins bound to the anti-idiotypic antibody 9G10 in a
dose-dependant manner. After capturing the HRS3 scFv of purified immu-
nocytokine or the fusion protein HRS3scFv-Fc, all respective protein do-
mains were detected. The resulting curves of the different domains were
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Figure 4.11: Detection of the individual domains of purified immunocytokines.
ELISA plates were coated with the anti-idiotypic antibody 9G10 and incubated with
serial dilutions of purified immunocytokine or the fusion protein HRS3scFv-Fc.
Bound protein was probed with the biotinylated anti-h-IgG, anti-h-IL-2 or anti-m-
IL-12 (p40/p70) antibodies and detected by streptavidin-β-peroxidase and ABTS as
substrate. Data represent the mean of three samples ± standard deviation.
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similar for each protein in respect to position of half-maximum and shape.
Interestingly, binding of the immunocytokine HRS3scFv-Fc-IL2 to the anti-
idiotypic antibody 9G10 was 3- to 6-fold lower compared to the other fu-
sion proteins. Detection was specific, as protein domains were only de-
tected in fusion proteins which contained the respective domain.
The fusion proteins bound to the anti-idiotypic antibody 9G10 in a dose-
dependant manner. Purified immunocytokines and the fusion protein
HRS3scFv-Fc were intact, as all domains of each protein were detected af-
ter capturing the HRS3 scFv.
4.2.2 Immunocytokines specifically bind to the anti-idiotypic
antibody 9G10
We determined whether binding of anti-CD30 immunocytokines via the
HRS3 scFv domain was specific by capturing immunocytokines with either
the anti-idiotypic antibody 9G10 or an isotype-matched control antibody.
Binding was analysed by ELISA using an antibody directed against the hu-
man Fcγ1 domain that is present in all of the tested proteins (figure 4.12).
Anti-CD30 immunocytokines and the fusion protein HRS3scFv-Fc bound
in a dose-dependant manner to the anti-idiotypic antibody 9G10. Maxi-
mum binding to the antibody 9G10 was 4- to 8-fold higher compared to the
isotype-matched control antibody. These differences in maximum binding
were statistically significant. Again, binding of the immunocytokine HRS3-
scFv-Fc-IL2 to the anti-idiotypic antibody 9G10 was 3- to 4-fold lower com-
pared to the other fusion proteins.
Purified anti-CD30 immunocytokines and the fusion protein HRS3scFv-Fc
specifically bound to the anti-idiotypic antibody 9G10.
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Figure 4.12: Immunocytokines specifically bind to the anti-idiotypic antibody
9G10. ELISA plates were coated with either the anti-idiotypic antibody 9G10 or
an isotype-matched control antibody and incubated with serial dilutions of puri-
fied immunocytokine, the fusion protein HRS3scFv-Fc or PBS as control. Bound
protein was probed with the biotinylated anti-h-IgG antibody and detected by
streptavidin-β-peroxidase and ABTS as substrate. Data represent the mean of three
samples ± standard deviation. Significance of differences in binding was deter-
mined by an unpaired two-sided Welch-corrected t-test.
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4.2.3 CD30 competes with the anti-idiotypic antibody 9G10 in
binding to immunocytokines
We determined whether CD30 competed with surface-bound anti-
idiotypic antibody 9G10 in binding to the anti-CD30 immunocytokines.
Purified anti-CD30 fusion proteins were captured by the anti-idiotypic
antibody 9G10 in presence of serial dilutions of CD30-Fc or Fc protein
as control. For specificity control, the anti-melanoma fusion protein
763.74scFv-Fc was captured by the anti-763.74 antibody MK2-72.8854 in
presence of serial dilutions of CD30-Fc. Bound protein was probed by
ELISA using an antibody directed against the human Fcγ1 domain that is
present in all of the tested anti-CD30 and anti-melanoma fusion proteins
(figure 4.13).
Co-incubation of the anti-CD30 fusion proteins with CD30 resulted in
dose-dependent binding inhibition. A molar ratio of 1 : 3 between fusion
protein and CD30 yielded binding inhibition ranging from 34% (HRS3-
scFv-hi-IL12-Fc-IL2) to 54% (HRS3scFv-Fc). Binding inhibition mediated
by CD30-Fc was significantly higher compared to binding inhibition medi-
ated by the Fc protein. Moreover, binding inhibition by CD30 was specific,
since binding of the anti-HMW-MAA fusion protein 763.74scFv-Fc to the
anti-763.74 antibody MK2-72.8854 was not inhibited by CD30.
We conclude that CD30 competed with surface-bound anti-idiotypic anti-
body 9G10 in binding to anti-CD30 immunocytokines and the fusion pro-
tein HRS3scFv-Fc. Furthermore, we infer that the anti-idiotypic antibody
9G10 is a valid substitute for CD30 to capture anti-CD30 fusion proteins.
4.2.4 Immunocytokines specifically bind to CD30+ tumour cells
To determine binding of anti-CD30 immunocytokines to tumour cells,
CD30+ HMW-MAA– L540 cells, HMW-MAA+ CD30– MeWo cells or hy-
bridoma cells secreting the anti-idiotypic antibody 9G10 as control were
incubated with purified immunocytokine or the fusion protein HRS3scFv-
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Figure 4.13: CD30 competes with the anti-idiotypic antibody 9G10 in binding to
immunocytokines. ELISA plates were coated with the anti-idiotypic antibody 9G10
and incubated with purified anti-CD30 fusion protein (1pmol) in presence of se-
rial dilutions of CD30-Fc or Fc protein as control (black lines). As specificity con-
trol, ELISA plates were coated with the anti-763.74 antibody MK2-72.8854 and in-
cubated with the purified anti-melanoma fusion protein 763.74scFv-Fc (1pmol) in
presence of serial dilutions of CD30-Fc (grey lines). Bound protein was probed with
the biotinylated anti-h-IgG antibody and detected by streptavidin-β-peroxidase
and ABTS as substrate. Data represent the mean of four samples ± standard de-
viation. Significance of differences in binding inhibition was determined by an un-
paired two-sided Welch-corrected t-test.
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Fc. The purified anti-melanoma fusion protein 763.74scFv-Fc or PBS
served as controls. Bound protein was detected by flow-cytometry using
the anti-h-IgG1-PE antibody which detects the Fcγ1 domain that is present
in all of the tested fusion proteins (figures 4.14 to 4.16). Data were analysed
by comparing the ratios of mean fluorescence intensity between incuba-
tion with and without protein (figure 4.17).
Anti-CD30 fusion proteins bound to CD30+ HMW-MAA– L540 cells and
to hybridoma cells secreting the anti-idiotypic antibody 9G10. No bind-
ing to HMW-MAA+ CD30– MeWo cells was recorded. In contrast, the
anti-HMW-MAA fusion protein 763.74scFv-Fc only bound to HMW-MAA+
CD30– MeWo cells. The immunocytokine HRS3scFv-Fc-IL2 bound 1.5-
fold stronger and the immunocytokine HRS3scFv-hi-IL12-Fc-IL2 bound 3-
fold stronger to L540 cells compared to the immunocytokine HRS3scFv-
Fc-hi-IL12 and the fusion protein HRS3scFv-Fc. In contrast, binding of
the anti-CD30 immunocytokines to hybridoma cells secreting the anti-
idiotypic antibody 9G10 was equally strong, except for the immunocyto-
kine HRS3scFv-Fc-IL2 which bound half as strong. Binding was specific, as
the anti-CD30 immunocytokines and the fusion protein HRS3scFv-Fc only
bound to CD30+ HMW-MAA– L540 cells and to hybridoma cells secreting
the anti-idiotypic antibody 9G10, whereas the anti-HMW-MAA fusion pro-
tein 763.74scFv-Fc only bound to HMW-MAA+ CD30– MeWo cells.
In summary, the anti-CD30 fusion proteins specifically bound to CD30+ tu-
mour cells and to hybridoma cells that secrete the anti-idiotypic antibody
9G10.
4.3 Purified immunocytokines exhibit cytokine
activity
Immunocytokines direct cytokine activity to specific sites of the body in
order to modulate immune responses. To determine whether the cytokine
domains of purified immunocytokines were active, lymphocytes were co-
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Figure 4.14: Immunocytokines bind to CD30+ L540 cells. CD30+ HMW-MAA–
L540 cells (2×105 cells) were incubated for 30min with purified immunocytokine,
the fusion protein HRS3scFv-Fc or the anti-HMW-MAA fusion protein 763.74scFv-
Fc as control (4pmol each; black lines). PBS served as control (grey lines). Bound
protein was detected by flow-cytometry using the anti-h-IgG1-PE antibody. In-
set: CD30+ HMW-MAA– L540 cells (2×105 cells) were stained with the anti-CD30-
PE antibody or the anti-HMW-MAA-PE antibody as control and analysed by flow-
cytometry.
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Figure 4.15: Immunocytokines do not bind to CD30– MeWo cells. HMW-MAA+
CD30– MeWo cells (2×105 cells) were incubated for 30min with purified immu-
nocytokine, the fusion protein HRS3scFv-Fc or the anti-HMW-MAA fusion protein
763.74scFv-Fc as control (4pmol each; black lines). PBS served as control (grey
lines). Bound protein was detected by flow-cytometry using the anti-h-IgG1-PE an-
tibody. Inset: HMW-MAA+ CD30– MeWo cells (2×105 cells) were stained with the
anti-CD30-PE antibody or the anti-HMW-MAA-PE antibody as control and anal-
ysed by flow-cytometry.
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Figure 4.16: Immunocytokines bind to 9G10 hybridoma cells. 9G10 hybridoma
cells (clone II-G05; 2×105 cells) were incubated for 30min with purified immu-
nocytokine, the fusion protein HRS3scFv-Fc or the anti-HMW-MAA fusion protein
763.74scFv-Fc as control (4pmol each; black lines). PBS served as control (grey
lines). Bound protein was detected by flow-cytometry using the anti-h-IgG1-PE
antibody. Inset: 9G10 hybridoma cells (clone II-G05; 2×105 cells) were stained
with the anti-CD30-PE antibody or the anti-HMW-MAA-PE antibody as control and
analysed by flow-cytometry.
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Figure 4.17: Immunocytokines bind to CD30+ tumour cells. CD30+ HMW-MAA–
L540 cells (2×105 cells; black bars), hybridoma cells producing the anti-idiotypic
antibody 9G10 (clone II-G05; 2×105 cells; grey bars) or HMW-MAA+ CD30– MeWo
cells (2×105 cells; white bars) were incubated for 30min with purified immu-
nocytokine, the fusion protein HRS3scFv-Fc or the anti-HMW-MAA fusion pro-
tein 763.74scFv-Fc as control (4pmol each). Bound protein was detected by flow-
cytometry using the anti-h-IgG1-PE antibody. Data represent the ratio of mean flu-
orescence intensity (MFI ratio) between incubation with and without protein. Each
bar represents one sample.
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incubated with immunocytokines and analysed for proliferation, secretion
of IFN-γ and phosphorylation of STAT4.
The anti-CD30 fusion proteins used in this study were generated to aid
the eradication of tumour cells. Therefore, we determined the influence
of these fusion proteins on the cytolysis of tumour cells by natural killer
(NK) cells.
4.3.1 Immunocytokines induce proliferation and IFN-γ
secretion in PBMCs
We determined whether the cytokine domains of purified immunocy-
tokines induced proliferation and IFN-γ secretion in peripheral blood
mononuclear cells (PBMCs). Pre-activated PBMCs were cultured in ab-
sence of IL-2 for 24 hours and incubated with solutions of purified anti-
CD30 immunocytokine or the fusion protein HRS3scFv-Fc as control. Al-
ternatively, PBMCs were incubated with anti-CD30 fusion proteins bound
to the immobilised anti-idiotypic antibody 9G10 or an isotype-matched
control antibody. For control, PBMCs were incubated with IL-2, IL-12
or with medium alone. Proliferation of PBMCs was quantified by incor-
poration of BrdU and subsequent ELISA (figure 4.18), while IFN-γ secre-
tion of PBMCs was determined from culture supernatants by ELISA (fig-
ure 4.19).
Anti-CD30 immunocytokines in solution induced proliferation in PBMCs,
whereas the fusion protein HRS3scFv-Fc without cytokine domain did
not. Immunocytokines which contain an IL-2 domain significantly in-
creased proliferation when bound to immobilised anti-idiotypic antibody
9G10 compared to immobilised isotype-matched control antibody. After
binding to the antibody 9G10, the immunocytokine HRS3scFv-hi-IL12-Fc-
IL2 with combined IL-2 and IL-12 domains resulted in significantly in-
creased proliferation of PBMCs compared to immunocytokines with a sin-
gle cytokine domain or the fusion protein HRS3scFv-Fc. As expected, co-
incubation of PBMCs with IL-2 or IL-12 also increased proliferation. The
extent of proliferation induced by 4pmol immunocytokine in solution or
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Figure 4.18: Immunocytokines induce proliferation in PBMCs. ELISA plates were
coated with the anti-idiotypic antibody 9G10 or an isotype-matched control anti-
body and incubated for 60min with purified immunocytokine or the fusion protein
HRS3scFv-Fc (4pmol each). Wells were either washed to remove unbound fusion
protein (grey and white bars) or not washed (black bars). Pre-activated human
PBMCs (2.5×104 cells) that had been cultured in absence of IL-2 for 24 hours were
added to each well and incubated for 96 hours. As controls, PBMCs were incubated
with human IL-2 (50IU), murine IL-12 (100fmol) or with medium alone (shaded
bars). Proliferation of PBMCs was quantified by incorporation of BrdU and subse-
quent ELISA. Data represent the mean of three samples; T-bars indicate standard
deviation. Significance of differences in proliferation was determined by an un-
paired two-sided Welch-corrected t-test.
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Figure 4.19: Immunocytokines induce IFN-γ secretion in PBMCs. ELISA plates
were coated with the anti-idiotypic antibody 9G10 or an isotype-matched con-
trol antibody and incubated for 60min with purified immunocytokine or the fu-
sion protein HRS3scFv-Fc (4pmol each). Wells were either washed to remove
unbound fusion protein (grey and white bars) or not washed (black bars). Pre-
activated human PBMCs (2.5×104 cells) that had been cultured in absence of
IL-2 for 24 hours were added to each well and incubated for 96 hours. As con-
trols, PBMCs were incubated with murine IL-12 (100fmol) or with medium alone
(shaded bars). IFN-γ concentrations in supernatants were determined by ELISA.
Data represent the mean of three samples; T-bars indicate standard deviation. Sig-
nificance of differences in IFN-γ secretion was determined by an unpaired two-
sided Welch-corrected t-test.
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4pmol bound immunocytokine HRS3scFv-hi-IL12-Fc-IL2 was 5- to 7-fold
that of 50IU (200fmol) IL-2 and 7- to 10-fold that of 100fmol IL-12, indicat-
ing 3- to 6-fold less cytokine activity of the immunocytokines compared to
the respective recombinant cytokine.
Anti-CD30 immunocytokines in solution induced IFN-γ secretion in
PBMCs, whereas the fusion protein HRS3scFv-Fc without cytokine do-
main did not. The immunocytokine HRS3scFv-hi-IL12-Fc-IL2 with com-
bined IL-2 and IL-12 domains significantly increased secretion of IFN-γ
when bound to immobilised anti-idiotypic antibody 9G10 compared to
immobilised isotype-matched control antibody. After binding to the an-
tibody 9G10, the immunocytokine HRS3scFv-hi-IL12-Fc-IL2 furthermore
resulted in significantly increased IFN-γ secretion compared to immuno-
cytokines with a single cytokine domain or the fusion protein HRS3scFv-
Fc. As expected, co-incubation of PBMCs with IL-12 also increased IFN-γ
secretion. The amount of IFN-γ secretion induced by 4pmol immunocy-
tokine in solution or bound immunocytokine HRS3scFv-hi-IL12-Fc-IL2
was 7- to 16-fold that of 100fmol IL-12, indicating 3- to 6-fold less cytokine
activity of the immunocytokines compared to recombinant IL-12.
Purified immunocytokines were active in solution and after binding to sur-
faces via the HRS3 scFv domain. After binding to the anti-idiotypic anti-
body 9G10, the immunocytokine HRS3scFv-hi-IL12-Fc-IL2 with combined
IL-2 and IL-12 domains resulted in significantly increased proliferation and
IFN-γ secretion of PBMCs compared to immunocytokines with a single cy-
tokine domain.
4.3.2 The IL-12 domain of immunocytokines induces
phosphorylation of STAT4 in T cells
Signal transducer and activator of transcription-4 (STAT4) is phosphory-
lated in lymphocytes in vitro after stimulation with IL-12, IL-23 or IFN-α
(Kaplan, 2005). We determined whether the murine single-chain IL-12 do-
main of anti-CD30 immunocytokines leads to phosphorylation of STAT4 in
human T cells.
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Figure 4.20: Murine IL-12 induces phosphorylation of STAT4 in human T cells.
Pre-activated human T cells (5×105 cells) that had been cultured in absence of
IL-2 for 24 hours were suspended in PBS containing 2% (v/v) FCS. Murine IL-12
(0.2pmol; black lines) or PBS as control (grey lines) were added and the reac-
tion tubes were incubated at 37°C. After 10, 20, 30, 60, 120 and 240min, cells
were fixed, permeabilised, stained with either the anti-pSTAT4-PE antibody or an
isotype-matched PE-conjugated control antibody (dotted lines) and analysed by
flow-cytometry. Inset: data represent the ratio of mean fluorescence intensity (MFI
ratio) between incubation with and without murine IL-12 in relation to incubation
time.
To determine the incubation time required for phosphorylation of STAT4
by stimulation with murine IL-12, pre-activated human T cells that had
been cultured in absence of IL-2 for 24 hours were incubated for different
lengths of time with murine IL-12 or PBS as control. T cells were fixed, per-
meabilised, stained with either the anti-pSTAT4-PE antibody or an isotype-
matched PE-conjugated control antibody and analysed by flow-cytometry
(figure 4.20). Phosphorylation of STAT4 was detected after 10min of incu-
bation and increased with incubation time. After reaching a maximum at
approximately 120min, the amount of phosphorylated STAT4 decreased to
starting levels (240min).
We repeated the experiment to determine whether the murine single-chain
IL-12 domain of immunocytokines leads to phosphorylation of STAT4.
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T cells were incubated for 30min with purified immunocytokine. The fu-
sion protein HRS3scFv-Fc, murine IL-12 or PBS served as controls (fig-
ure 4.21).
The immunocytokine HRS3scFv-Fc-hi-IL12 with IL-12 cytokine domain
yielded similar phosphorylation of STAT4 compared to recombinant IL-12,
while the immunocytokine HRS3scFv-hi-IL12-Fc-IL2 with combined IL-2
and IL-12 domains led to 1.2-fold higher phosphorylation of STAT4. The
immunocytokine HRS3scFv-Fc-IL2 also showed a shift, as did – unexpect-
edly – the fusion protein HRS3scFv-Fc without cytokine domain. However,
STAT4 phosphorylation induced by the fusion protein HRS3scFv-Fc was 4-
fold lower compared to the immunocytokine HRS3scFv-hi-IL12-Fc-IL2 or
recombinant IL-12.
Purified immunocytokines containing an IL-12 domain induced phospho-
rylation of STAT4 in human T cells.
4.3.3 Immunocytokines induce NK cells to lyse tumour cells
The cytokines IL-2 and IL-12 enhance cytolysis by NK cells (Thèze, 1999).
Furthermore, the Fcγ1 domain of immunocytokines can trigger antibody-
dependent cellular cytotoxicity (ADCC) by binding to Fcγ receptors on NK
cells (Davis and Gillies, 2003). Therefore, we determined the impact of anti-
CD30 fusion proteins on the cytolysis of tumour cells by NK cells.
CD30+ CEA– MC38 cells stably transfected with pcDNA3.1 CD30 (#841)
plasmid DNA or CEA+ CD30– C15A3 cells as control (figure 4.22) were in-
cubated with purified immunocytokine or the fusion protein HRS3scFv-
Fc. After washing the tumour cells, human NK cells were added and in-
cubated for 24 hours. As control, tumour cells were incubated with NK
cells in presence of human IL-2. Viability of NK cells and tumour cells was
quantified by colour change of XTT reagent, and cytolysis was calculated
(figure 4.23).
Within 24 hours, NK cells lysed CD30+ tumour cells coated with anti-CD30
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Figure 4.21: The IL-12 domain of immunocytokines induces phosphorylation of
STAT4 in T cells. Pre-activated human T cells (2×105 cells) that had been cul-
tured in absence of IL-2 for 24 hours were suspended in PBS containing 2% (v/v)
FCS. Purified immunocytokine, the fusion protein HRS3scFv-Fc or murine IL-12 as
control (0.2pmol each; black lines) were added and the reaction tubes were incu-
bated at 37°C. Purified immunocytokines had been dissolved in PBS containing
3% (v/v) normal mouse serum for storage, therefore this solvent was used as con-
trol (grey lines). After 30min, cells were fixed, permeabilised, stained with either
the anti-pSTAT4-PE antibody or an isotype-matched PE-conjugated control anti-
body (dotted lines) and analysed by flow-cytometry (A). The ratio of mean fluo-
rescence intensity (MFI ratio) between incubation with and without protein was
calculated. Each bar corresponds to one sample (B).
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Figure 4.22: Characterisation of modified MC38 and C15A3 cells. CD30+
CEA– MC38 cells stably transfected with pcDNA3.1 CD30 (#841) plasmid DNA
(2×105 cells) or CEA+ CD30– C15A3 cells (2×105 cells) were stained with either the
anti-CD30-PE antibody (black lines) or an isotype-matched PE-conjugated control
antibody (dotted lines). Alternatively, cells were incubated with the anti-CEA an-
tibody HB-8747 (1µg) and stained with the anti-m-IgG1-PE antibody (grey lines).
Finally, cells were analysed by flow-cytometry.
fusion proteins with an efficiency of 15% to 50%. The effector-to-target
cell ratio was 4 : 5. Cytolysis of CD30+ tumour cells that were coated with
immunocytokines containing an IL-12 domain or the fusion protein HRS3-
scFv-Fc was significantly higher than lysis of CD30– tumour cells. More-
over, the immunocytokine HRS3scFv-hi-IL12-Fc-IL2 with combined IL-2
and IL-12 domains significantly increased cytolysis of CD30+ tumour cells
compared to the fusion protein HRS3scFv-Fc. As expected, co-incubation
of NK cells with human IL-2 induced cytolysis of CD30+ and CD30– tumour
cells, whereas incubation of NK cells without added cytokines did not. In
absence of NK cells, anti-CD30 fusion proteins did not induce cytolysis of
tumour cells.
In summary, NK cells were induced to specifically lyse CD30+ tumour
cells coated with anti-CD30 fusion proteins. The immunocytokine HRS3-
scFv-hi-IL12-Fc-IL2 with combined IL-2 and IL-12 domains resulted in in-
creased cytolysis of CD30+ tumour cells compared to the fusion protein
HRS3scFv-Fc without cytokine domain. We conclude that the Fcγ1 and cy-
tokine domains of anti-CD30 fusion proteins activate NK cells for the spe-
cific lysis of CD30+ tumour cells.
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Figure 4.23: Immunocytokines induce NK cells to lyse tumour cells. CD30+
CEA– MC38 cells stably transfected with pcDNA3.1 CD30 (#841) plasmid DNA
(5×104 cells; black bars) or CEA+ CD30– C15A3 cells as control (5×104 cells; white
bars) were incubated for 60min with purified immunocytokine or the fusion pro-
tein HRS3scFv-Fc (5ng each). Cells were washed and plated in round-bottom mi-
crotitre plates. Human NK cells (4×104 cells) were added and plates were incu-
bated at 37°C for 24 hours. As controls, tumour cells were incubated with NK cells
either in presence of human IL-2 (100IU) or with medium alone (shaded bars). Vi-
ability of NK cells and tumour cells was quantified by colour change of XTT reagent,
and cytolysis was calculated. Data represent the mean of three samples; T-bars in-
dicate standard deviation. Significance of differences in cytolysis was determined
by an unpaired two-sided Welch-corrected t-test.
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4.4 Immunocytokines accumulate at the tumour site
Immunocytokines were designed to target cytokines to specific sites within
the body in order to increase local accumulation and decrease adminis-
tered doses, thereby limiting the severe side effects associated with sys-
temic application of cytokines. We therefore investigated the biodistri-
bution of two anti-CD30 immunocytokines and determined the biological
half-life of these proteins.
4.4.1 Immunocytokines retain specificity of binding after
radiolabelling
Labelling with Na131I and chloramine-T leads to modified histidine and
tyrosine residues, whereas Bolton-Hunter reagent is coupled to both N-
terminus and lysine residues (Coligan, 2005). The N-terminal HRS3 scFv
domain of anti-CD30 immunocytokines contains three histidine residues,
eleven lysine residues and nineteen tyrosine residues. We therefore as-
sessed binding specificity of immunocytokines after radiolabelling.
Purified immunocytokine HRS3scFv-hi-IL12 or HRS3scFv-Fc-hi-IL12 was
radiolabelled with Na131I and chloramine-T to specific activities ranging
from 23MBq/nmol to 46MBq/nmol and desalted (figure 4.24). To remove
immunocytokine that had lost binding affinity for CD30, labelled immuno-
cytokine was affinity-purified using the anti-idiotypic antibody 9G10 cou-
pled to a HiTrap™ HP column (figure 4.25). Finally, binding of radiola-
belled protein to either the anti-idiotypic antibody 9G10 or an isotype-
matched control antibody was determined by RIA (figure 4.26).
Immunocytokines that had been radiolabelled with Na131I and
chloramine-T bound to the anti-idiotypic antibody 9G10 in a dose-
dependant manner. Maximum binding to the anti-idiotypic antibody
9G10 was 14-fold higher compared to the isotype-matched control an-
tibody. Furthermore, the elution profile during affinity purification of
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Figure 4.24: Desalting of radiolabelled immunocytokines. Purified immunocyto-
kine HRS3scFv-Fc-hi-IL12 (400pmol) was radiolabelled with Na131I (31MBq) and
chloramine-T (6nmol) to a specific activity of 23MBq/nmol (chloramine-T). Alter-
natively, purified immunocytokine HRS3scFv-Fc-hi-IL12 (400pmol) was coupled
to Bolton-Hunter reagent (300pmol), yielding a specific activity of 0.5MBq/nmol
(Bolton-Hunter reagent). Labelled immunocytokine was desalted using a PD-10™
column to remove chemical reagents and unbound radioactivity. Effluent was col-
lected in 1-ml fractions and radioactivity of each fraction was counted. Finally, frac-
tion #4 of the desalted immunocytokine (grey sections) was used for biodistribu-
tion experiments.
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Figure 4.25: Purification of radiolabelled immunocytokine HRS3scFv-hi-IL12.
Purified immunocytokine HRS3scFv-hi-IL12 (1.7nmol) was radiolabelled with
Na131I (17MBq) and chloramine-T (2.7nmol) to a specific activity of 0.5MBq/nmol.
After desalting, the immunocytokine was affinity-purified using the anti-idiotypic
antibody 9G10 coupled to a HiTrap™ HP column (column volume: 1ml). The col-
umn was washed with PBS until effluent was free from radioactivity. Bound im-
munocytokine was eluted with 0.1 M glycine buffer (pH 3.0) in steps of 250µl (first
5ml) or 1ml and radioactivity of each fraction was counted. pH of the first twenty
fractions was raised by adding 1 M NaHCO3 (12.5µl). Finally, fractions #7 and #8 of
each batch (grey section) were pooled and used for biodistribution experiments
(radiolabelled). As reference, a characteristic purification of unlabelled immu-
nocytokine HRS3scFv-hi-IL12 from cell culture supernatants (1.5l) using the anti-
idiotypic antibody 9G10 coupled to a HiTrap™ HP column (column volume: 1ml)
and 0.1 M glycine buffer (pH 3.0) is shown. Absorbance of effluent (280nm) was
monitored continuously (unlabelled).
98
Accumulation at the tumour site
Figure 4.26: Radiolabelled immunocytokines specifically bind to the anti-
idiotypic antibody 9G10. Purified immunocytokine HRS3scFv-hi-IL12 (180pmol)
was radiolabelled with Na131I (33MBq) and chloramine-T (3.6nmol) to a specific
activity of 46MBq/nmol, desalted and affinity-purified. PolySorp™ tubes were
coated with either the anti-idiotypic antibody 9G10 or an isotype-matched con-
trol antibody and incubated with serial dilutions of radiolabelled immunocyto-
kine. After washing with PBS, radioactivity in each tube was counted (chloramine-
T). Alternatively, purified immunocytokine HRS3scFv-Fc-hi-IL12 (400pmol) was
coupled to Bolton-Hunter reagent (95pmol) and desalted (specific activity:
1.7MBq/nmol). PolySorp™ LockWell™ strips were coated with either the anti-
idiotypic antibody 9G10 or an isotype-matched control antibody and incubated
with serial dilutions of radiolabelled immunocytokine. After washing with PBS, ra-
dioactivity in each well was counted (Bolton-Hunter reagent). Each data point
represents one sample.
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radiolabelled immunocytokine corresponded to that of unlabelled immu-
nocytokine.
Alternatively, we labelled immunocytokine using the Bolton-Hunter
method in order to avoid the harsh conditions of labelling with
chloramine-T, thus obviating subsequent affinity purification. Purified
immunocytokine HRS3scFv-hi-IL12 or HRS3scFv-Fc-hi-IL12 was radiola-
belled to specific activities ranging from 0.7MBq/nmol to 1.7MBq/nmol
by coupling to Bolton-Hunter reagent. Labelled immunocytokine was
desalted (figure 4.24) and binding of radiolabelled protein to either the
anti-idiotypic antibody 9G10 or an isotype-matched control antibody was
determined by RIA (figure 4.26).
Immunocytokines that had been radiolabelled using the Bolton-Hunter
method bound to the anti-idiotypic antibody 9G10 in a dose-dependant
manner. Maximum binding to the anti-idiotypic antibody 9G10 was 3.5-
fold higher compared to the isotype-matched control antibody.
Purified anti-CD30 immunocytokines radiolabelled either with Na131I and
chloramine-T or by coupling to Bolton-Hunter reagent specifically bound
to the anti-idiotypic antibody 9G10.
4.4.2 Immunocytokines accumulate at the tumour site
To determine accumulation at the tumour site, immunocytokines were ra-
diolabelled and their biodistribution was analysed after systemic applica-
tion in SCID mice which harboured tumours of CD30+ L540Cy cells (fig-
ure 4.27). The influence of an Fcγ1 domain on the biodistribution of im-
munocytokines was assessed by comparing immunocytokines with and
without an Fcγ1 domain.
Tumour cells and immunocytokine were injected by Jan-Philipp Hering,
who also dissected mice and counted the radioactivity of organs. Biodis-
tribution of the immunocytokine HRS3scFv-Fc-hi-IL12 was determined by
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Figure 4.27: L540Cy cells express CD30. L540Cy cells (1×105 cells) were incu-
bated with the anti-CD30 antibody HRS3 (400ng; black line) or PBS as control (grey
line), stained with the anti-m-IgG1-PE antibody and analysed by flow-cytometry.
PD Dr. Stefan Guhlke and Jan-Philipp Hering, according to my detailed in-
structions.
Two batches of purified immunocytokine HRS3scFv-hi-IL12 without Fcγ1
domain were radiolabelled with Na131I and chloramine-T. Labelled immu-
nocytokine was desalted (figure 4.24) and affinity-purified using the anti-
idiotypic antibody 9G10 coupled to a HiTrap™ HP column in order to re-
move immunocytokine that had lost binding affinity for CD30 (figure 4.25).
Groups of mice (n = 6) bearing tumours of CD30+ L540Cy cells received i.v.
injections of 90pmol (specific activity: 0.5MBq/nmol) or 11pmol (specific
activity: 3.7MBq/nmol) radiolabelled immunocytokine. Two mice from
each group were sacrificed after 24, 48 or 72 hours. Organs were recovered,
weighed and radioactivity was counted. Detected counts were compen-
sated for radioactive decay, and injected dose per gram of tissue (% ID/g)
was calculated (figure 4.28).
Tissue retention was calculated as % ID/g (72h) divided by % ID/g (24h).
Highest tissue retentions of the immunocytokine HRS3scFv-hi-IL12 were
found in small intestine (39%), blood (37%), tumour (35%) and liver (33%).
After 21 hours, mice had excreted 32% of total injected radioactivity, as de-
tected in combined litter from all groups.
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Figure 4.28: Immunocytokine HRS3scFv-hi-IL12 accumulates at the tumour
site. Twelve female SCID mice received s.c. injections of CD30+ L540Cy cells
(3×107 cells) in the flank. After three weeks, two batches of purified immunocy-
tokine HRS3scFv-hi-IL12 (1.7nmol / 300pmol) were labelled with Na131I (17MBq
/ 6MBq) and chloramine-T (2.7nmol / 1.4nmol), desalted and affinity-purified.
Groups of mice (n = 6) received i.v. injections of 90pmol (0.5MBq/nmol; black
points) or 11pmol immunocytokine (3.7MBq/nmol; grey points). Two mice from
each group were sacrificed after 24, 48 or 72 hours. Organs were recovered, weighed
and radioactivity was counted. Counts were compensated for radioactive decay,
and injected dose per gram of tissue (% ID/g) was calculated. Mean tissue reten-
tion was calculated as % ID/g (72h) divided by % ID/g (24h).
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Figure 4.29: Immunocytokine HRS3scFv-Fc-hi-IL12 accumulates at the tumour
site. Twelve female SCID mice received s.c. injections of CD30+ L540Cy cells
(3×107 cells) in the flank. After five weeks, purified immunocytokine HRS3scFv-
Fc-hi-IL12 (1.2nmol) was coupled to Bolton-Hunter reagent (630pmol) and de-
salted. Mice received i.v. injections of immunocytokine (45pmol, 1.3MBq/nmol).
Groups of mice (n = 3) were sacrificed after 12, 24, 48 or 72 hours. Organs were
recovered, weighed and radioactivity was counted. Counts were compensated for
radioactive decay, and injected dose per gram of tissue (% ID/g) was calculated.
Mean tissue retention was calculated as % ID/g (72h) divided by % ID/g (24h).
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Alternatively, purified immunocytokine HRS3scFv-Fc-hi-IL12 with Fcγ1
domain was coupled to Bolton-Hunter reagent and desalted (figure 4.24).
Mice bearing tumours of CD30+ L540Cy cells received i.v. injections of
45pmol radiolabelled immunocytokine (specific activity: 1.3MBq/nmol).
Groups of three animals were sacrificed after 12, 24, 48 or 72 hours. Organs
were recovered, weighed and radioactivity was counted. Detected counts
were compensated for radioactive decay, and injected dose per gram of tis-
sue (% ID/g) was calculated (figure 4.29).
Tissue retention was calculated as % ID/g (72h) divided by % ID/g (24h).
Highest tissue retentions of the immunocytokine HRS3scFv-Fc-hi-IL12
were found in tumour (30%), the lungs (20%), small intestine (18%) and
blood (18%).
The influence of the Fcγ1 domain on biodistribution was assessed by com-
paring mean tissue retentions of the immunocytokines HRS3scFv-hi-IL12
and HRS3scFv-Fc-hi-IL12. These immunocytokines are identical except
for lacking or containing an Fcγ1 domain. Mean tissue retentions of both
immunocytokines were similar for tumour, muscle and lungs. Tissue re-
tentions of the immunocytokine HRS3scFv-hi-IL12 without Fcγ1 domain
were 1.6- to 4-fold higher for kidneys, blood, small intestine and liver com-
pared to the immunocytokine HRS3scFv-Fc-hi-IL12 with Fcγ1 domain,
whereas tissue retentions of colon and stomach were 1.6- to 2.5-fold lower.
After 72 hours, radiolabelled immunocytokine HRS3scFv-hi-IL12 without
Fcγ1 domain was completely cleared from heart, spleen and bones in all
animals and from muscle, colon, stomach, kidney and the lungs in at least
two animals. In contrast, the immunocytokine HRS3scFv-Fc-hi-IL12 with
Fcγ1 domain was only cleared from the bones of one animal in this inter-
val. Furthermore, the lowest mean tissue retention of the immunocytokine
HRS3scFv-Fc-hi-IL12 with Fcγ1 domain amounted to 8.5%.
4.4.3 Biological half-life of immunocytokines
We estimated biological half-life of immunocytokines in blood by linear
regression from % ID/g values that were determined in biodistribution
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experiments (section 4.4.2), using equations for an i.v. bolus in a one-
compartment pharmacokinetic model: ln (ct ) = ln(c0)− k ∗ t and t1/2 =
ln(2)
k (figure 4.30). These equations are also valid for a two-compartment
pharmacokinetic model when drug distribution between central and pe-
ripheral compartment has reached equilibrium (β-phase; Schoenwald,
2001).
Biological half-life of radiolabelled immunocytokine HRS3scFv-hi-IL12
was determined as 32 hours (dose: 90pmol; R2 = 0.90, p = 0.004) and
34 hours (dose: 11pmol; R2 = 0.51, not significant), whereas half-life of ra-
diolabelled immunocytokine HRS3scFv-Fc-hi-IL12 amounted to 20 hours
(R2 = 0.92, p < 0.001). However, when only taking the last 24 hours into
account where the β-phase had most likely been reached, half-life of the
immunocytokine HRS3scFv-Fc-hi-IL12 was determined as 34 hours (R2 =
0.71, p = 0.03).
4.5 Immunocytokine HRS3scFv-hi-IL12-Fc-IL2
inhibits tumour growth in immunocompetent
mice
The immunocytokines used in this study were designed to inhibit tumour
growth in vivo. After finding that hybridoma cells which produce the anti-
idiotypic antibody 9G10 grew tumours in immunocompetent Balb/c mice,
we determined the influence of the immunocytokine HRS3scFv-hi-IL12-
Fc-IL2 with combined IL-2 and IL-12 domains on tumour growth of these
cells. Subsequently, mouse sera were tested for the presence of immunocy-
tokine and for antibodies directed against the immunocytokine backbone
HRS3scFv-Fc. Finally, we estimated biological half-life of the immunocy-
tokine.
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Figure 4.30: Biological half-life of immunocytokines. Two batches of purified im-
munocytokine HRS3scFv-hi-IL12 (1.7nmol / 300pmol) were labelled with Na131I
(17MBq / 6MBq) and chloramine-T (2.7nmol / 1.4nmol), desalted and affinity-
purified. Groups of female SCID mice (n = 6) bearing s.c. tumours of CD30+
L540Cy cells received i.v. injections of 90pmol (0.5MBq/nmol) or 11pmol immu-
nocytokine (3.7MBq/nmol). Two mice from each group were sacrificed after 24,
48 or 72 hours (grey lines). Alternatively, purified immunocytokine HRS3scFv-
Fc-hi-IL12 (1.2nmol) was coupled to Bolton-Hunter reagent (630pmol) and de-
salted. Twelve female SCID mice bearing s.c. tumours of CD30+ L540Cy cells re-
ceived i.v. injections of immunocytokine (45pmol, 1.3MBq/nmol). Groups of mice
(n = 3) were sacrificed after 12, 24, 48 or 72 hours (black line). Blood was recov-
ered, weighed and radioactivity was counted. Counts were compensated for ra-
dioactive decay, and injected dose per gram of tissue (% ID/g) was calculated. Data
represent the mean of two (HRS3scFv-hi-IL12) or three samples (HRS3scFv-Fc-hi-
IL12) ± standard deviation. Dotted lines: linear regression over all points in time.
Dashed line: linear regression over the last 24 hours.
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4.5.1 Immunocytokine HRS3scFv-hi-IL12-Fc-IL2 inhibits
tumour growth
To determine the tolerated dose of anti-CD30 immunocytokines in
tumour-bearing immunocompetent mice, these animals received es-
calating doses of the immunocytokine HRS3scFv-hi-IL12-Fc-IL2 with
combined IL-2 and IL-12 domains.
Ten female Balb/c mice received s.c. injections of 9G10 hybridoma cells
(figure 4.16) in the flank. Six animals developed tumours. When tumours
were clearly visible after two weeks, mice received escalating doses of
purified immunocytokine HRS3scFv-hi-IL12-Fc-IL2 (40pmol to 500pmol)
three times intravenously at 48-hour intervals. To estimate half-life of the
immunocytokine and detect antibodies raised against the immunocyto-
kine, sera were sampled before each injection and, subsequently, addi-
tional serum samples were taken. Tumour growth was monitored and mice
were sacrificed a week after the last injection or when tumours became
necrotic. Mice were grouped by total amount of immunocytokine (fig-
ure 4.31). As control, six female Balb/c mice received s.c. injections of 9G10
hybridoma cells in the flank, but no subsequent injections of immunocyto-
kine. Five animals developed tumours. Tumour growth was monitored and
mice were sacrificed when tumour volumes reached 600mm3. For statisti-
cal analysis, tumour volumes were normalised to the day of first injection
of immunocytokine or, for control mice, to the day when visible tumours
started to grow (figure 4.32).
Mice tolerated cumulated doses of up to 1nmol immunocytokine HRS3-
scFv-hi-IL12-Fc-IL2, the highest single dose being 500pmol. Observed ad-
verse events were enduring inflammations of the ears in three animals,
starting on day 2 to 4 after first injection of immunocytokine. As two an-
imals of the control group displayed the same symptoms, however, we do
not consider this a side effect of immunocytokine administration. At days 3
and 7 after first injection of immunocytokine, relative tumour growth was
significantly lower in animals that received cumulated doses of 300pmol
immunocytokine and above, compared to animals that received lower
doses and control mice. In contrast, tumours of animals which received
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Figure 4.31: Dose escalation of immunocytokine HRS3scFv-hi-IL12-Fc-IL2 in
mice. Ten female Balb/c mice received s.c. injections of 9G10 hybridoma cells
(clone II-G05; 1×106 cells) in the flank; six animals developed tumours. When tu-
mours were clearly visible after two weeks, mice received escalating doses of puri-
fied immunocytokine HRS3scFv-hi-IL12-Fc-IL2 (40pmol to 500pmol) three times
intravenously at 48-hour intervals. Sera were sampled before each injection and,
subsequently, additional serum samples were taken. Tumour growth was moni-
tored and mice were sacrificed a week after the last injection or when tumours be-
came necrotic. Mice were grouped by total amount of immunocytokine (230 pmol,
300 pmol and >500 pmol; n = 2). Each line represents tumour growth in one
mouse (grey lines) or mean tumour growth for each group (black lines). Arrows
indicate days of injection; numbers indicate immunocytokine doses in pmol.
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less than 300pmol immunocytokine and tumours of control mice grew at
the same rate. Seven days after the first injection of immunocytokine, the
tumour volume of animals that received cumulated doses of 300pmol im-
munocytokine and above had increased by 1.5-fold compared to a 9.5-fold
increase in animals that received lower doses.
Immunocompetent Balb/c mice tolerated single doses of up to 500pmol
and cumulated doses of up to 1nmol of the immunocytokine HRS3scFv-hi-
IL12-Fc-IL2. Tumour growth was inhibited in animals that received cumu-
lated doses of 300pmol immunocytokine and above. Side effects related to
immunocytokine administration were not observed.
4.5.2 Immunocytokine HRS3scFv-hi-IL12-Fc-IL2 accumulates
in serum
To determine whether immunocytokine accumulated in the peripheral cir-
culation of mice, sera from two mice that received the immunocytokine
HRS3scFv-hi-IL12-Fc-IL2 and one mouse that did not receive immunocy-
tokine as control were analysed by ELISA for presence of the immunocyto-
kine’s human Fcγ1 domain (figure 4.33).
Serum concentrations of immunocytokine increased starting from the day
of the first immunocytokine injection, reached its maximum two days af-
ter the last injection and decreased again. In contrast, no immunocytokine
was detected in sera of the control animal. Biological half-life of the immu-
nocytokine HRS3scFv-hi-IL12-Fc-IL2 was estimated by approximation of
calculated to detected serum concentrations, using the equations for an i.v.
bolus in a one-compartment model: ln (ct )= ln(c0)−k ∗ t and t1/2 = ln(2)k .
As detected serum concentrations of immunocytokine were 13-fold lower
than theoretical concentrations, we divided administered doses by 13 prior
to calculation. Biological half-life of the immunocytokine HRS3scFv-hi-
IL12-Fc-IL2 was estimated to 41 hours for animal #6 and to 32 hours for
animal #8.
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Figure 4.32: Immunocytokine HRS3scFv-hi-IL12-Fc-IL2 inhibits tumour growth
in mice. Ten female Balb/c mice received s.c. injections of 9G10 hybridoma cells
(clone II-G05; 1×106 cells) in the flank; six animals developed tumours. When
tumours were clearly visible after two weeks, mice received escalating doses of
purified immunocytokine HRS3scFv-hi-IL12-Fc-IL2 (40pmol to 500pmol) three
times intravenously at 48-hour intervals. Tumour growth was monitored and mice
were sacrificed a week after the last injection or when tumours became necrotic.
Mice were grouped by total amount of immunocytokine (≥300pmol (n = 4) and
<300pmol (n = 2); black lines). As control, six female Balb/c mice received s.c.
injections of 9G10 hybridoma cells (5×106 cells) in the flank, but no subsequent
injections of immunocytokine. Five animals developed tumours. Tumour growth
was monitored and mice were sacrificed when tumour volumes reached 600mm3
(n = 5; grey line). Time is given as days since first injection of immunocytokine
or, for control mice, since start of tumour growth. Tumour volume at day 0 was
set to 1. Arrows indicate days of injection. Data represent mean relative tumour
volume ± standard deviation. Significance of differences in relative tumour vol-
ume was determined at days 3 and 7 by an unpaired two-sided Welch-corrected
t-test. Difference between ≥300pmol immunocytokine and <300pmol immuno-
cytokine: p < 0.001 (days 3 and 7); difference between≥300pmol immunocytokine
and control: p = 0.02 (day 3); difference between <300pmol immunocytokine and
control: not significant (day 3).
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Figure 4.33: Immunocytokine HRS3scFv-hi-IL12-Fc-IL2 accumulates in serum.
Sera from two mice that received the immunocytokine HRS3scFv-hi-IL12-Fc-IL2
(>500pmol in three doses; figure 4.31; filled points) and one mouse that did not re-
ceive immunocytokine as control (open points) were diluted in PBS (1 : 100). ELISA
plates were coated with the anti-h-IgG antibody and incubated with serial dilutions
of pre-diluted sera. Bound protein was probed with the biotinylated anti-h-IgG an-
tibody and detected by streptavidin-β-peroxidase and ABTS as substrate. Biologi-
cal half-life of the immunocytokine was estimated by approximation of calculated
to detected serum concentrations, using the equations for an i.v. bolus in a one-
compartment model (dotted black line: animal #6, t1/2 = 41 hours, dotted grey
line: animal #8, t1/2 = 32 hours). As detected serum concentrations of immuno-
cytokine were 13-fold lower than theoretical concentrations, administered doses
were divided by 13 prior to calculation. Each line represents serum samples from
one mouse. Arrows indicate days of injection.
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Figure 4.34: Mice raise antibodies directed against the immunocytokine HRS3-
scFv-hi-IL12-Fc-IL2. Sera from two mice that received the immunocytokine HRS3-
scFv-hi-IL12-Fc-IL2 (>500pmol in three doses; figure 4.31; filled points) and one
mouse that did not receive immunocytokine as control (open points) were diluted
in PBS (1 : 100). ELISA plates were coated with purified fusion protein HRS3scFv-
Fc and incubated with serial dilutions of pre-diluted sera. Bound mouse anti-
bodies were probed with the biotinylated anti-m-IgG antibody and detected by
streptavidin-β-peroxidase and ABTS as substrate. Each line represents serum sam-
ples from one mouse. Arrows indicate days of injection.
4.5.3 Mice raise antibodies directed against the
immunocytokine HRS3scFv-hi-IL12-Fc-IL2
To determine whether mice had raised anti-immunocytokine antibodies,
sera from two mice that received the immunocytokine HRS3scFv-hi-IL12-
Fc-IL2 and one mouse that did not receive immunocytokine as control
were analysed by ELISA for IgG antibodies binding to the fusion protein
HRS3scFv-Fc. This fusion protein forms the backbone of all anti-CD30
immunocytokines. We used an anti-IgG antibody that had been cross-
adsorbed to both pooled human sera and purified human paraproteins
by the manufacturer, thus allowing us to detect murine IgG antibodies in
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presence of the fusion protein HRS3scFv-Fc which contains a human Fcγ1
domain (figure 4.34).
Serum concentrations of murine IgG antibodies directed against the im-
munocytokine backbone HRS3scFv-Fc increased with time, starting from
day 4 after the first injection. In contrast, no IgG antibodies directed
against the immunocytokine backbone were detected in sera of the con-
trol animal.
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5 Discussion
Researchers have proposed to treat cancer with a combination of IL-2
and IL-12, as these cytokines activate separate pathways, reciprocally up-
regulate each other’s receptors and induce complimentary biological ef-
fects (Weiss et al., 2007). Accordingly, our group has found that the combi-
nation of an immunocytokine with IL-2 domain and an immunocytokine
with IL-12 domain enhances activation of resting NK cells and tumour cell
lysis in vitro, compared to a single immunocytokine alone (Hombach et al.,
2005). As the simultaneous administration of two immunocytokines may
induce problems such as competition on binding to CD30, we have gener-
ated the novel anti-CD30 immunocytokine HRS3scFv-hi-IL12-Fc-IL2. This
immunocytokine has been designed for the therapy of classical Hodgkin’s
lymphoma, targets CD30 on the surface of the malignant Hodgkin-Reed-
Sternberg cells and combines human IL-2 and single-chain murine IL-12
in one molecule.
Production of immunocytokines has turned out to be a major issue. In or-
der to compare different immunocytokines at the same time, it has been
necessary to express and purify large amounts of protein within a reason-
able time frame. Therefore, we have expressed anti-CD30 fusion proteins
in the SL2 cell line derived from Drosophila melanogaster. Moreover, we
have chosen to use the FibraStage™ bioreactor for its ability to culture cells
in high densities and simultaneously express up to four recombinant pro-
teins. In this bioreactor, bottles filled with fibre disks for cell adhesion are
locked in a holder and medium is pumped through the disk layer by the
programmable vertical motion of a platform.
We have inserted the expression cassettes coding for anti-CD30 fusion pro-
teins into the Drosophila Expression System™ DNA vector pMT/BiP V5-
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His A (#1070) and stably transfected SL2 cells with the generated plasmids
using the transfection reagent Fugene™ HD. This transfection reagent has
been chosen for delivering high transfection efficiencies while retaining
the morphology of transfected SL2 cells. In the FibraStage™ bioreactor,
stably transfected SL2 clones produce 2mg/l to 8mg/l recombinant fusion
protein within three days at an estimated cell density of 5×106 cells/ml.
Protein expression has been constant over the observation time of four to
five weeks.
Baxter et al. (2006) have reported that SL2 cells cultured in a bioreactor at
cell densities of 1.5×107 cells/ml yield up to 27mg/l recombinant soluble
human IL-5 receptor-α per day and compare this with a 17mg/l yield of the
same protein produced in a shaker culture (3×107 cells/ml). Furthermore,
SL2 cells cultured in spinner flasks at cell densities of 8×106 cells/ml have
been reported to produce from 10mg/l to 15mg/l recombinant human
plasminogen within three days (Nilsen and Castellino, 1999). After normal-
ising these protein yields to one day and cell densities of 5×106 cells/ml,
our yields of 1mg/l to 5mg/l immunocytokine per day compare well to the
reported 4mg/l to 18mg/l recombinant protein per day. Such yields fa-
cilitate bulk production of immunocytokines for clinical trials, especially
as the FibraStage™ system can be operated according to GMP guidelines,
may easily be scaled up and needs minimal maintenance.
In our group, immunocytokines have previously been affinity purified us-
ing pre-packed columns, which is a time-consuming process taking three
to four days from thawing of supernatants to freezing of the concentrated
protein. Pumping supernatants through the column at low flow rates is
the time-determining step of this process, taking from one to two days for
1.5l of supernatant. By incubating supernatants with antibody-coupled
Sepharose™ beads in a moving roller bottle for 4 hours and packing an
empty column with the centrifuged beads, we have shortened the affinity
purification process to one and a half days, at the cost of losing approxi-
mately 10% of the Sepharose™ beads – including bound protein – per pu-
rification. Finally, we have completely automated the äktaPrime™ chro-
matograph that has been used for affinity purification, thereby minimising
operator intervention and producing consistent purification results.
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We have routinely obtained 0.5mg to 2.0mg purified immunocytokine or
fusion protein from 1.5l of supernatant, this being only a sixth of the
3mg to 12mg protein present in the supernatant. As we have re-used su-
pernatants until purifications yielded no more protein, loss of protein is
probably due to unspecific adsorption during clarification of crude sam-
ples and application of supernatants to either columns or Sepharose™
beads.
For stabilisation, we have supplemented purified immunocytokines and
the fusion protein HRS3scFv-Fc with 3% (v/v) of either heat-inactivated
FCS (in vitro studies) or heat-inactivated normal mouse serum (studies in
mice) and stored the protein solutions at −80°C until use. We have cho-
sen not to use protease inhibitors, as they may interfere with cell growth in
vitro or exhibit toxicity in vivo. Neither the addition of sera, nor freezing to
−80°C influence binding of purified proteins to the anti-idiotypic antibody
9G10 or the biotinylated anti-h-IgG, anti-h-IL-2 or anti-m-IL-12 (p40/p70)
antibodies as detected by ELISA (data not shown). We therefore conclude
that the used animal sera do not interact with the anti-CD30 fusion pro-
teins. Furthermore, storage at −80°C does not alter the basic characteris-
tics of these proteins.
Specific binding of immunocytokines is essential for targeted drug delivery.
We have therefore analysed the binding of anti-CD30 immunocytokines to
immobilised antigen and tumour cells, as well as competition between so-
lute CD30 and surface-bound antigen in binding to immunocytokines. Pu-
rified anti-CD30 fusion proteins specifically bind to the immobilised anti-
idiotypic antibody 9G10 in a dose-dependant manner. This internal-image
antibody mimics the HRS3-binding epitope on CD30 (Pohl et al., 1992). In-
terestingly, binding of the immunocytokine HRS3scFv-Fc-IL2 to the anti-
body 9G10 is 3- to 4-fold lower compared to the other anti-CD30 fusion
proteins. These results are consistent with those published by our group
(Hombach et al., 2005).
Co-incubation of immunocytokines with CD30 results in dose-dependent
inhibition of binding to the immobilised anti-idiotypic antibody 9G10.
Thus, anti-CD30 fusion proteins specifically bind via the HRS3 scFv do-
main, and the anti-idiotypic antibody 9G10 is a valid substitute for CD30
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to capture these fusion proteins. The recorded binding inhibitions of
34% to 54% are lower than what would be expected for a 3-fold molar ex-
cess of CD30 over fusion protein. We conclude that the anti-CD30 fusion
proteins, particularly the immunocytokine HRS3scFv-hi-IL12-Fc-IL2, pref-
erentially bind to surface-bound antigen in presence of solute CD30. Im-
munotherapy of Hodgkin’s lymphoma would benefit from this property,
as Hodgkin-Reed-Sternberg cells shed CD30 in large quantities (Matthey
et al., 2004). Recorded binding inhibitions are lower than those published
by our group (Hombach et al., 2005). This discrepancy may be due to the
fact that immunocytokine concentrations in the aforementioned publica-
tion have been determined using “Advanced Protein Assay Reagent” (Cy-
toskeleton, Denver, CO, USA). We have found that this reagent results in a
2- to 3-fold overestimate of immunocytokine concentrations compared to
the prediction of molar absorption coefficients used in this study. When
taking this into account, the results of this study are consistent with pub-
lished data.
Anti-CD30 fusion proteins specifically bind to CD30+ tumour cells and to
hybridoma cells that secrete the anti-idiotypic antibody 9G10. Unexpect-
edly, fusion proteins containing an IL-2 domain bind 1.5- to 3-fold stronger
to L540 cells compared to fusion proteins without IL-2 domain. In contrast,
binding of the anti-CD30 immunocytokines to hybridoma cells secreting
the anti-idiotypic antibody 9G10 is equally strong. In both cases, binding
of the immunocytokine HRS3scFv-Fc-IL2 is decreased twofold compared
to HRS3scFv-hi-IL12-Fc-IL2, which is in accordance with the observed de-
crease in binding to immobilised antibody 9G10. Excess binding of IL-2-
containing immunocytokines to L540 cells may result from binding to IL-2
receptors found on these cells. Interestingly, the Hodgkin-derived cell line
L540 rapidly internalises IL-2 after binding to the receptor, but does not re-
spond to IL-2 stimuli with increased proliferation (Tesch et al., 1990). Thus,
binding of immunocytokines to IL-2 receptors on malignant cells will not
endanger therapeutic success by inducing these cells to grow, but might
necessitate higher doses for efficient immunotherapy of Hodgkin’s lym-
phoma.
Decreased binding of the immunocytokine HRS3scFv-Fc-IL2 to cells and
surface-bound antigen compared to the other anti-CD30 immunocy-
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tokines might be due to protein degradation or differences in protein
folding. It does not originate from production in insect cells, however, as
this immunocytokine shows a similar decrease in binding when produced
in mammalian cells. The immunocytokine HRS3scFv-hi-IL12-Fc-IL2 with
combined IL-2 and IL-12 domains exhibits unobstructed binding and thus
presents itself as a substitute for the immunocytokine HRS3scFv-Fc-IL2.
The cytokines IL-2 and IL-12 induce proliferation and IFN-γ secretion in
activated T and natural killer (NK) cells in vitro (Thèze, 1999). Accord-
ingly, pre-activated peripheral blood mononuclear cells (PBMCs) prolifer-
ate and secrete IFN-γ when stimulated by purified immunocytokines in
solution. After specific binding via the HRS3 scFv domain, the immunocy-
tokine HRS3scFv-hi-IL12-Fc-IL2 with combined IL-2 and IL-12 domains
increases proliferation and IFN-γ secretion of PBMCs compared to im-
munocytokines with a single cytokine domain. As expected, the fusion
protein HRS3scFv-Fc without cytokine domain does not activate PBMCs.
Immunocytokines that contain a murine IL-12 cytokine domain also in-
duce phosphorylation of signal transducer and activator of transcription-
4 (STAT4) in pre-activated T cells (cf. figure 4.21). This is consistent with
a publication that reports phosphorylation of STAT4 in lymphocytes after
stimulation with IL-12, IL-23 or IFN-α (Kaplan, 2005).
Anti-CD30 immunocytokines in solution and the bound immunocytokine
HRS3scFv-hi-IL12-Fc-IL2 show 3- to 6-fold less cytokine activity in respect
to induction of proliferation and IFN-γ secretion compared to the respec-
tive recombinant cytokine. This concurs with Gillies et al. (1992, 2002)
who have reported 3- to 4-fold diminished cytokine activity for immunocy-
tokines. In contrast, the immunocytokine HRS3scFv-Fc-hi-IL12 yields the
same amount of phosphorylation of STAT4 as recombinant IL-12, while the
immunocytokine HRS3scFv-hi-IL12-Fc-IL2 with combined IL-2 and IL-12
domains leads to 1.2-fold increased phosphorylation of STAT4. To our best
knowledge, no reports on the influence of immunocytokines on the phos-
phorylation status of STAT4 have been published.
The cytokines IL-2 and IL-12 enhance cytolysis by NK cells (Thèze, 1999).
In addition, the Fcγ1 domain of immunocytokines can trigger antibody-
dependent cellular cytotoxicity (ADCC) by binding to Fcγ receptors on NK
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cells and other lymphocytes (Davis and Gillies, 2003). Accordingly, rest-
ing NK cells are induced to specifically lyse CD30+ tumour cells after coat-
ing with anti-CD30 immunocytokines or the fusion protein HRS3scFv-Fc
without cytokine domain. As the immunocytokine HRS3scFv-hi-IL12-Fc-
IL2 with combined IL-2 and IL-12 domains induces higher cytolysis than
the fusion protein HRS3scFv-Fc, we conclude that immunocytokines in-
duce cytolysis by both antibody-dependent cellular cytotoxicity via bind-
ing to Fcγ receptors and cytokine-mediated cytotoxicity. This conclusion
is substantiated by the fact that we have used 5ng anti-CD30 fusion protein
instead of equimolar amounts, thus 44fmol (5ng) of the immunocytokine
HRS3scFv-Fc-hi-IL12 or 72fmol of the immunocytokine HRS3scFv-Fc-IL2
induce the same amount of cytolysis as 93fmol of the fusion protein HRS3-
scFv-Fc. Within 24 hours, efficiency of cytolysis ranges between 15% and
50% for an effector-to-target cell ratio of 4 : 5. It is not possible to directly
compare our results to other publications due to differing incubation times
(from hours to days) and effector-to-target cell ratios (from 10 : 1 to 1 : 100).
Despite these differences, however, reported cytolysis of immunocytokines
usually lies between 20% and 70% (Anderson et al., 1997; Hornick et al.,
1997; Peng et al., 1999), which corresponds with our data.
Immunocytokines have been designed to target cytokines to specific sites
within the body in order to decrease administered doses, thus limiting the
severe side effects associated with systemic application of cytokines. To
determine accumulation at the tumour site, we have radiolabelled two im-
munocytokines. Radiolabelling leads to modified amino acids, and thus
may change the properties of proteins. As radiolabelled anti-CD30 im-
munocytokines specifically bind to the anti-idiotypic antibody 9G10 and
the elution profile of radiolabelled immunocytokine during affinity purifi-
cation corresponds to that of unlabelled immunocytokine, however, we
conclude that radiolabelling has not changed the binding affinities of im-
munocytokines.
We have analysed the biodistribution of radiolabelled immunocytokines
after systemic application in SCID mice harbouring tumours of the CD30+
Hodgkin-derived cell line L540Cy. The substantial excretion of injected
radioactivity within a day as well as high tissue retentions in small intes-
tine may result from dehalogenation and accord with the known elimina-
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tion routes of free iodine (Bakker et al., 1991; Riccobene et al., 2003). We
have recorded decreased injected dose per gram of tissue (% ID/g) val-
ues in tumours and increased % ID/g values in the blood compared to
data published by Hornick et al. (1997) and Kaspar et al. (2007). This may
be due to shedding of CD30 from the surface of L540Cy cells (Matthey
et al., 2004). Nevertheless, highest tissue retention of the immunocytokine
HRS3scFv-Fc-hi-IL12 is found at the tumour (30%) compared to healthy
tissues (≤ 20%). In case of the immunocytokine HRS3scFv-hi-IL12, reten-
tion at the tumour amounts to 35% and is among the three highest ob-
served tissue retentions (small intestine: 39%, blood: 37%). We therefore
conclude that anti-CD30 immunocytokines specifically accumulate at the
tumour site.
We have determined the influence of dimerisation mediated by the Fcγ1
domain on biodistribution by using two immunocytokines that are iden-
tical except for lacking or containing an Fcγ1 domain. The immunocyto-
kine HRS3scFv-hi-IL12 without Fcγ1 domain is secreted as a monomer of
110kDa (Heuser et al., 2003), while the immunocytokine HRS3scFv-Fc-hi-
IL12 is secreted as a homodimer of 260kDa (Hombach et al., 2005). Despite
the difference in molecular weight, however, neither biological half-life in
β-phase, nor retention at the tumour site of these immunocytokines differ
significantly. This concurs with Rennen et al. (2001), who have reported
slow blood clearance for proteins of intermediate size (70kDa to 210kDa)
compared to rapid clearance of smaller (< 30kDa) and larger (> 660kDa)
proteins. On the other hand, the tested immunocytokines show different
distribution to tissues. After 72 hours, the immunocytokine HRS3scFv-Fc-
hi-IL12 with Fcγ1 domain is detected in all tissues, whereas the immunocy-
tokine HRS3scFv-hi-IL12 without Fcγ1 domain is cleared within 72 hours
from heart, spleen and bones in all animals and from muscle, colon, stom-
ach, kidney and the lungs in at least two animals. While both immunocy-
tokines are retained at the tumour, our results are clearly in favour of the
immunocytokine HRS3scFv-hi-IL12 without Fcγ1 domain, as it combines
fast clearance in off-target tissues with retention at the tumour site, thus
adding tumour selectivity to cytokine therapy.
Biological half-life in β-phase of radiolabelled immunocytokines in SCID
mice amounts to 33 hours (HRS3scFv-hi-IL12) and 34 hours (HRS3scFv-
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Fc-hi-IL12), while we have estimated half-life of the immunocytokine
HRS3scFv-hi-IL12-Fc-IL2 in two Balb/c mice to 32 hours and 41 hours.
These values are close to each other and thus justify calculation of a
mean value. The mean biological half-life of anti-CD30 immunocytokines
amounts to 35 hours and lies well within the reported half-life of 30 hours
(Hornick et al., 1997), 31 hours (Xu et al., 2000) and 37 hours (Powers et al.,
2001) for immunocytokines and scFv-Fc fusion proteins. Moreover, bio-
logical half-life in β-phase of immunocytokines is much higher than that
of recombinant cytokine in humans (human IL-2: 0.4 hours; human IL-12:
5 hours to 10 hours; Atkins et al., 1986, 1997). An increased biological half-
life allows to decrease administered doses. If the drug also selectively accu-
mulates at the target site, administered doses may be lowered even further,
thus decreasing side effects. We therefore expect anti-CD30 immunocy-
tokines to require lower doses and elicit less side effects compared to con-
ventional cytokine therapy.
The anti-CD30 immunocytokines used in this study have been designed
to inhibit tumour growth in vivo. We have therefore assessed influence
of the immunocytokine HRS3scFv-hi-IL12-Fc-IL2 with combined IL-2 and
IL-12 domains on the growth of established tumours in immunocompe-
tent mice. Mice tolerate single doses of up to 500pmol (3.3mg/kg body
weight) and cumulated doses of up to 1nmol (6.5mg/kg) of this immuno-
cytokine. Cumulated immunocytokine doses of 300pmol (1.9mg/kg) and
above inhibit tumour growth in immunocompetent mice when adminis-
tered three times intravenously at 48-hour intervals. In contrast, tumour
growth is not inhibited by lower cumulated doses or in control animals.
This concurs with Gillies et al. (2002) who have reported that an immu-
nocytokine with combined IL-2 and IL-12 domains delays tumour growth,
but does not lead to tumour regression unless injected directly into the tu-
mour (cumulated dose: ≈ 5mg/kg). Finally, we have not observed side ef-
fects related to immunocytokine administration.
Within certain limits, drug doses can be translated from mice to human
adults by normalisation to average body surface area (Reagan-Shaw et al.,
2008). The minimum effective cumulated dose in mice (1.9mg/kg admin-
istered in three doses) translates to 160µg/kg for human adults. Thus, a
third of this dose (i.e. 55µg/kg) might be a feasible single dose for tumour
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therapy. This dose is much lower than the 0.8mg/kg to 7.5mg/kg dosing
regimes used in current clinical trials of immunocytokines (Ribas et al.,
2009), which might be attributed to synergism meditated by the combined
cytokine domains of the immunocytokine HRS3scFv-hi-IL12-Fc-IL2. How-
ever, Hodgkin-Reed-Sternberg cells as well as the tumour-infiltrating lym-
phocytes produce a complex pattern of cytokines and chemokines (Skin-
nider and Mak, 2002). This situation cannot be reproduced in laboratory
animals and might necessitate increased immunocytokine doses for effec-
tive therapy. In addition, antibodies directed against the immunocytokine
might limit the clinical use of this protein. On the other hand, immunoge-
nicity of the immunocytokine may be minimised by humanising the HRS3
scFv and exchanging the murine single-chain IL-12 domain with its human
counterpart. Moreover, many patients with classical Hodgkin’s lymphoma
display signs of immunosuppression (Romagnani et al., 1985) and might
thus exhibit enhanced tolerance to foreign proteins.
We have recorded 13-fold lower immunocytokine concentrations in the
peripheral circulation of mice compared to concentrations calculated
from administered doses for a pharmacokinetic one-compartment model.
Thus, large amounts of immunocytokine are either retained in tissues and
at the tumour, as shown by the biodistribution experiment, or cleared from
the body. While we cannot quantify distribution and clearance, it is obvi-
ous that at least a fraction of the administered immunocytokine reaches
the tumour, as tumour growth has been effectively inhibited. As expected,
immunocompetent mice raise antibodies directed against the immunocy-
tokine backbone consisting of the scFv HRS3 and human IgG1. However,
antibodies first appeared on day 4 after the first injection, therefore clear-
ance by antibodies does not account for the low immunocytokine concen-
trations in peripheral blood.
Classical Hodgkin’s lymphoma is characterised by an immunosuppression
in patients that is attributed to an overproduction of TH2 cytokines. As
the balance between TH1 and TH2 cytokines determines which immune
response results from infection with a pathogen, the defective immune re-
sponse might be turned into an efficient anti-tumour response by the ad-
ministration of TH1 cytokines. In this study, we have demonstrated that the
anti-CD30 immunocytokine HRS3scFv-hi-IL12-Fc-IL2 with combined IL-2
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and IL-12 domains selectively binds to CD30+ cells derived from Hodgkin’s
lymphoma and induces secretion of the TH1 cytokine IFN-γ in resting NK
cells and pre-activated PBMCs. IFN-γ and IL-12 are potent immunomod-
ulators that drive immune reactions to the TH1 type, and the endogenous
production of IFN-γ is required for an effective anti-tumour response. The
immunocytokine HRS3scFv-hi-IL12-Fc-IL2 enhances IFN-γ secretion of
effector cells compared to immunocytokines with a single cytokine domain
and induces resting natural killer cells to cytolysis of tumour cells, while
its IL-2 domain is thought to prevent the immunosuppression mediated
by IL-12 monotherapy. Thus, the misguided TH2 immune reaction could
be overcome by the immunocytokine HRS3scFv-hi-IL12-Fc-IL2, resulting
in an efficient anti-tumour response against the malignant Hodgkin-Reed-
Sternberg cells.
The ideal anti-cancer drug combines high tumour selectivity with long bi-
ological half-life and fast clearance in off-target tissues. Anti-CD30 im-
munocytokines selectively bind to CD30+ tumour tissue in vivo and have a
prolonged biological half-life compared to recombinant cytokines. These
properties allow to decrease administered immunocytokine doses, thereby
decreasing the incidence of side effects. This is reflected by the fact that
effective doses of the immunocytokine HRS3scFv-hi-IL12-Fc-IL2 do not
elicit noticeable side effects in immunocompetent mice. Our data sug-
gest that immunocytokines without an Fcγ1 domain are cleared faster from
off-target tissues than immunocytokines which contain an Fcγ1 domain.
On the other hand, an Fcγ1 domain mediates antibody-dependent cellu-
lar cytotoxicity, thus adding to anti-tumour activity, and allows convenient
purification and detection of immunocytokines using anti-IgG antibodies.
Currently, clinical trials of immunocytokines with and without Fc domain
are under way and may reveal the benefits of either configuration (Schlie-
mann et al., 2009; Ribas et al., 2009).
In clinical studies, immunocytokines with an IL-2 domain have led to sta-
ble disease in 81% (n = 16) or 24% (n = 33) of cancer patients, whereas tri-
als with 27 pediatric patients and 9 adults have not shown clinical response.
However, most patients have shown immunologic response to immuno-
cytokine therapy such as lymphopenia followed by rebound lymphocyto-
sis, increased NK cell activity, antibody-dependent cellular cytotoxicity and
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increased levels of soluble IL-2 receptor-α in peripheral blood. Although
a large number of patients has developed antibodies against immunocy-
tokines, these antibodies have not negatively influenced therapy, except for
anaphylaxis in one patient. Toxicities induced by immunocytokines with
an IL-2 domain have been reversible and mostly resemble those of therapy
with IL-2 or monoclonal antibodies. Dose-limiting toxicities include hy-
potension, hypoxia, allergic reactions, vascular leak syndrome and pain re-
quiring morphine. (Johannsen et al., 2008; King et al., 2004; Ko et al., 2004;
Osenga et al., 2006; Ribas et al., 2009). In contrast to high-dose IL-2 ther-
apy, however, no grade 4 events or treatment-related deaths have been re-
ported (Dutcher et al., 2001). Thus, treatment with immunocytokines elic-
its manageable and reversible toxicities, which is a definite improvement
over conventional cytokine therapy. Even though case numbers are small,
it also seems that a higher proportion of patients responds to therapy with
immunocytokines compared to the 5% to 10% that respond to high-dose
IL-2 therapy (Atkins, 2009; Dutcher et al., 2001).
Current efforts in cancer therapy aim to specifically target the malignant
cells in a tumour lesion. Already, monoclonal antibodies, anti-estrogens
and tyrosine kinase inhibitors have revolutionised cancer therapy. Im-
munotherapy aspires to activate a patient’s immune system and elicit an
immune response directed against the tumour without inducing autoim-
munity. Promising approaches with regard to targeted immunotherapy
are bispecific antibodies that exert their anti-tumour activity by cross-
linking malignant cells and effector cells (Deckert, 2009), and adoptive im-
munotherapy that aims to kill tumour cells by expressing recombinant re-
ceptors on the surface of T cells (Hombach and Abken, 2007). In the case of
classical Hodgkin’s lymphoma, however, these approaches may be limited
by the inherent immunosuppression and T cell anergy in patients. On the
other hand, combining bispecific antibodies or adoptive immunotherapy
with immunocytokines makes for an intriguing prospect, as immunosup-
pression and T cell anergy may be overcome and synergetic anti-tumour
reactivity ensue, especially if competition in binding to malignant cells is
circumvented by targeting different antigens or epitopes on these cells.
In summary, the immunocytokine concept has matured in the last years
and the first immunocytokines are being tested in clinical trials. Im-
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munocytokines elicit immunological and clinical response in patients
with advanced stages of cancer, while toxicities are manageable and re-
versible. This improvement over conventional cytokine therapy may fa-
cilitate that more patients benefit from cytokine-based immunotherapy.
We have adopted the immunocytokine concept for the therapy of classi-
cal Hodgkin’s lymphoma and generated the immunocytokine HRS3scFv-
hi-IL12-Fc-IL2. This recombinant protein shares the favourable properties
of immunocytokines, which are specific binding to tumour cells, retained
cytokine activity and accumulation at the tumour lesion. In addition, the
immunocytokine HRS3scFv-hi-IL12-Fc-IL2 combines IL-2 and IL-12 do-
mains in one molecule and thus exhibits enhanced anti-tumour reactivity
compared to immunocytokines with each cytokine domain. The result-
ing activation of resting NK cells might be able to overcome the immuno-
suppression in classical Hodgkin’s lymphoma. Moreover, the immunocy-
tokine HRS3scFv-hi-IL12-Fc-IL2 inhibits tumour growth in immunocom-
petent mice without noticeable side effects, thus presenting itself as a well-
tolerated and potent new drug for the therapy of classical Hodgkin’s lym-
phoma.
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6 Summary
Classical Hodgkin’s lymphoma is one of the most curable cancers. How-
ever, non-responders, tumour relapses and long-term toxicities of the
treatment make it necessary to look for alternative drugs. Immunotherapy
with cytokines could result in an immune response against the malignant
Hodgkin-Reed-Sternberg cells, while antibody-cytokine conjugates (im-
munocytokines) may reduce side effects by directing cytokine activity to
the tumour. As combining the cytokines IL-2 and IL-12 elicits strong syner-
gistic anti-tumour activity, we have generated the novel immunocytokine
HRS3scFv-hi-IL12-Fc-IL2 that targets CD30 on the surface of Hodgkin-
Reed-Sternberg cells and combines IL-2 and IL-12 domains in one mole-
cule. We have characterised this immunocytokine for binding and activity,
both in vitro and in vivo. Furthermore, we have compared the biodistribu-
tion of two immunocytokines that are identical except for lacking or con-
taining the Fc domain of human IgG1.
In this study, we have established bulk production of immunocytokines in
insect cells and purified recombinant protein in the milligramme range.
Anti-CD30 immunocytokines specifically bind to CD30+ tumour cells, ac-
tivate peripheral blood mononuclear cells and induce resting natural killer
cells to specific lysis of CD30+ tumour cells. The immunocytokine HRS3-
scFv-hi-IL12-Fc-IL2 with combined IL-2 and IL-12 domains has proved su-
perior to immunocytokines with a single cytokine domain by exhibiting
higher cytokine activity, and increases lysis of tumour cells compared to
the fusion protein HRS3scFv-Fc without cytokine domain. In vivo, anti-
CD30 immunocytokines accumulate at the tumour site and have a long bi-
ological half-life of 1.5 days, while the immunocytokine HRS3scFv-hi-IL12-
Fc-IL2 inhibits tumour growth in immunocompetent mice without notice-
able side effects. Data suggest that immunocytokines without an Fc do-
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main may be superior to those containing an Fc domain due to faster clear-
ance in off-target tissues. In summary, the immunocytokine HRS3scFv-
hi-IL12-Fc-IL2 with combined IL-2 and IL-12 domains exhibits enhanced
anti-tumour reactivity, might overcome the T cell anergy in Hodgkin’s lym-
phoma by activating tumour-infiltrating natural killer cells and may de-
crease side effects by accumulation at the tumour lesion. Thus, this im-
munocytokine presents itself as a well-tolerated and potent new drug for
the therapy of Hodgkin’s lymphoma.
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A Abbreviations
ABTS
diazanium(2Z)-3-ethyl-2-[(Z)-(3-ethyl-6-sulfonato-1,3-benzothiazol-2-
ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonate
ABVD adriamycin (doxorubicin), bleomycin, vinblastine, dacarbazine
ADCC antibody-dependent cellular cytotoxicity
AEC 9-ethylcarbazol-3-amine
AKT protein kinase B
asinh area sinus hyperbolicus
ATCC American type culture collection
ATTACK Adoptive engineered T cell targeting to activate cancer killing
BEACOPP bleomycin, etoposide, adriamycin (doxorubicin),
cyclophosphamide, oncovin (vincristine), procarbazine, prednisone
BiP immunoglobulin heavy chain binding protein
bp base pairs
BrdU 5-bromo-2’-deoxyuridine (5-bromo-1-[(2R,4S,5R)-4-hydroxy-5-
(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione)
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Abbreviations
BSA bovine serum albumin
CD cluster of differentiation
CEA carcinoembryonic antigen
cpm counts per minute
Da Dalton
ddH2O double distilled water
DMSO methylsulfinylmethane
DNA deoxyribonucleic acid
dNTP deoxynucleoside triphosphate
ED effective dose
EDTA
2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic
acid
ELISA enzyme-linked immunosorbent assay
FCS foetal calf serum
Fab antigen-binding fragment
Fc crystallisable fragment
FITC fluorescein (mistakenly abbreviated by its commonly-used reactive
form fluorescein-5-isothiocyanate)
GMP good manufacturing practise
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Abbreviations
hi hinge
HEPES 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid
HMW-MAA high-molecular-weight melanoma-associated antigen
HRS Hodgkin-Reed-Sternberg
ID identification number / injected dose
IFN interferon
IL interleukin
IU international unit
Jak Janus family tyrosine kinase
kb kilo base pairs
LB Luria broth (also known as Lenox broth)
Lk Lkappa
mAb monoclonal antibody
MACS magnetic cell separation
MAP kinase mitogen-activated protein kinase
MCS multiple cloning site
MFI mean fluorescence intensity
MHC major histocompatibility complex
MOPS 3-morpholin-4-ylpropane-1-sulfonic acid
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Abbreviations
MW molecular weight
MWCO molecular weight cut-off
n.d. not detected
NHS 1-hydroxy-2,5-pyrrolidinedione
NK cell natural killer cell
OAc acetate
OD optical density
PAGE polyacrylamide gel electrophoresis
PBMC peripheral blood mononuclear cell
PBS phosphate buffered saline
PCR polymerase chain reaction
PE phycoerythrin
PHA-L leucoagglutinin
PI3 kinase phosphatidyl inositol 3 kinase
pMT Drosophila metallothionein promotor
RIA radioimmunoassay
RPMI Roswell Park Memorial Institute medium
rpm revolutions per minute
scFv single-chain fragment variant
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Abbreviations
SCID severe combined immunodeficiency
SDS sodium dodecyl sulfate
SL2 Schneider’s Drosophila line 2
SPF specific pathogen free
STAT signal transducer and activator of transcription
TAE TRIS / acetate / EDTA buffer
TGF transforming growth factor
tm transmembrane
TRIS 2-amino-2-(hydroxymethyl)propane-1,3-diol
Tyk tyrosine kinase
U unit
UV ultraviolet
WHO World Health Organization
XTT 4-methoxy-5-[3-(2-methoxy-4-nitro-5-sulfophenyl)-5-
(phenylcarbamoyl)tetrazol-3-ium-2-yl]-2-nitrobenzenesulfonate
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B DNA sequence data
B.1 pBullet HRS3scFv-CD3ζ (#1078)
Begin End Domain
1973bp 2713bp HRS3 scFv
2720bp 3127bp CD3ζ
NcoI (1968)
| HRS3 scFv (1973-2713)
| |
V A Q V Q L Q Q S G A E L A R P G A
1964 CTGCCATGG GTGGCCCAG GTGCAACTG CAGCAGTCA GGGGCTGAG CTGGCTAGA CCTGGGGCT
S V K M S C K A S G Y T F T T Y T I H W V
2027 TCAGTGAAG ATGTCCTGC AAGGCTTCT GGCTACACC TTTACTACC TACACAATA CACTGGGTA
R Q R P G H D L E W I G Y I N P S S G Y S
2090 AGACAGAGG CCTGGACAC GATCTGGAA TGGATTGGA TACATTAAT CCTAGCAGT GGATATTCT
D Y N Q N F K G K T T L T A D K S S N T A
2153 GACTACAAT CAAAACTTC AAGGGCAAG ACCACATTG ACTGCAGAC AAGTCCTCC AACACAGCC
Y M Q L N S L T S E D S A V Y Y C A R R A
2216 TACATGCAA CTGAACAGC CTGACATCT GAGGACTCT GCGGTCTAT TACTGTGCA AGAAGAGCG
D Y G N Y E Y T W F A Y W G Q G T T V T A
2279 GACTATGGT AACTACGAA TATACCTGG TTTGCTTAC TGGGGCCAA GGGACCACG GTCACCGCC
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DNA sequence data
S S S G G G S G G G G S G G G G S D I E L
2342 TCCTCAAGT GGAGGCGGT TCAGGTGGA GGTGGCTCT GGCGGTGGC GGATCGGAC ATCGAGCTC
T Q S P K F M S T S V G D R V N V T Y K A
2405 ACTCAGTCT CCAAAATTC ATGTCCACA TCAGTAGGA GACAGGGTC AACGTCACC TACAAGGCC
S Q N V G T N V A W F Q Q K P G Q S P K V
2468 AGTCAGAAT GTGGGTACT AATGTAGCC TGGTTTCAA CAAAAACCA GGGCAATCT CCTAAAGTT
L I Y S A S Y R Y S G V P D R F T G S G S
2531 CTGATTTAC TCGGCATCT TACCGATAC AGTGGAGTC CCTGATCGC TTCACAGGC AGTGGATCT
G T D F T L T I S N V Q S E D L A E Y F C
2594 GGAACAGAT TTCACTCTC ACCATCAGC AATGTGCAG TCTGAAGAC TTGGCAGAG TATTTCTGT
Q Q Y H T Y P L T F G G G T K L E I K R A
2657 CAGCAATAT CACACCTAT CCTCTCACG TTCGGAGGG GGCACCAAG CTGGAAATC AAACGGGCG
CD3ζ (2720-3127)
BamHI (2720)
|
D P K L C Y L L D G I L F I Y G V I L T A
2720 GATCCCAAA CTCTGCTAC CTGCTGGAT GGAATCCTC TTCATCTAT GGTGTCATT CTCACTGCC
L F L R V K F S R S A D A P A Y Q Q G Q N
2783 TTGTTCCTG AGAGTGAAG TTCAGCAGG AGCGCAGAC GCCCCCGCG TACCAGCAG GGCCAGAAC
Q L Y N E L N L G R R E E Y D V L D K R R
2846 CAGCTCTAT AACGAGCTC AATCTAGGA CGAAGAGAG GAGTACGAT GTTTTGGAC AAGAGACGT
G R D P E M G G K P R R K N P Q E G L Y N
2909 GGCCGGGAC CCTGAGATG GGGGGAAAG CCGAGAAGG AAGAACCCT CAGGAAGGC CTGTACAAT
E L Q K D K M A E A Y S E I G M K G E R R
2972 GAACTGCAG AAAGATAAG ATGGCGGAG GCCTACAGT GAGATTGGG ATGAAAGGC GAGCGCCGG
R G K G H D G L Y Q G L S T A T K D T Y D
3035 AGGGGCAAG GGGCACGAT GGCCTTTAC CAGGGTCTC AGTACAGCC ACCAAGGAC ACCTACGAC
NotI (3148)
|
A L H M Q A L P P R *
3098 GCCCTTCAC ATGCAGGCC CTGCCCCCT CGCTAACAG GTCGACAGA TCCGCGGCC GCTCGCGAC
138
pBullet HRS3scFv-CD3ζ (#1078)
XhoI (3161)
|
3161 TCGAGAGAT CCGGATTAG TCCAATTTG TTAAAGACA GGATATCAG TGGTCCAGG CTCTAGTTT
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DNA sequence data
B.2 pMT/BiP HRS3scFv-Fc (#1082)
Begin End Domain
851bp 904bp BiP signal sequence
917bp 1657bp HRS3 scFv
1670bp 2368bp human Fcγ1
BiP signal sequence (851-904)
|
M K L C I L L A V V A F V G L S L G
842 GATCTCAAT ATGAAGTTA TGCATATTA CTGGCCGTC GTGGCCTTT GTTGGCCTC TCGCTCGGG
NcoI (912)
| HRS3 scFv (917-1657)
| |
R S P W V A Q V Q L Q Q S G A E L A R P G
905 AGATCTCCA TGGGTGGCC CAGGTGCAA CTGCAGCAG TCAGGGGCT GAGCTGGCT AGACCTGGG
A S V K M S C K A S G Y T F T T Y T I H W
968 GCTTCAGTG AAGATGTCC TGCAAGGCT TCTGGCTAC ACCTTTACT ACCTACACA ATACACTGG
V R Q R P G H D L E W I G Y I N P S S G Y
1031 GTAAGACAG AGGCCTGGA CACGATCTG GAATGGATT GGATACATT AATCCTAGC AGTGGATAT
S D Y N Q N F K G K T T L T A D K S S N T
1094 TCTGACTAC AATCAAAAC TTCAAGGGC AAGACCACA TTGACTGCA GACAAGTCC TCCAACACA
A Y M Q L N S L T S E D S A V Y Y C A R R
1157 GCCTACATG CAACTGAAC AGCCTGACA TCTGAGGAC TCTGCGGTC TATTACTGT GCAAGAAGA
A D Y G N Y E Y T W F A Y W G Q G T T V T
1220 GCGGACTAT GGTAACTAC GAATATACC TGGTTTGCT TACTGGGGC CAAGGGACC ACGGTCACC
A S S S G G G S G G G G S G G G G S D I E
1283 GCCTCCTCA AGTGGAGGC GGTTCAGGT GGAGGTGGC TCTGGCGGT GGCGGATCG GACATCGAG
L T Q S P K F M S T S V G D R V N V T Y K
1346 CTCACTCAG TCTCCAAAA TTCATGTCC ACATCAGTA GGAGACAGG GTCAACGTC ACCTACAAG
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pMT/BiP HRS3scFv-Fc (#1082)
A S Q N V G T N V A W F Q Q K P G Q S P K
1409 GCCAGTCAG AATGTGGGT ACTAATGTA GCCTGGTTT CAACAAAAA CCAGGGCAA TCTCCTAAA
V L I Y S A S Y R Y S G V P D R F T G S G
1472 GTTCTGATT TACTCGGCA TCTTACCGA TACAGTGGA GTCCCTGAT CGCTTCACA GGCAGTGGA
S G T D F T L T I S N V Q S E D L A E Y F
1535 TCTGGAACA GATTTCACT CTCACCATC AGCAATGTG CAGTCTGAA GACTTGGCA GAGTATTTC
C Q Q Y H T Y P L T F G G G T K L E I K R
1598 TGTCAGCAA TATCACACC TATCCTCTC ACGTTCGGA GGGGGCACC AAGCTGGAA ATCAAACGG
BamHI (1664)
| h-Fcγ1 (1670-2368)
| |
A D P A E P K S P D K T H T C P P C P A P
1661 GCGGATCCC GCCGAGCCC AAATCTCCT GACAAAACT CACACATGC CCACCGTGC CCAGCACCT
E L L G G P S V F L F P P K P K D T L M I
1724 GAACTCCTG GGGGGACCG TCAGTCTTC CTCTTCCCC CCAAAACCC AAGGACACC CTCATGATC
S R T P E V T C V V V D V S H E D P E V K
1787 TCCCGGACC CCTGAGGTC ACATGCGTG GTGGTGGAC GTGAGCCAC GAAGACCCT GAGGTCAAG
F N W Y V D G V E V H N A K T K P R E E Q
1850 TTCAACTGG TACGTGGAC GGCGTGGAG GTGCATAAT GCCAAGACA AAGCCGCGG GAGGAGCAG
Y N S T Y R V V S V L T V L H Q D W L N G
1913 TACAACAGC ACGTACCGT GTGGTCAGC GTCCTCACC GTCCTGCAC CAGGACTGG CTGAATGGC
K E Y K C K V S N K A L P A P I E K T I S
1976 AAGGAGTAC AAGTGCAAG GTCTCCAAC AAAGCCCTC CCAGCCCCC ATCGAGAAA ACCATCTCC
K A K G Q P R E P Q V Y T L P P S R D E L
2039 AAAGCCAAA GGGCAGCCC CGAGAACCA CAGGTGTAC ACCCTGCCC CCATCCCGG GATGAGCTG
T K N Q V S L T C L V K G F Y S S D I A V
2102 ACCAAGAAC CAGGTCAGC CTGACCTGC CTGGTCAAA GGCTTCTAT TCCAGCGAC ATCGCCGTG
E W E S N G Q P E N N Y K T T P P V L D S
2165 GAGTGGGAG AGCAATGGG CAGCCGGAG AACAACTAC AAGACCACG CCTCCCGTG CTGGACTCC
D G S F F L Y S K L T V D K S R W Q Q G N
2228 GACGGCTCC TTCTTCCTC TACAGCAAG CTCACCGTG GACAAGAGC AGGTGGCAG CAGGGGAAC
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DNA sequence data
V F S C S V M H G A L H N H Y T Q K S L S
2291 GTCTTCTCA TGCTCCGTG ATGCATGGG GCTCTGCAC AACCACTAC ACGCAGAAG AGCCTCTCC
XhoI (2376)
|
L S P G K I *
2354 CTGTCTCCG GGTAAGATC TAGCTCGAG TCTAGAGGG CCCTTCGAA GGTAAGCCT ATCCCTAAC
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pMT/BiP HRS3scFv-Fc-hi-IL12 (#1083)
B.3 pMT/BiP HRS3scFv-Fc-hi-IL12 (#1083)
Begin End Domain
851bp 904bp BiP signal sequence
917bp 1657bp HRS3 scFv
1670bp 2368bp human Fcγ1
2381bp 2416bp hinge (human IgG1)
2420bp 3358bp murine IL-12 (p40)
3359bp 3403bp murine IL-12 (linker)
3404bp 3982bp murine IL-12 (∆p35)
BiP signal sequence (851-904)
|
M K L C I L L A V V A F V G L S L G
842 GATCTCAAT ATGAAGTTA TGCATATTA CTGGCCGTC GTGGCCTTT GTTGGCCTC TCGCTCGGG
NcoI (912)
| HRS3 scFv (917-1657)
| |
R S P W V A Q V Q L Q Q S G A E L A R P G
905 AGATCTCCA TGGGTGGCC CAGGTGCAA CTGCAGCAG TCAGGGGCT GAGCTGGCT AGACCTGGG
A S V K M S C K A S G Y T F T T Y T I H W
968 GCTTCAGTG AAGATGTCC TGCAAGGCT TCTGGCTAC ACCTTTACT ACCTACACA ATACACTGG
V R Q R P G H D L E W I G Y I N P S S G Y
1031 GTAAGACAG AGGCCTGGA CACGATCTG GAATGGATT GGATACATT AATCCTAGC AGTGGATAT
S D Y N Q N F K G K T T L T A D K S S N T
1094 TCTGACTAC AATCAAAAC TTCAAGGGC AAGACCACA TTGACTGCA GACAAGTCC TCCAACACA
A Y M Q L N S L T S E D S A V Y Y C A R R
1157 GCCTACATG CAACTGAAC AGCCTGACA TCTGAGGAC TCTGCGGTC TATTACTGT GCAAGAAGA
A D Y G N Y E Y T W F A Y W G Q G T T V T
1220 GCGGACTAT GGTAACTAC GAATATACC TGGTTTGCT TACTGGGGC CAAGGGACC ACGGTCACC
A S S S G G G S G G G G S G G G G S D I E
1283 GCCTCCTCA AGTGGAGGC GGTTCAGGT GGAGGTGGC TCTGGCGGT GGCGGATCG GACATCGAG
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DNA sequence data
L T Q S P K F M S T S V G D R V N V T Y K
1346 CTCACTCAG TCTCCAAAA TTCATGTCC ACATCAGTA GGAGACAGG GTCAACGTC ACCTACAAG
A S Q N V G T N V A W F Q Q K P G Q S P K
1409 GCCAGTCAG AATGTGGGT ACTAATGTA GCCTGGTTT CAACAAAAA CCAGGGCAA TCTCCTAAA
V L I Y S A S Y R Y S G V P D R F T G S G
1472 GTTCTGATT TACTCGGCA TCTTACCGA TACAGTGGA GTCCCTGAT CGCTTCACA GGCAGTGGA
S G T D F T L T I S N V Q S E D L A E Y F
1535 TCTGGAACA GATTTCACT CTCACCATC AGCAATGTG CAGTCTGAA GACTTGGCA GAGTATTTC
C Q Q Y H T Y P L T F G G G T K L E I K R
1598 TGTCAGCAA TATCACACC TATCCTCTC ACGTTCGGA GGGGGCACC AAGCTGGAA ATCAAACGG
BamHI (1664)
| h-Fcγ1 (1670-2368)
| |
A D P A E P K S P D K T H T C P P C P A P
1661 GCGGATCCC GCCGAGCCC AAATCTCCT GACAAAACT CACACATGC CCACCGTGC CCAGCACCT
E L L G G P S V F L F P P K P K D T L M I
1724 GAACTCCTG GGGGGACCG TCAGTCTTC CTCTTCCCC CCAAAACCC AAGGACACC CTCATGATC
S R T P E V T C V V V D V S H E D P E V K
1787 TCCCGGACC CCTGAGGTC ACATGCGTG GTGGTGGAC GTGAGCCAC GAAGACCCT GAGGTCAAG
F N W Y V D G V E V H N A K T K P R E E Q
1850 TTCAACTGG TACGTGGAC GGCGTGGAG GTGCATAAT GCCAAGACA AAGCCGCGG GAGGAGCAG
Y N S T Y R V V S V L T V L H Q D W L N G
1913 TACAACAGC ACGTACCGT GTGGTCAGC GTCCTCACC GTCCTGCAC CAGGACTGG CTGAATGGC
K E Y K C K V S N K A L P A P I E K T I S
1976 AAGGAGTAC AAGTGCAAG GTCTCCAAC AAAGCCCTC CCAGCCCCC ATCGAGAAA ACCATCTCC
K A K G Q P R E P Q V Y T L P P S R D E L
2039 AAAGCCAAA GGGCAGCCC CGAGAACCA CAGGTGTAC ACCCTGCCC CCATCCCGG GATGAGCTG
T K N Q V S L T C L V K G F Y S S D I A V
2102 ACCAAGAAC CAGGTCAGC CTGACCTGC CTGGTCAAA GGCTTCTAT TCCAGCGAC ATCGCCGTG
E W E S N G Q P E N N Y K T T P P V L D S
2165 GAGTGGGAG AGCAATGGG CAGCCGGAG AACAACTAC AAGACCACG CCTCCCGTG CTGGACTCC
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pMT/BiP HRS3scFv-Fc-hi-IL12 (#1083)
D G S F F L Y S K L T V D K S R W Q Q G N
2228 GACGGCTCC TTCTTCCTC TACAGCAAG CTCACCGTG GACAAGAGC AGGTGGCAG CAGGGGAAC
V F S C S V M H G A L H N H Y T Q K S L S
2291 GTCTTCTCA TGCTCCGTG ATGCATGGG GCTCTGCAC AACCACTAC ACGCAGAAG AGCCTCTCC
hinge (h-IgG1) (2381-2416)
|
L S P G K K D P A E P K S P D K T H T C P
2354 CTGTCTCCG GGTAAAAAA GATCCCGCC GAGCCCAAA TCTCCTGAC AAAACTCAT ACATGCCCA
m-IL12 (p40) (2420-3358)
| BstXI (2422)
| |
P M W E L E K D V Y V V E V D W T P D A P
2417 CCAATGTGG GAGCTGGAG AAAGACGTT TATGTTGTA GAGGTGGAC TGGACTCCC GATGCCCCT
G E T V N L T C D T P E E D D I T W T S D
2480 GGAGAAACA GTGAACCTC ACCTGTGAC ACGCCTGAA GAAGATGAC ATCACCTGG ACCTCAGAC
BstXI (2550)
|
Q R H G V I G S G K T L T I T V K E F L D
2543 CAGAGACAT GGAGTCATA GGCTCTGGA AAGACCCTG ACCATCACT GTCAAAGAG TTTCTAGAT
A G Q Y T C H K G G E T L S H S H L L L H
2606 GCTGGCCAG TACACCTGC CACAAAGGA GGCGAGACT CTGAGCCAC TCACATCTG CTGCTCCAC
K K E N G I W S T E I L K N F K N K T F L
2669 AAGAAGGAA AATGGAATT TGGTCCACT GAAATTTTA AAAAATTTC AAAAACAAG ACTTTCCTG
K C E A P N Y S G R F T C S W L V Q R N M
2732 AAGTGTGAA GCACCAAAT TACTCCGGA CGGTTCACG TGCTCATGG CTGGTGCAA AGAAACATG
D L K F N I K S S S S P P D S R A V T C G
2795 GACTTGAAG TTCAACATC AAGAGCAGT AGCAGTCCC CCCGACTCT CGGGCAGTG ACATGTGGA
M A S L S A E K V T L D Q R D Y E K Y S V
2858 ATGGCGTCT CTGTCTGCA GAGAAGGTC ACACTGGAC CAAAGGGAC TATGAGAAG TATTCAGTG
BstXI (2975)
|
S C Q E D V T C P T A E E T L P I E L A L
2921 TCCTGCCAG GAGGATGTC ACCTGCCCA ACTGCCGAG GAGACCCTG CCCATTGAA CTGGCGTTG
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DNA sequence data
E A R Q Q N K Y E N Y S T S F F I R D I I
2984 GAAGCACGG CAGCAGAAT AAATATGAG AACTACAGC ACCAGCTTC TTCATCAGG GACATCATC
K P D P P K N L Q M K P L K N S Q V E V S
3047 AAACCAGAC CCGCCCAAG AACTTGCAG ATGAAGCCT TTGAAGAAC TCACAGGTG GAGGTCAGC
W E Y P D S W S T P H S Y F S L K F F V R
3110 TGGGAGTAC CCTGACTCC TGGAGCACT CCCCATTCC TACTTCTCC CTCAAGTTC TTTGTTCGA
I Q R K K E K M K E T E E G C N Q K G A F
3173 ATCCAGCGC AAGAAAGAA AAGATGAAG GAGACAGAG GAGGGGTGT AACCAGAAA GGTGCGTTC
L V E K T S T E V Q C K G G N V C V Q A Q
3236 CTCGTAGAG AAGACATCT ACCGAAGTC CAATGCAAA GGCGGGAAT GTCTGCGTG CAAGCTCAG
m-IL12 (linker) (3359-3403)
|
D R Y Y N S S C S K W A C V P C R V R S G
3299 GATCGCTAT TACAATTCC TCATGCAGC AAGTGGGCA TGTGTTCCC TGCAGGGTC CGATCCGGT
m-IL12 (∆p35) (3404-3982)
|
G G G S G G G G S G G G G S R V I P V S G
3362 GGCGGTGGC TCGGGCGGT GGTGGGTCG GGTGGCGGC GGATCTAGG GTCATTCCA GTCTCTGGA
P A R C L S Q S R N L L K T T D D M V K T
3425 CCTGCCAGG TGTCTTAGC CAGTCCCGA AACCTGCTG AAGACCACA GATGACATG GTGAAGACG
A R E K L K H Y S C T A E D I D H E D I T
3488 GCCAGAGAA AAGCTGAAA CATTATTCC TGCACTGCT GAAGACATC GATCATGAA GACATCACA
R D Q T S T L K T C L P L E L H K N E S C
3551 CGGGACCAA ACCAGCACA TTGAAGACC TGTTTACCA CTGGAACTA CACAAGAAC GAGAGTTGC
L A T R E T S S T T R G S C L P P Q K T S
3614 CTGGCTACT AGAGAGACT TCTTCCACA ACAAGAGGG AGCTGCCTG CCCCCACAG AAGACGTCT
L M M T L C L G S I Y E D L K M Y Q T E F
3677 TTGATGATG ACCCTGTGC CTTGGTAGC ATCTATGAG GACTTGAAG ATGTACCAG ACAGAGTTC
Q A I N A A L Q N H N H Q Q I I L D K G M
3740 CAGGCCATC AACGCAGCA CTTCAGAAT CACAACCAT CAGCAGATC ATTCTAGAC AAGGGCATG
L V A I D E L M Q S L N H N G E T L R Q K
3803 CTGGTGGCC ATCGATGAG CTGATGCAG TCTCTGAAT CATAATGGC GAGACTCTG CGCCAGAAA
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pMT/BiP HRS3scFv-Fc-hi-IL12 (#1083)
P P V G E A D P Y R V K M K L C I L L H A
3866 CCTCCTGTG GGAGAAGCA GACCCTTAC AGAGTGAAA ATGAAGCTC TGCATCCTG CTTCACGCC
XhoI (3987)
|
F S T R V V T I N R V M G Y L S S A *
3929 TTCAGCACC CGCGTCGTG ACCATCAAC AGGGTGATG GGCTATCTG AGCTCCGCC TGACTCGAG
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DNA sequence data
B.4 pMT/BiP HRS3scFv-Fc-IL2 (#1086)
Begin End Domain
851bp 904bp BiP signal sequence
917bp 1657bp HRS3 scFv
1670bp 2368bp human Fcγ1
2378bp 2776bp human IL-2
BiP signal sequence (851-904)
|
M K L C I L L A V V A F V G L S L G
842 GATCTCAAT ATGAAGTTA TGCATATTA CTGGCCGTC GTGGCCTTT GTTGGCCTC TCGCTCGGG
NcoI (912)
| HRS3 scFv (917-1657)
| |
R S P W V A Q V Q L Q Q S G A E L A R P G
905 AGATCTCCA TGGGTGGCC CAGGTGCAA CTGCAGCAG TCAGGGGCT GAGCTGGCT AGACCTGGG
A S V K M S C K A S G Y T F T T Y T I H W
968 GCTTCAGTG AAGATGTCC TGCAAGGCT TCTGGCTAC ACCTTTACT ACCTACACA ATACACTGG
V R Q R P G H D L E W I G Y I N P S S G Y
1031 GTAAGACAG AGGCCTGGA CACGATCTG GAATGGATT GGATACATT AATCCTAGC AGTGGATAT
S D Y N Q N F K G K T T L T A D K S S N T
1094 TCTGACTAC AATCAAAAC TTCAAGGGC AAGACCACA TTGACTGCA GACAAGTCC TCCAACACA
A Y M Q L N S L T S E D S A V Y Y C A R R
1157 GCCTACATG CAACTGAAC AGCCTGACA TCTGAGGAC TCTGCGGTC TATTACTGT GCAAGAAGA
A D Y G N Y E Y T W F A Y W G Q G T T V T
1220 GCGGACTAT GGTAACTAC GAATATACC TGGTTTGCT TACTGGGGC CAAGGGACC ACGGTCACC
A S S S G G G S G G G G S G G G G S D I E
1283 GCCTCCTCA AGTGGAGGC GGTTCAGGT GGAGGTGGC TCTGGCGGT GGCGGATCG GACATCGAG
L T Q S P K F M S T S V G D R V N V T Y K
1346 CTCACTCAG TCTCCAAAA TTCATGTCC ACATCAGTA GGAGACAGG GTCAACGTC ACCTACAAG
148
pMT/BiP HRS3scFv-Fc-IL2 (#1086)
A S Q N V G T N V A W F Q Q K P G Q S P K
1409 GCCAGTCAG AATGTGGGT ACTAATGTA GCCTGGTTT CAACAAAAA CCAGGGCAA TCTCCTAAA
V L I Y S A S Y R Y S G V P D R F T G S G
1472 GTTCTGATT TACTCGGCA TCTTACCGA TACAGTGGA GTCCCTGAT CGCTTCACA GGCAGTGGA
S G T D F T L T I S N V Q S E D L A E Y F
1535 TCTGGAACA GATTTCACT CTCACCATC AGCAATGTG CAGTCTGAA GACTTGGCA GAGTATTTC
C Q Q Y H T Y P L T F G G G T K L E I K R
1598 TGTCAGCAA TATCACACC TATCCTCTC ACGTTCGGA GGGGGCACC AAGCTGGAA ATCAAACGG
BamHI (1664)
| h-Fcγ1 (1670-2368)
| |
A D P A E P K S P D K T H T C P P C P A P
1661 GCGGATCCC GCCGAGCCC AAATCTCCT GACAAAACT CACACATGC CCACCGTGC CCAGCACCT
E L L G G P S V F L F P P K P K D T L M I
1724 GAACTCCTG GGGGGACCG TCAGTCTTC CTCTTCCCC CCAAAACCC AAGGACACC CTCATGATC
S R T P E V T C V V V D V S H E G P E V K
1787 TCCCGGACC CCTGAGGTC ACATGCGTG GTGGTGGAC GTGAGCCAC GAAGGCCCT GAGGTCAAG
F N W Y V D G V E V H N A K T K P R E E Q
1850 TTCAACTGG TACGTGGAC GGCGTGGAG GTGCATAAT GCCAAGACA AAGCCGCGG GAGGAGCAG
Y N S T Y R V V S V L T V L H Q D W L N G
1913 TACAACAGC ACGTACCGT GTGGTCAGC GTCCTCACC GTCCTGCAC CAGGACTGG CTGAATGGC
K E Y K C K V S N K A L P A P I E K T I S
1976 AAGGAGTAC AAGTGCAAG GTCTCCAAC AAAGCCCTC CCAGCCCCC ATCGAGAAA ACCATCTCC
K A K G Q P R E P Q V Y T L P P S R D E L
2039 AAAGCCAAA GGGCAGCCC CGAGAACCA CAGGTGTAC ACCCTGCCC CCATCCCGG GATGAGCTG
T K N Q V S L T C L V K G F Y P S D I A V
2102 ACCAAGAAC CAGGTCAGC CTGACCTGC CTGGTCAAA GGCTTCTAT CCCAGCGAC ATCGCCGTG
E W E S N G Q P E N N Y K T T P P V L D S
2165 GAGTGGGAG AGCAATGGG CAGCCGGAG AACAACTAC AAGACCACG CCTCCCGTG CTGGACTCC
D G S F F L Y S K L T V D K S R W Q Q G N
2228 GACGGCTCC TTCTTCCTC TACAGCAAG CTCACCGTG GACAAGAGC AGGTGGCAG CAGGGGAAC
149
DNA sequence data
V F S C S V M H E A L H N H Y T Q K S L S
2291 GTCTTCTCA TGCTCCGTG ATGCATGAG GCTCTGCAC AACCACTAC ACGCAGAAG AGCCTCTCC
h-IL2 (2378-2776)
|
L S P G K K D P A P T S S S T K K T Q L Q
2354 CTGTCTCCG GGTAAAAAA GATCCTGCA CCTACTTCA AGTTCTACA AAGAAAACA CAGCTACAA
L E H L L L D L Q M I L N G I N N Y K N P
2417 CTGGAGCAT TTACTGCTG GATTTACAG ATGATTTTG AATGGAATT AATAATTAC AAGAATCCC
K L T R V L T F K F Y M P K K A T E L K H
2480 AAACTCACC AGGGTGCTC ACATTTAAG TTTTACATG CCCAAGAAG GCCACAGAA CTGAAACAT
L Q C L E E E L K P L E E V L N L A Q S K
2543 CTTCAGTGT CTAGAAGAA GAACTCAAA CCTCTGGAG GAAGTGCTA AATTTAGCT CAAAGCAAA
N F H L R P R D L I S N I N V I V L E L K
2606 AACTTTCAC TTAAGACCC AGGGACTTA ATCAGCAAT ATCAACGTA ATAGTTCTG GAACTAAAG
G S E T T F M C E Y A D E T A T I V E F L
2669 GGATCTGAA ACAACATTC ATGTGTGAA TATGCTGAT GAGACAGCA ACCATTGTA GAATTTCTA
XhoI (2786)
|
N R W I T F C Q S I I S T L T *
2732 AACAGATGG ATTACCTTT TGTCAAAGC ATCATCTCA ACACTGACT TGAGTCGAC TCGAGTCTA
150
pMT/BiP HRS3scFv-hi-IL12-Fc-IL2 (#1100)
B.5 pMT/BiP HRS3scFv-hi-IL12-Fc-IL2 (#1100)
Begin End Domain
851bp 904bp BiP signal sequence
917bp 1657bp HRS3 scFv
1673bp 1708bp hinge (human IgG1)
1712bp 2650bp murine IL-12 (p40)
2651bp 2695bp murine IL-12 (linker)
2696bp 3274bp murine IL-12 (∆p35)
3284bp 3982bp human Fcγ1
3992bp 4390bp human IL-2
BiP signal sequence (851-904)
|
M K L C I L L A V V A F V G L S L G
842 GATCTCAAT ATGAAGTTA TGCATATTA CTGGCCGTC GTGGCCTTT GTTGGCCTC TCGCTCGGG
NcoI (912)
| HRS3 scFv (917-1657)
| |
R S P W V A Q V Q L Q Q S G A E L A R P G
905 AGATCTCCA TGGGTGGCC CAGGTGCAA CTGCAGCAG TCAGGGGCT GAGCTGGCT AGACCTGGG
A S V K M S C K A S G Y T F T T Y T I H W
968 GCTTCAGTG AAGATGTCC TGCAAGGCT TCTGGCTAC ACCTTTACT ACCTACACA ATACACTGG
V R Q R P G H D L E W I G Y I N P S S G Y
1031 GTAAGACAG AGGCCTGGA CACGATCTG GAATGGATT GGATACATT AATCCTAGC AGTGGATAT
S D Y N Q N F K G K T T L T A D K S S N T
1094 TCTGACTAC AATCAAAAC TTCAAGGGC AAGACCACA TTGACTGCA GACAAGTCC TCCAACACA
A Y M Q L N S L T S E D S A V Y Y C A R R
1157 GCCTACATG CAACTGAAC AGCCTGACA TCTGAGGAC TCTGCGGTC TATTACTGT GCAAGAAGA
A D Y G N Y E Y T W F A Y W G Q G T T V T
1220 GCGGACTAT GGTAACTAC GAATATACC TGGTTTGCT TACTGGGGC CAAGGGACC ACGGTCACC
151
DNA sequence data
V S S S G G G S G G G G S G G G G S D I E
1283 GTCTCCTCA AGTGGAGGC GGTTCAGGT GGAGGTGGC TCTGGCGGT GGCGGATCG GACATCGAG
L T Q S P K F M S T S V G D R V N V T Y K
1346 CTCACTCAG TCTCCAAAA TTCATGTCC ACATCAGTA GGAGACAGG GTCAACGTC ACCTACAAG
A S Q N V G T N V A W F Q Q K P G Q S P K
1409 GCCAGTCAG AATGTGGGT ACTAATGTA GCCTGGTTT CAACAAAAA CCAGGGCAA TCTCCTAAA
V L I Y S A S Y R Y S G V P D R F T G S G
1472 GTTCTGATT TACTCGGCA TCTTACCGA TACAGTGGA GTCCCTGAT CGCTTCACA GGCAGTGGA
S G T D F T L T I S N V Q S E D L A E Y F
1535 TCTGGAACA GATTTCACT CTCACCATC AGCAATGTG CAGTCTGAA GACTTGGCA GAGTATTTC
C Q Q Y H T Y P L T F G G G T K L E I K R
1598 TGTCAGCAA TATCACACC TATCCTCTC ACGTTCGGA GGGGGCACC AAGCTGGAA ATCAAACGG
BamHI (1664) m-IL12 (p40) (1712-2650)
| hinge (h-IgG1) (1673-1708) |BstXI (1714)
| | | |
A D P T E P K S P D K T H T C P P M W E L
1661 GCGGATCCC ACCGAGCCC AAATCTCCT GACAAAACT CATACATGC CCACCAATG TGGGAGCTG
E K D V Y V V E V D W T P D A P G E T V N
1724 GAGAAAGAC GTTTATGTT GTAGAGGTG GACTGGACT CCCGATGCC CCTGGAGAA ACAGTGAAC
BstXI (1842)
|
L T C D T P E E D D I T W T S D Q R H G V
1787 CTCACCTGT GACACGCCT GAAGAAGAT GACATCACC TGGACCTCA GACCAGAGA CATGGAGTC
I G S G K T L T I T V K E F L D A G Q Y T
1850 ATAGGCTCT GGAAAGACC CTGACCATC ACTGTCAAA GAGTTTCTA GATGCTGGC CAGTACACC
C H K G G E T L S H S H L L L H K K E N G
1913 TGCCACAAA GGAGGCGAG ACTCTGAGC CACTCACAT CTGCTGCTC CACAAGAAG GAAAATGGA
I W S T E I L K N F K N K T F L K C E A P
1976 ATTTGGTCC ACTGAAATT TTAAAAAAT TTCAAAAAC AAGACTTTC CTGAAGTGT GAAGCACCA
N Y S G R F A C S W L V Q R N M D L K F N
2039 AATTACTCC GGACGGTTC GCGTGCTCA TGGCTGGTG CAAAGAAAC ATGGACTTG AAGTTCAAC
152
pMT/BiP HRS3scFv-hi-IL12-Fc-IL2 (#1100)
I K S S S S P P D S R A V T C G M A S L S
2102 ATCAAGAGC AGTAGCAGT CCCCCCGAC TCTCGGGCA GTGACATGT GGAATGGCG TCTCTGTCT
A E K V T L D Q R D Y E K Y S V S C Q E D
2165 GCAGAGAAG GTCACACTG GACCAAAGG GACTATGAG AAGTATTCA GTGTCCTGC CAGGAGGAT
BstXI (2267)
|
V T C P T A E E T L P I E L A L E A R Q Q
2228 GTCACCTGC CCAACTGCC GAGGAGACC CTGCCCATT GAACTGGCG TTGGAAGCA CGGCAGCAG
N K Y E N Y S T S F F I R D I I K P D P P
2291 AATAAATAT GAGAACTAC AGCACCAGC TTCTTCATC AGGGACATC ATCAAACCA GACCCGCCC
K N L Q M K P L K N S Q V E V S W E Y P D
2354 AAGAACTTG CAGATGAAG CCTTTGAAG AACTCACAG GTGGAGGTC AGCTGGGAG TACCCTGAC
S W S T P H S Y F S L K F F V R I Q R K K
2417 TCCTGGAGC ACTCCCCAT TCCTACTTC TCCCTCAAG TTCTTTGTT CGAATCCAG CGCAAGAAA
E K M K E T E E G C N Q K G A F L V E K T
2480 GAAAAGATG AAGGAGACA GAGGAGGGG TGTAACCAG AAAGGTGCG TTCCTCGTA GAGAAGACA
S T E V Q C K G G N V C V Q A Q D R Y Y N
2543 TCTACCGAA GTCCAATGC AAAGGCGGG AATGTCTGC GTGCAAGCT CAGGATCGC TATTACAAT
m-IL12 (linker) (2651-2695)
|
S S C S K W A C V P C R V R S G G G G S G
2606 TCCTCATGC AGCAAGTGG GCATGTGTT CCCTGCAGG GTCCGATCC GGTGGCGGT GGCTCGGGC
m-IL12 (∆p35) (2696-3274)
|
G G G S G G G G S R V I P V S G P A R C L
2669 GGTGGTGGG TCGGGTGGC GGCGGATCT AGGGTCATT CCAGTCTCT GGACCTGCC AGGTGTCTT
S Q S R N L L K T T D D M V K T A R E K L
2732 AGCCAGTCC CGAAACCTG CTGAAGACC ACAGATGAC ATGGTGAAG ACGGCCAGA GAAAAGCTG
K H Y S C T A E D I D H E D I T R D Q T S
2795 AAACATTAT TCCTGCACT GCTGAAGAC ATCGATCAT GAAGACATC ACACGGGAC CAAACCAGC
T L K T C L P L E L H K N E S C L A T R E
2858 ACATTGAAG ACCTGTTTA CCACTGGAA CTACACAAG AACGAGAGT TGCCTGGCT ACTAGAGAG
153
DNA sequence data
T S S T T R G S C L P P Q K T S L M M T L
2921 ACTTCTTCC ACAACAAGA GGGAGCTGC CTGCCCCCA CAGAAGACG TCTTTGATG ATGACCCTG
C L G S I Y E D L K M Y Q T E F Q A I N A
2984 TGCCTTGGT AGCATCTAT GAGGACTTG AAGATGTAC CAGACAGAG TTCCAGGCC ATCAACGCA
A L Q N H N H Q Q I I L D K G M L V A I D
3047 GCACTTCAG AATCACAAC CATCAGCAG ATCATTCTA GACAAGGGC ATGCTGGTG GCCATCGAT
E L M Q S L N H N G E T L R Q K P P V G E
3110 GAGCTGATG CAGTCTCTG AATCATAAT GGCGAGACT CTGCGCCAG AAACCTCCT GTGGGAGAA
A D P Y R V K M K L C I L L H A F S T R V
3173 GCAGACCCT TACAGAGTG AAAATGAAG CTCTGCATC CTGCTTCAC GCCTTCAGC ACCCGCGTC
h-Fcγ1 (3284-3982)
|
V T I N R V M G Y L S S A G D P A E P K S
3236 GTGACCATC AACAGGGTG ATGGGCTAT CTGAGCTCC GCCGGAGAT CCCGCCGAG CCCAAATCT
P D K T H T C P P C P A P E L L G G P S V
3299 CCTGACAAA ACTCACACA TGCCCACCG TGCCCAGCA CCTGAACTC CTGGGGGGA CCGTCAGTC
F L F P P K P K D T L M I S R T P E V T C
3362 TTCCTCTTC CCCCCAAAA CCCAAGGAC ACCCTCATG ATCTCCCGG ACCCCTGAG GTCACATGC
V V V D V S H E G P E V K F N W Y V D G V
3425 GTGGTGGTG GACGTGAGC CACGAAGGC CCTGAGGTC AAGTTCAAC TGGTACGTG GACGGCGTG
E V H N A K T K P R E E Q Y N S T Y R V V
3488 GAGGTGCAT AATGCCAAG ACAAAGCCG CGGGAGGAG CAGTACAAC AGCACGTAC CGTGTGGTC
S V L T V L H Q D W L N G K E Y K C K V S
3551 AGCGTCCTC ACCGTCCTG CACCAGGAC TGGCTGAAT GGCAAGGAG TACAAGTGC AAGGTCTCC
N K A L P A P I E K T I S K A K G Q P R E
3614 AACAAAGCC CTCCCAGCC CCCATCGAG AAAACCATC TCCAAAGCC AAAGGGCAG CCCCGAGAA
P Q V Y T L P P S R D E L T K N Q V S L T
3677 CCACAGGTG TACACCCTG CCCCCATCC CGGGATGAG CTGACCAAG AACCAGGTC AGCCTGACC
C L V K G F Y P S D I A V E W E S N G Q P
3740 TGCCTGGTC AAAGGCTTC TATCCCAGC GACATCGCC GTGGAGTGG GAGAGCAAT GGGCAGCCG
154
pMT/BiP HRS3scFv-hi-IL12-Fc-IL2 (#1100)
E N N Y K T T P P V L D S D G S F F L Y S
3803 GAGAACAAC TACAAGACC ACGCCTCCC GTGCTGGAC TCCGACGGC TCCTTCTTC CTCTACAGC
K L T V D K S R W Q Q G N V F S C S V M H
3866 AAGCTCACC GTGGACAAG AGCAGGTGG CAGCAGGGG AACGTCTTC TCATGCTCC GTGATGCAT
E A L H N H Y T Q K S L S L S P G K K D P
3929 GAGGCTCTG CACAACCAC TACACGCAG AAGAGCCTC TCCCTGTCT CCGGGTAAA AAAGATCCT
h-IL2 (3992-4390)
|
A P T S S S T K K T Q L Q L E H L L L D L
3992 GCACCTACT TCAAGTTCT ACAAAGAAA ACACAGCTA CAACTGGAG CATTTACTG CTGGATTTA
Q M I L N G I N N Y K N P K L T R V L T F
4055 CAGATGATT TTGAATGGA ATTAATAAT TACAAGAAT CCCAAACTC ACCAGGGTG CTCACATTT
K F Y M P K K A T E L K H L Q C L E E E L
4118 AAGTTTTAC ATGCCCAAG AAGGCCACA GAACTGAAA CATCTTCAG TGTCTAGAA GAAGAACTC
K P L E E V L N L A Q S K N F H L R P R D
4181 AAACCTCTG GAGGAAGTG CTAAATTTA GCTCAAAGC AAAAACTTT CACTTAAGA CCCAGGGAC
L I S N I N V I V L E L K G S E T T F M C
4244 TTAATCAGC AATATCAAC GTAATAGTT CTGGAACTA AAGGGATCT GAAACAACA TTCATGTGT
E Y A D E T A T I V E F L N R W I T F C Q
4307 GAATATGCT GATGAGACA GCAACCATT GTAGAATTT CTAAACAGA TGGATTACC TTTTGTCAA
XhoI (4400)
|
S I I S T L T *
4370 AGCATCATC TCAACACTG ACTTGAGTC GACTCGAGT CTAGAGGGC CCTTCGAAG GTAAGCCTA
155
DNA sequence data
B.6 pMT/BiP SCA431scFv-Fc (#1103)
Begin End Domain
851bp 904bp BiP signal sequence
917bp 1660bp SCA431 scFv
1661bp 2341bp murine Fcγ1
BiP signal sequence (851-904)
|
M K L C I L L A V V A F V G L S L G
842 GATCTCAAT ATGAAGTTA TGCATATTA CTGGCCGTC GTGGCCTTT GTTGGCCTC TCGCTCGGG
NcoI (912)
| SCA431 scFv (917-1660)
| |
R S P W R G V H S Q V Q L Q E S G P D L V
905 AGATCTCCA TGGAGAGGT GTCCACTCC CAGGTCCAA CTGCAGGAG TCAGGACCT GACCTGGTG
K P S Q S L S L T C T V T G Y S I T S G Y
968 AAACCTTCT CAGTCACTT TCACTCACC TGCACTGTC ACTGGCTAC TCCATCACC AGTGGTTAT
BamHI (1042)
|
S W H W I R Q F P G N K L E W M G Y I Q Y
1031 AGCTGGCAC TGGATCCGG CAGTTTCCA GGAAACAAA CTGGAATGG ATGGGCTAC ATACAATAC
XhoI (1144)
|
S G I T N Y N P S L K S R I S I T R D T S
1094 AGTGGTATC ACTAACTAC AACCCCTCT CTCAAAAGT CGAATCTCT ATCACTCGA GACACATCC
EcoRI (1181)
|
K N Q F F L Q L N S V T T E D T A T Y Y C
1157 AAGAACCAG TTCTTCCTG CAGTTGAAT TCTGTGACT ACTGAGGAC ACAGCCACA TATTACTGT
A R E D Y D Y H W Y F D V W G Q G T T V T
1220 GCAAGAGAA GACTATGAT TACCACTGG TACTTCGAT GTCTGGGGC CAAGGGACC ACGGTCACC
156
pMT/BiP SCA431scFv-Fc (#1103)
V S S G G G G S G G G G S G G G G S D I Q
1283 GTCTCCTCA GGAGGTGGT GGATCGGGC GGTGGCGGG TCGGGTGGC GGCGGATCT GACATCCAG
L T Q S P A I M S A S L G E E I T L T C S
1346 CTGACCCAG TCTCCAGCA ATCATGTCT GCATCTCTA GGGGAGGAG ATCACCCTA ACCTGCAGT
XhoI (1415)
|
A S S S V S Y M H W Y Q Q K S G T S P K L
1409 GCCAGCTCG AGTGTAAGT TACATGCAC TGGTACCAG CAGAAGTCA GGCACTTCT CCCAAACTC
L I Y S T S N L A S G V P S R F S G S G S
1472 TTGATTTAT AGCACATCC AACCTGGCT TCTGGAGTC CCTTCTCGC TTCAGTGGC AGTGGGTCT
G T F Y S L T I S S V E A E D A A D Y Y C
1535 GGGACCTTT TATTCTCTC ACAATCAGC AGTGTGGAG GCTGAAGAT GCTGCCGAT TATTACTGC
H Q W S S Y P T F G G G T K L E I K V D P
1598 CATCAGTGG AGTAGTTAT CCCACGTTC GGAGGGGGG ACCAAGCTG GAGATCAAA GTAGATCCT
m-Fcγ1 (1661-2341)
|
V P R D G G C K P C I C T V P E V S S V F
1661 GTGCCCAGG GATGGTGGT TGTAAGCCT TGCATATGT ACAGTCCCA GAAGTATCA TCTGTCTTC
I F P P K P K D V L T I T L T P K V T C V
1724 ATCTTCCCC CCAAAGCCC AAGGATGTG CTCACCATT ACTCTGACT CCTAAGGTC ACGTGTGTT
V V D I S K D D P E V Q F S W F V D D V E
1787 GTGGTAGAC ATCAGCAAG GATGATCCC GAGGTCCAG TTCAGCTGG TTTGTAGAT GATGTGGAG
V H T A Q T Q P R E E Q F N S T F R S V S
1850 GTGCACACA GCTCAGACG CAACCCCGG GAGGAGCAG TTCAACAGC ACTTTCCGC TCAGTCAGT
E L P I M H Q D W L N G K E F K C R V N S
1913 GAACTTCCC ATCATGCAC CAGGACTGG CTCAATGGC AAGGAGTTC AAATGCAGG GTCAACAGT
A A F P A P I E K T I S K T K G R P K A P
1976 GCAGCTTTC CCTGCCCCC ATCGAGAAA ACCATCTCC AAAACCAAA GGCAGACCG AAGGCTCCA
Q V C T I P P P K E Q M A K D K V S L T C
2039 CAGGTGTGC ACCATTCCA CCTCCCAAG GAGCAGATG GCCAAGGAT AAAGTCAGT CTGACCTGC
M I T D F F P E D I T V E W Q W N G Q P A
2102 ATGATAACA GACTTCTTC CCTGAAGAC ATTACTGTG GAGTGGCAG TGGAATGGG CAGCCAGCG
157
DNA sequence data
E N Y K N T Q P I M D T D G S Y F V Y S K
2165 GAGAACTAC AAGAACACT CAGCCCATC ATGGACACA GATGGCTCT TACTTCGTC TACAGCAAG
L N V Q K S N W E A G N T F T C S V L H E
2228 CTCAATGTG CAGAAGAGC AACTGGGAG GCAGGAAAT ACTTTCACC TGCTCTGTG TTACATGAG
XhoI (2353)
NotI (2347) |
BstXI (2334) | |
| | |
G L H N H H T E K S L S H S P G K *
2291 GGCCTGCAC AACCACCAT ACTGAGAAG AGCCTCTCC CACTCTCCT GGTAAGTGA GCGGCCGCT
158
pMT/BiP SCA431scFv-Fc-IL7 (#1117)
B.7 pMT/BiP SCA431scFv-Fc-IL7 (#1117)
Begin End Domain
851bp 904bp BiP signal sequence
917bp 1660bp SCA431 scFv
1661bp 2341bp murine Fcγ1
2342bp 2728bp murine IL-7
BiP signal sequence (851-904)
|
M K L C I L L A V V A F V G L S L G
842 GATCTCAAT ATGAAGTTA TGCATATTA CTGGCCGTC GTGGCCTTT GTTGGCCTC TCGCTCGGG
NcoI (912)
| SCA431 scFv (917-1660)
| |
R S P W R G V H S Q V Q L Q E S G P D L V
905 AGATCTCCA TGGAGAGGT GTCCACTCC CAGGTCCAA CTGCAGGAG TCAGGACCT GACCTGGTG
K P S Q S L S L T C T V T G Y S I T S G Y
968 AAACCTTCT CAGTCACTT TCACTCACC TGCACTGTC ACTGGCTAC TCCATCACC AGTGGTTAT
BamHI (1042)
|
S W H W I R Q F P G N K L E W M G Y I Q Y
1031 AGCTGGCAC TGGATCCGG CAGTTTCCA GGAAACAAA CTGGAATGG ATGGGCTAC ATACAATAC
XhoI (1144)
|
S G I T N Y N P S L K S R I S I T R D T S
1094 AGTGGTATC ACTAACTAC AACCCCTCT CTCAAAAGT CGAATCTCT ATCACTCGA GACACATCC
EcoRI (1181)
|
K N Q F F L Q L N S V T T E D T A T Y Y C
1157 AAGAACCAG TTCTTCCTG CAGTTGAAT TCTGTGACT ACTGAGGAC ACAGCCACA TATTACTGT
A R E D Y D Y H W Y F D V W G Q G T T V T
1220 GCAAGAGAA GACTATGAT TACCACTGG TACTTCGAT GTCTGGGGC CAAGGGACC ACGGTCACC
159
DNA sequence data
V S S G G G G S G G G G S G G G G S D I Q
1283 GTCTCCTCA GGAGGTGGT GGATCGGGC GGTGGCGGG TCGGGTGGC GGCGGATCT GACATCCAG
L T Q S P A I M S A S L G E E I T L T C S
1346 CTGACCCAG TCTCCAGCA ATCATGTCT GCATCTCTA GGGGAGGAG ATCACCCTA ACCTGCAGT
XhoI (1415)
|
A S S S V S Y M H W Y Q Q K S G T S P K L
1409 GCCAGCTCG AGTGTAAGT TACATGCAC TGGTACCAG CAGAAGTCA GGCACTTCT CCCAAACTC
L I Y S T S N L A S G V P S R F S G S G S
1472 TTGATTTAT AGCACATCC AACCTGGCT TCTGGAGTC CCTTCTCGC TTCAGTGGC AGTGGGTCT
G T F Y S L T I S S V E A E D A A D Y Y C
1535 GGGACCTTT TATTCTCTC ACAATCAGC AGTGTGGAG GCTGAAGAT GCTGCCGAT TATTACTGC
H Q W S S Y P T F G G G T K L E I K V D P
1598 CATCAGTGG AGTAGTTAT CCCACGTTC GGAGGGGGG ACCAAGCTG GAGATCAAA GTAGATCCT
m-Fcγ1 (1661-2341)
|
V P R D G G C K P C I C T V P E V S S V F
1661 GTGCCCAGG GATGGTGGT TGTAAGCCT TGCATATGT ACAGTCCCA GAAGTATCA TCTGTCTTC
I F P P K P K D V L T I T L T P K V T C V
1724 ATCTTCCCC CCAAAGCCC AAGGATGTG CTCACCATT ACTCTGACT CCTAAGGTC ACGTGTGTT
V V D I S K D D P E V Q F S W F V D D V E
1787 GTGGTAGAC ATCAGCAAG GATGATCCC GAGGTCCAG TTCAGCTGG TTTGTAGAT GATGTGGAG
V H T A Q T Q P R E E Q F N S T F R S V S
1850 GTGCACACA GCTCAGACG CAACCCCGG GAGGAGCAG TTCAACAGC ACTTTCCGC TCAGTCAGT
E L P I M H Q D W L N G K E F K C R V N S
1913 GAACTTCCC ATCATGCAC CAGGACTGG CTCAATGGC AAGGAGTTC AAATGCAGG GTCAACAGT
A A F P A P I E K T I S K T K G R P K A P
1976 GCAGCTTTC CCTGCCCCC ATCGAGAAA ACCATCTCC AAAACCAAA GGCAGACCG AAGGCTCCA
Q V C T I P P P K E Q M A K D K V S L T C
2039 CAGGTGTGC ACCATTCCA CCTCCCAAG GAGCAGATG GCCAAGGAT AAAGTCAGT CTGACCTGC
M I T D F F P E D I T V E W Q W N G Q P A
2102 ATGATAACA GACTTCTTC CCTGAAGAC ATTACTGTG GAGTGGCAG TGGAATGGG CAGCCAGCG
160
pMT/BiP SCA431scFv-Fc-IL7 (#1117)
E N Y K N T Q P I M D T D G S Y F V Y S K
2165 GAGAACTAC AAGAACACT CAGCCCATC ATGGACACA GATGGCTCT TACTTCGTC TACAGCAAG
L N V Q K S N W E A G N T F T C S V L H E
2228 CTCAATGTG CAGAAGAGC AACTGGGAG GCAGGAAAT ACTTTCACC TGCTCTGTG TTACATGAG
BstXI (2334)
| m-IL7 (2342-2728)
| |
G L H N H H T E K S L S H S P G K E C H I
2291 GGCCTGCAC AACCACCAT ACTGAGAAG AGCCTCTCC CACTCTCCT GGTAAGGAG TGCCACATT
K D K E G K A Y E S V L M I S I D E L D K
2354 AAAGACAAA GAAGGTAAA GCATATGAG AGTGTACTG ATGATCAGC ATCGATGAA TTGGACAAA
M T G T D S N C P N N E P N F F R K H V C
2417 ATGACAGGA ACTGATAGT AATTGCCCG AATAATGAA CCAAACTTT TTTAGAAAA CATGTATGT
D D T K E A A F L N R A A R K L K Q F L K
2480 GATGATACA AAGGAAGCT GCTTTTCTA AATCGTGCT GCTCGCAAG TTGAAGCAA TTTCTTAAA
EcoRI (2559)
|
M N I S E E F N V H L L T V S Q G T Q T L
2543 ATGAATATC AGTGAAGAA TTCAATGTC CACTTACTA ACAGTATCA CAAGGCACA CAAACACTG
V N C T S K E E K N V K E Q K K N D A C F
2606 GTGAACTGC ACAAGTAAG GAAGAAAAA AACGTAAAG GAACAGAAA AAGAATGAT GCATGTTTC
L K R L L R E I K T C W N K I L K G S I *
2669 CTAAAGAGA CTACTGAGA GAAATAAAA ACTTGTTGG AATAAAATT TTGAAGGGC AGTATATGA
NotI (2734)
| XhoI (2740)
| |
2732 GCGGCCGCT CGAGTCTAG AGGGCCCTT CGAAGGTAA GCCTATCCC TAACCCTCT CCTCGGTCT
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DNA sequence data
B.8 pMT/BiP SCA431scFv-Fc-IL15 (#1118)
Begin End Domain
851bp 904bp BiP signal sequence
917bp 1660bp SCA431 scFv
1661bp 2341bp murine Fcγ1
2342bp 2683bp human IL-15
BiP signal sequence (851-904)
|
M K L C I L L A V V A F V G L S L G
842 GATCTCAAT ATGAAGTTA TGCATATTA CTGGCCGTC GTGGCCTTT GTTGGCCTC TCGCTCGGG
NcoI (912)
| SCA431 scFv (917-1660)
| |
R S P W R G V H S Q V Q L Q E S G P D L V
905 AGATCTCCA TGGAGAGGT GTCCACTCC CAGGTCCAA CTGCAGGAG TCAGGACCT GACCTGGTG
K P S Q S L S L T C T V T G Y S I T S G Y
968 AAACCTTCT CAGTCACTT TCACTCACC TGCACTGTC ACTGGCTAC TCCATCACC AGTGGTTAT
BamHI (1042)
|
S W H W I R Q F P G N K L E W M G Y I Q Y
1031 AGCTGGCAC TGGATCCGG CAGTTTCCA GGAAACAAA CTGGAATGG ATGGGCTAC ATACAATAC
XhoI (1144)
|
S G I T N Y N P S L K S R I S I T R D T S
1094 AGTGGTATC ACTAACTAC AACCCCTCT CTCAAAAGT CGAATCTCT ATCACTCGA GACACATCC
EcoRI (1181)
|
K N Q F F L Q L N S V T T E D T A T Y Y C
1157 AAGAACCAG TTCTTCCTG CAGTTGAAT TCTGTGACT ACTGAGGAC ACAGCCACA TATTACTGT
A R E D Y D Y H W Y F D V W G Q G T T V T
1220 GCAAGAGAA GACTATGAT TACCACTGG TACTTCGAT GTCTGGGGC CAAGGGACC ACGGTCACC
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pMT/BiP SCA431scFv-Fc-IL15 (#1118)
V S S G G G G S G G G G S G G G G S D I Q
1283 GTCTCCTCA GGAGGTGGT GGATCGGGC GGTGGCGGG TCGGGTGGC GGCGGATCT GACATCCAG
L T Q S P A I M S A S L G E E I T L T C S
1346 CTGACCCAG TCTCCAGCA ATCATGTCT GCATCTCTA GGGGAGGAG ATCACCCTA ACCTGCAGT
XhoI (1415)
|
A S S S V S Y M H W Y Q Q K S G T S P K L
1409 GCCAGCTCG AGTGTAAGT TACATGCAC TGGTACCAG CAGAAGTCA GGCACTTCT CCCAAACTC
L I Y S T S N L A S G V P S R F S G S G S
1472 TTGATTTAT AGCACATCC AACCTGGCT TCTGGAGTC CCTTCTCGC TTCAGTGGC AGTGGGTCT
G T F Y S L T I S S V E A E D A A D Y Y C
1535 GGGACCTTT TATTCTCTC ACAATCAGC AGTGTGGAG GCTGAAGAT GCTGCCGAT TATTACTGC
H Q W S S Y P T F G G G T K L E I K V D P
1598 CATCAGTGG AGTAGTTAT CCCACGTTC GGAGGGGGG ACCAAGCTG GAGATCAAA GTAGATCCT
m-Fcγ1 (1661-2341)
|
V P R D G G C K P C I C T V P E V S S V F
1661 GTGCCCAGG GATGGTGGT TGTAAGCCT TGCATATGT ACAGTCCCA GAAGTATCA TCTGTCTTC
I F P P K P K D V L T I T L T P K V T C V
1724 ATCTTCCCC CCAAAGCCC AAGGATGTG CTCACCATT ACTCTGACT CCTAAGGTC ACGTGTGTT
V V D I S K D D P E V Q F S W F V D D V E
1787 GTGGTAGAC ATCAGCAAG GATGATCCC GAGGTCCAG TTCAGCTGG TTTGTAGAT GATGTGGAG
V H T A Q T Q P R E E Q F N S T F R S V S
1850 GTGCACACA GCTCAGACG CAACCCCGG GAGGAGCAG TTCAACAGC ACTTTCCGC TCAGTCAGT
E L P I M H Q D W L N G K E F K C R V N S
1913 GAACTTCCC ATCATGCAC CAGGACTGG CTCAATGGC AAGGAGTTC AAATGCAGG GTCAACAGT
A A F P A P I E K T I S K T K G R P K A P
1976 GCAGCTTTC CCTGCCCCC ATCGAGAAA ACCATCTCC AAAACCAAA GGCAGACCG AAGGCTCCA
Q V C T I P P P K E Q M A K D K V S L T C
2039 CAGGTGTGC ACCATTCCA CCTCCCAAG GAGCAGATG GCCAAGGAT AAAGTCAGT CTGACCTGC
M I T D F F P E D I T V E W Q W N G Q P A
2102 ATGATAACA GACTTCTTC CCTGAAGAC ATTACTGTG GAGTGGCAG TGGAATGGG CAGCCAGCG
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DNA sequence data
E N Y K N T Q P I M D T D G S Y F V Y S K
2165 GAGAACTAC AAGAACACT CAGCCCATC ATGGACACA GATGGCTCT TACTTCGTC TACAGCAAG
L N V Q K S N W E A G N T F T C S V L H E
2228 CTCAATGTG CAGAAGAGC AACTGGGAG GCAGGAAAT ACTTTCACC TGCTCTGTG TTACATGAG
BstXI (2334)
| h-IL15 (2342-2683)
| |
G L H N H H T E K S L S H S P G K N W V N
2291 GGCCTGCAC AACCACCAT ACTGAGAAG AGCCTCTCC CACTCTCCT GGTAAGAAC TGGGTGAAT
V I S D L K K I E D L I Q S M H I D A T L
2354 GTAATAAGT GATTTGAAA AAAATTGAA GATCTTATT CAATCTATG CATATTGAT GCTACTTTA
Y T E S D V H P S C K V T A M K C F L L E
2417 TATACGGAA AGTGATGTT CACCCCAGT TGCAAAGTA ACAGCAATG AAGTGCTTT CTCTTGGAG
L Q V I S L E S G D A S I H D T V E N L I
2480 TTACAAGTT ATTTCACTT GAGTCCGGA GATGCAAGT ATTCATGAT ACAGTAGAA AATCTGATC
I L A N N S L S S N G N V T E S G C K E C
2543 ATCCTAGCA AACAACAGT TTGTCTTCT AATGGGAAT GTAACAGAA TCTGGATGC AAAGAATGT
E E L E E K N I K E F L Q S F V H I V Q M
2606 GAGGAACTG GAGGAAAAA AATATTAAA GAATTTTTG CAGAGTTTT GTACATATT GTCCAAATG
NotI (2689)
| XhoI (2695)
| |
F I N T S *
2669 TTCATCAAC ACTTCTTGA GCGGCCGCT CGAGTCTAG AGGGCCCTT CGAAGGTAA GCCTATCCC
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C äktaPrime™ methods
Methods for the äktaPrime™ chromatograph can be stored as plain text
files in the directory C:\UNICORN\Bin\Prime\. Such methods are run from
the main menu with the commands Run Stored Method, OK, From PC and
OK. The method number is entered and OK is pressed twice to start the
method. The äktaPrime™ should be set-up as follows:
Injection Valve: 2 connected to column output
4 blocked with a stop plug
6 connected to column input
Buffer inlets: A1 PBS
B 100mM glycine buffer (pH 3.0)
Each run is split into two parts so that an operator may respond to prob-
lems during conditioning. The method “conditioning” flushes inlet tubing
with the connected buffers to remove trapped air bubbles and save time
during elution. When the procedure has finished, buffer inlet A1 has to
be immersed in a flask containing PBS with 0.1% (w/v) sodium azide. The
“elution” method then elutes the protein and washes the column.
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äktaPrime™ methods
C.1 Purification of immunocytokines
C.1.1 1ml HiTrap™ HP column (Conditioning)
1 *****************************************************************
2 ** Method Dump
3 **
4 ** AKTAprime Ver , V2.01
5 **
6 ** Dump Format Ver , V1.00
7 **
8 *****************************************************************
9
10
11 ******************
12 ** Method Settings
13 ******************
14 Method Type ,-
15 Method ,-
16 Method base ,ml
17 Frac base ,ml
18 Max pressure (kPa) ,500
19 Alarm (min/ml) ,0.0
20
21 *********************
22 ** Method Breakpoints
23 *********************
24
25 Brkp Volume Conc Flow Frac Buff Inj Peak Autozero Eventmark
26 (mAu/min)
27
28 ,1 ,0.0 ,100 ,50.0 ,0.0 ,1 ,Waste ,0 ,N ,N
29 ,2 ,19.9 ,100 ,50.0 ,0.0 ,1 ,Waste ,0 ,N ,N
30 ,3 ,20.0 ,0 ,50.0 ,0.0 ,1 ,Waste ,0 ,N ,N
31 ,4 ,69.5 ,0 ,1.0 ,0.0 ,1 ,Waste ,0 ,N ,N
32 ,5 ,70.0 ,0 ,1.0 ,0.0 ,1 ,Inj ,0 ,N ,Y
33 ,6 ,80.0 ,0 ,1.0 ,0.0 ,1 ,Inj ,0 ,Y ,Y
34 ,7 ,90.0 ,0 ,1.0 ,0.0 ,1 ,Inj ,0 ,Y ,N
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Purification of immunocytokines
C.1.2 1ml HiTrap™ HP column (Elution)
1 *****************************************************************
2 ** Method Dump
3 **
4 ** AKTAprime Ver , V2.01
5 **
6 ** Dump Format Ver , V1.00
7 **
8 *****************************************************************
9
10
11 ******************
12 ** Method Settings
13 ******************
14 Method Type ,-
15 Method ,-
16 Method base ,ml
17 Frac base ,ml
18 Max pressure (kPa) ,500
19 Alarm (min/ml) ,0.0
20
21 *********************
22 ** Method Breakpoints
23 *********************
24
25 Brkp Volume Conc Flow Frac Buff Inj Peak Autozero Eventmark
26 (mAu/min)
27
28 ,1 ,0.0 ,100 ,1.0 ,0.0 ,1 ,Inj ,0 ,N ,Y
29 ,2 ,1.0 ,100 ,1.0 ,0.0 ,1 ,Inj ,0 ,Y ,Y
30 ,3 ,5.0 ,100 ,1.0 ,1.5 ,1 ,Inj ,10.0 ,N ,Y
31 ,4 ,25.0 ,100 ,1.0 ,0.0 ,1 ,Inj ,0 ,N ,Y
32 ,5 ,39.9 ,100 ,1.0 ,0.0 ,1 ,Inj ,0 ,N ,N
33 ,6 ,40.0 ,0 ,1.0 ,0.0 ,1 ,Inj ,0 ,N ,Y
34 ,7 ,70.0 ,0 ,1.0 ,0.0 ,1 ,Waste ,0 ,N ,N
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äktaPrime™ methods
C.1.3 5ml HiTrap™ HP column (Conditioning)
1 *****************************************************************
2 ** Method Dump
3 **
4 ** AKTAprime Ver , V2.01
5 **
6 ** Dump Format Ver , V1.00
7 **
8 *****************************************************************
9
10
11 ******************
12 ** Method Settings
13 ******************
14 Method Type ,-
15 Method ,-
16 Method base ,ml
17 Frac base ,ml
18 Max pressure (kPa) ,500
19 Alarm (min/ml) ,0.0
20
21 *********************
22 ** Method Breakpoints
23 *********************
24
25 Brkp Volume Conc Flow Frac Buff Inj Peak Autozero Eventmark
26 (mAu/min)
27
28 ,1 ,0.0 ,100 ,50.0 ,0.0 ,1 ,Waste ,0 ,N ,N
29 ,2 ,19.9 ,100 ,50.0 ,0.0 ,1 ,Waste ,0 ,N ,N
30 ,3 ,20.0 ,0 ,50.0 ,0.0 ,1 ,Waste ,0 ,N ,N
31 ,4 ,69.0 ,0 ,2.5 ,0.0 ,1 ,Waste ,0 ,N ,N
32 ,5 ,70.0 ,0 ,2.5 ,0.0 ,1 ,Inj ,0 ,N ,Y
33 ,6 ,95.0 ,0 ,2.5 ,0.0 ,1 ,Inj ,0 ,Y ,Y
34 ,7 ,120.0 ,0 ,2.5 ,0.0 ,1 ,Inj ,0 ,Y ,N
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Purification of immunocytokines
C.1.4 5ml HiTrap™ HP column (Elution)
1 *****************************************************************
2 ** Method Dump
3 **
4 ** AKTAprime Ver , V2.01
5 **
6 ** Dump Format Ver , V1.00
7 **
8 *****************************************************************
9
10
11 ******************
12 ** Method Settings
13 ******************
14 Method Type ,-
15 Method ,-
16 Method base ,ml
17 Frac base ,ml
18 Max pressure (kPa) ,500
19 Alarm (min/ml) ,0.0
20
21 *********************
22 ** Method Breakpoints
23 *********************
24
25 Brkp Volume Conc Flow Frac Buff Inj Peak Autozero Eventmark
26 (mAu/min)
27
28 ,1 ,0.0 ,100 ,2.5 ,0.0 ,1 ,Inj ,0 ,N ,Y
29 ,2 ,1.0 ,100 ,2.5 ,0.0 ,1 ,Inj ,0 ,Y ,Y
30 ,3 ,5.0 ,100 ,2.5 ,1.5 ,1 ,Inj ,20.0 ,N ,Y
31 ,4 ,50.0 ,100 ,2.5 ,0.0 ,1 ,Inj ,0 ,N ,Y
32 ,5 ,99.9 ,100 ,2.5 ,0.0 ,1 ,Inj ,0 ,N ,N
33 ,6 ,100.0 ,0 ,2.5 ,0.0 ,1 ,Inj ,0 ,N ,Y
34 ,7 ,250.0 ,0 ,2.5 ,0.0 ,1 ,Waste ,0 ,N ,N
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äktaPrime™ methods
C.1.5 C10/10™ column packed with Sepharose™ beads
(Conditioning)
1 *****************************************************************
2 ** Method Dump
3 **
4 ** AKTAprime Ver , V2.01
5 **
6 ** Dump Format Ver , V1.00
7 **
8 *****************************************************************
9
10
11 ******************
12 ** Method Settings
13 ******************
14 Method Type ,-
15 Method ,-
16 Method base ,ml
17 Frac base ,ml
18 Max pressure (kPa) ,500
19 Alarm (min/ml) ,0.0
20
21 *********************
22 ** Method Breakpoints
23 *********************
24
25 Brkp Volume Conc Flow Frac Buff Inj Peak Autozero Eventmark
26 (mAu/min)
27
28 ,1 ,0.0 ,100 ,50.0 ,0.0 ,1 ,Waste ,0 ,N ,N
29 ,2 ,19.9 ,100 ,50.0 ,0.0 ,1 ,Waste ,0 ,N ,N
30 ,3 ,20.0 ,0 ,50.0 ,0.0 ,1 ,Waste ,0 ,N ,N
31 ,4 ,69.0 ,0 ,2.0 ,0.0 ,1 ,Waste ,0 ,N ,N
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Purification of immunocytokines
C.1.6 C10/10™ column packed with Sepharose™ beads
(Elution)
1 *****************************************************************
2 ** Method Dump
3 **
4 ** AKTAprime Ver , V2.01
5 **
6 ** Dump Format Ver , V1.00
7 **
8 *****************************************************************
9
10
11 ******************
12 ** Method Settings
13 ******************
14 Method Type ,-
15 Method ,-
16 Method base ,ml
17 Frac base ,ml
18 Max pressure (kPa) ,500
19 Alarm (min/ml) ,0.0
20
21 *********************
22 ** Method Breakpoints
23 *********************
24
25 Brkp Volume Conc Flow Frac Buff Inj Peak Autozero Eventmark
26 (mAu/min)
27
28 ,1 ,0.0 ,100 ,2.0 ,0.0 ,1 ,Inj ,0 ,N ,Y
29 ,2 ,1.0 ,100 ,2.0 ,0.0 ,1 ,Inj ,0 ,Y ,Y
30 ,3 ,5.0 ,100 ,2.0 ,1.5 ,1 ,Inj ,20.0 ,N ,Y
31 ,4 ,60.0 ,100 ,2.0 ,0.0 ,1 ,Inj ,0 ,N ,Y
32 ,5 ,119.9 ,100 ,2.0 ,0.0 ,1 ,Inj ,0 ,N ,N
33 ,6 ,120.0 ,0 ,2.0 ,0.0 ,1 ,Inj ,0 ,N ,Y
34 ,7 ,170.0 ,0 ,2.0 ,0.0 ,1 ,Waste ,0 ,N ,N
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äktaPrime™ methods
C.2 Purification of antibodies
C.2.1 C10/10™ column (Conditioning)
1 *****************************************************************
2 ** Method Dump
3 **
4 ** AKTAprime Ver , V2.01
5 **
6 ** Dump Format Ver , V1.00
7 **
8 *****************************************************************
9
10
11 ******************
12 ** Method Settings
13 ******************
14 Method Type ,-
15 Method ,-
16 Method base ,ml
17 Frac base ,ml
18 Max pressure (kPa) ,300
19 Alarm (min/ml) ,0.0
20
21 *********************
22 ** Method Breakpoints
23 *********************
24
25 Brkp Volume Conc Flow Frac Buff Inj Peak Autozero Eventmark
26 (mAu/min)
27
28 ,1 ,0.0 ,100 ,50.0 ,0.0 ,1 ,Waste ,0 ,N ,N
29 ,2 ,19.9 ,100 ,50.0 ,0.0 ,1 ,Waste ,0 ,N ,N
30 ,3 ,20.0 ,0 ,50.0 ,0.0 ,1 ,Waste ,0 ,N ,N
31 ,4 ,69.0 ,0 ,1.0 ,0.0 ,1 ,Waste ,0 ,N ,N
32 ,5 ,70.0 ,0 ,1.0 ,0.0 ,1 ,Inj ,0 ,N ,Y
33 ,6 ,95.0 ,0 ,1.0 ,0.0 ,1 ,Inj ,0 ,Y ,Y
34 ,7 ,120.0 ,0 ,1.0 ,0.0 ,1 ,Inj ,0 ,Y ,N
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Purification of antibodies
C.2.2 C10/10™ column (Elution)
1 *****************************************************************
2 ** Method Dump
3 **
4 ** AKTAprime Ver , V2.01
5 **
6 ** Dump Format Ver , V1.00
7 **
8 *****************************************************************
9
10
11 ******************
12 ** Method Settings
13 ******************
14 Method Type ,-
15 Method ,-
16 Method base ,ml
17 Frac base ,ml
18 Max pressure (kPa) ,300
19 Alarm (min/ml) ,0.0
20
21 *********************
22 ** Method Breakpoints
23 *********************
24
25 Brkp Volume Conc Flow Frac Buff Inj Peak Autozero Eventmark
26 (mAu/min)
27
28 ,1 ,0.0 ,100 ,1.0 ,0.0 ,1 ,Inj ,0 ,N ,Y
29 ,2 ,1.0 ,100 ,1.0 ,0.0 ,1 ,Inj ,0 ,Y ,Y
30 ,3 ,5.0 ,100 ,1.0 ,1.5 ,1 ,Inj ,20.0 ,N ,Y
31 ,4 ,60.0 ,100 ,1.0 ,0.0 ,1 ,Inj ,0 ,N ,Y
32 ,5 ,119.9 ,100 ,1.0 ,0.0 ,1 ,Inj ,0 ,N ,N
33 ,6 ,120.0 ,0 ,1.0 ,0.0 ,1 ,Inj ,0 ,N ,Y
34 ,7 ,170.0 ,0 ,1.0 ,0.0 ,1 ,Waste ,0 ,N ,N
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